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Abstract  
 
Mitochondria are cellular organelles that have evolved from the eubacterial ancestor 
into highly specialized compartment of the eukaryotic cell. They are unique among 
animal cells in that they retain a level of autonomy through the genetic information in 
their genome. Human mtDNA is built of ~16.5 kbp encoding 13 polypeptides, which 
are synthesised by mitoribosomes. The latter consist of two RNA species also 
transcribed from mtDNA and approximately 80 proteins originating from the nucleus. 
All 13 products of intramitochondrial translation are incorporated into the inner 
mitochondrial membrane where they co-build the oxidative phosphorylation 
(OXPHOS) system. OXPHOS is a multicomplex machinery, the final product of which 
is adenosine triphosphate, ATP, a carrier of energy that is necessary to sustain cell 
homeostasis and growth.   
The malfunctions of mitochondria have a severe impact on the ‘host’ organism and are 
the causative factor in many human diseases. Pathological changes of mitochondrial 
function can be triggered by mutations in the mitochondrial genome and/or defects in 
nuclear genes involved in mitochondrial activity. The mitochondrial gene expression 
pathway has been increasingly investigated during last twenty years and combines both 
types of factors, those translated in the cytosol and those synthesised in the 
mitochondrial matrix. A functional mitochondrion requires over 1500 proteins to be 
imported from the cytosol, a significant subset of these are devoted to the maintenance, 
replication, transcription and subsequently for translation of the minimal mitochondrial 
genome fostered within. In the course of my PhD study three of these nuclear encoded 
but mitochondrially destined proteins were investigated.  
 
The first of these proteins that I contributed to investigating was SLIRP. As the 
specificity of this RNA binding protein had not been established I performed CLIP 
(cross-linking immunoprecipitation) assay in order to assess the ability of SLIRP to 
bind RNA. The data generated from this analysis directly showed that SLIRP can 
interact with all mt-mRNAs apart from MTND6. This work confirmed that SLIRP 
participates in the stability of mt-mRNA species, as has now been subsequently 
published by other research groups. 
 
A main part of my PhD studies centred on characterisation of MRPL12. This protein 
belongs to the pool of conserved mitochondrial proteins having the bacterial orthologue 
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called L7/L12. One of the unique features of these proteins is their dynamic character 
and ability to exchange location between ribosomal LSU and the free pool. This has 
been postulated to be a regulatory mechanism of translation process in response to 
fluctuations in cell metabolism. To test this hypothesis I characterised immortalised 
fibroblasts obtained from a patient with a homozygous mutation in MRPL12 caused by 
c.542C to T transition in exon 5. This cell line allowed me to study the consequence of 
this defect on the regulation of translation in human mitochondria. I could conclude that 
a reduced number of MRPL12 molecules per mt-LSU in subject fibroblasts did not 
affect overall mitoribosome assembly, but a visible decline in mitochondrial translation 
was detected although the reduction in translational efficiency for different 
mitochondrially encoded subunits varied. 
 
The third protein that I characterised was mitochondrial RBFA. This protein was 
identified in my host laboratory and preliminary characterisation performed prior to my 
involvement. My studies included the CLIP assay that showed direct interaction of this 
protein with a 3’ terminal stem loop of helix 45 of the 12S mt-rRNA. The methylation 
status of two conserved neighbouring adenines located in helix 45 was altered by 
changes in steady state level of RBFA. Moreover, the CLIP data identified a second 
rRNA species associated with RBFA. This was an unexpected RNA species in the form 
of 5S rRNA. The data regarding the mitochondrial localisation and specifically any 
submitochondrial location has been controversial. Intriguingly my data identified a 
number of chimeric CLIP sequences containing both 5S and 12S rRNA fragments, 
strongly suggesting that within the mitochondrial matrix RBFA interacts simultaneously 
with both RNA species. Similarity between the 5S rRNA secondary structure and 
snoRNA, which guides modifications on cytosolic rRNA, led to the hypothesis 
proposing a novel function for 5S rRNA guiding methylation at helix 45 of the 12S mt-
rRNA. My data therefore assign RBFA as a new member of the group of maturation 
factors of the mammalian mt-SSU. 
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1.   Chapter 1: Introduction 
 
1.1   General overview of the mitochondrion. 
 1.1.1 Origin of mitochondria. 
The human mitochondrial network is a multifunctional organelle, the origin of which 
has been widely discussed and analysed. One of the most accepted theories combines a 
rise of eukaryotic cells and mitochondria in one event, in a symbiotic association of an 
anaerobic archaebacterium (the host) with aerobic eubacterium (the symbiont) (Martin 
and Müller, 1998, Rivera and Lake, 2004, Cox et al., 2008, Yutin et al., 2008, Williams 
et al., 2013). Mitochondria are the only organelle in non-plant eukaryotic cells, outside 
the nucleus, containing their own DNA. Variations in the size of mitochondrial genetic 
information, physical form and content of coding and noncoding fragments raised the 
question of possible multisymbiotic events occurring during cellular evolution. The size 
of mammalian mtDNA oscillates around 16 kb and investigation in non-animal species 
revealed much smaller genomes of just ~6 kbp genome of Plasmodium falciparum 
(human malaria parasite) and related apicomplexans (Feagin, 2000). In contrast the 
mitochondrial genome of land plants hugely expanded in size to 570 kbp in corn or even 
larger than 2000 kbp in some cucurbit plants (Bullerwell and Gray, 2004). The largest 
known by far is mtDNA of Silene conica (~11000 kb) with a massive proliferation of 
noncoding content that exceeds the size of even some nuclear genomes (Sloan et al., 
2012). Despite these genetic variations, data obtained from gene sequencing strongly 
suggest that the mitochondrial genome is monophyletic (Gray et al., 1999, Bullerwell 
and Gray, 2004). Although the mitochondrial network has retained its autonomy in the 
cell, its genome has become hugely reduced during the course of evolutionary changes. 
The number of encoded proteins has dropped in some cases from 67 to 3, and from a 
maximum of 27 mt-tRNAs to none (Adams and Palmer, 2003). Indeed some non-
respiring microbial eukaryotes such as parasitic trichomonads lack mtDNA completely 
but still contain derived mitochondria called hydrogenosomes producing ATP 
anaerobically (Embley et al., 2003). Other eukaryote species that for many years were 
believed to lack mitochondria, such as Trachipleistophora, contain reduced 
mitochondrial structures termed mitosomes (Roger and Silberman, 2002). This 
mitochondrion-related organelle also lacks mtDNA but in contrast to hydrogenosomes 
is unable to generate ATP (Gray, 2012). Extremely reduced metabolic capacity of 
mitosomes manifests in Fe-S cluster formation (Regoes et al., 2005). Overall, it seems 
that evolutionary changes in some unicellular organisms where the need for aerobic 
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respiratory function of mitochondria was no longer required caused the reduction or 
remodelling of the organelle. Nevertheless mitochondria are highly organised and 
complex structures, requiring many hundreds of proteins (over 1500 in mammals) to 
maintain their functions (Bar-Yaacov et al., 2012). 
 
Interestingly mitochondria in four major lineages of aerobic eukaryotes; animals, 
most fungi, apicomplexans and chlamydomonad green algae have lost the coding 
capacity for all of the ribosomal proteins but retained at least 3 respiratory chain 
proteins with cyt c and cox1 considered as universal (Adams and Palmer, 2003). Many 
mitochondria have also retained two genes encoding the small and large ribosomal 
RNA species, which exhibit a striking spectrum in size, in contrast to those of their 
eubacterial and chloroplast orthologues. Moreover, some of mitochondrial rRNA are 
highly fragmented and dispersed throughout the mitochondrial genome, examples 
include Plasmodium falciparum and Chlamydomonas reinhardtii (Adams and Palmer, 
2003). Most of mitochondrial genomes have lost the gene encoding 5S rRNA. The 
reported absence of it, in many of the organisms analysed may be due to a failure in 
experimental and /or bioinformatic approaches (Adams and Palmer, 2003) or can be the 
result of an evolutionary driven substitution by a cytosolic orthologue (Entelis et al., 
2001). Furthermore, there is a specific hierarchy in the gene loss, with some genes lost 
more readily than others (Lang et al., 1999). However, certain genes have been retained 
in the mtDNA and these require the involvement of hundreds of proteins imported from 
cytosol for their maintenance, replication, repair, and all the steps of their expression 
and regulation. The reasons for this energetically demanding service are not clear. One 
of the hypotheses addressing this issue, points out the hydrophobic nature of OXPHOS 
subunits, which make them very difficult to transport across the mitochondrial 
membranes and sort to a precise location (Claros et al., 1995). Another explanation 
proposes potential toxicity of the gene products if they were present in cytosol, but 
which remain ‘safe’ when enclosed in the mitochondrion (Adams and Palmer, 2003). A 
further hypothesis suggests that the non-standard genetic code applied in the 
mitochondrion of many eukaryotes, including animals, would act as a block to further 
gene transfer to the nucleus. The rapid development of bioinformatic tools as well as 
progressing research in biology of mitochondria should soon clarify the biogenesis and 
mutual dependence between the eukaryotic cell and one of the mysteries of its 
organelles.  
 
21 
 
1.1.2 The dynamic complexity of mitochondrial structure. 
Although the basics about structure of mitochondria have been known for many years, 
the advanced microscopy developed more recently has been used to investigate its 
morphology to generate a more accurate and complex picture (Ernster and Schatz, 1981, 
Frey et al., 2002). Mitochondrial shapes vary widely between different cell types from 
long filaments in fibroblasts to spheres in hepatocytes (Youle and Van der Bliek, 2012). 
Moreover, morphologies of mitochondria are far from static, continuously changing via 
the combined processes of fission, fusion and motility.  
Mitochondria consist of two membranes: outer (OM) and inner (IM) that create 5 
compartments, which provide specific environments for many metabolic and regulatory 
processes (Figure 1.1). In addition to the OM and IM, the cavity between these is the 
intermembrane space (IMS), the invaginations of the IM create the cristae and the 
innermost compartment is the matrix harbouring the mtDNA, mt-RNA and the soluble 
proteins responsible for their expression. 
 
 
The OM is the first barrier separating the mitochondrion from the cytosol. It stops the 
entrance of macromolecules but allows smaller particles, up to a few kDa, free passage 
due to its porous structure. The inner membrane is a very complex and dynamic 
compartment, which is still intensively investigated. It seals the matrix and strictly 
regulates the movement of particles even as small as ions. This protein rich membrane 
 
 
 
Figure 1.1 Structure of the mitochondrion. A transmission electron micrograph 
showing a section through a mitochondrion that illustrates the 5 different 
compartments. Description of each compartment is given in the text. IM, inner 
membrane; OM, outer membrane.  
Image adapted from http://academic.brooklyn.cuny.edu/biology/bio4fv/page/mito.htm 
 
matrix cristae IM 
OM intermembrane 
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is subdivided into two domains. First, named the inner boundary membrane (IBM) is in 
very close proximity to OM with the intermembrane space dividing them. The second 
domain consists of cristae invaginations, in which two leaflets of inner membrane are 
juxtaposed to each other creating range of structures from tubules to complex, 
interconnected plates. The more energy demanding the cell, the more of the IM is 
reportedly structured into cristae (Vogel et al., 2006). The IBM is connected with its 
invaginations by narrow, tubular structures termed cristae junctions (CJs) of around 28 
nm diameter. There are a few theoretical models explaining formation and maintenance 
of cristae but none fully explain this complex process (Zick et al., 2009). It has been 
proposed that F1F0-ATP synthase supercomplexes are involved in maintaining cristae 
structure and they could possibly influence the membrane curvature that locally 
increases the pH gradient and in the result optimize the synthase performance.  
 
 
Figure 1.2. Schematic representation of the mitochondrial IM subcompartmentalisation. 
Location of proteins is based on research in S. cerevisiae. Mia40p; facilitates the oxidative 
biogenesis of intermembrane space proteins, Tim23; translocase of the inner mitochondrial 
membrane, Mgm1p; mitochondrial fusion, are enriched in the inner boundary membrane. ANC, 
CIII, CIV and F1F0-ATP synthase dominate in cristae membrane. CS, cytosol; OM, outer 
membrane; IMS, intermembrane space; IM, inner membrane; M, matrix. Image taken from Zick 
et al., 2009. 
 
Recently performed research on yeast shows subcompartmental localization of 
protein complexes in the inner mitochondrial membrane (Vogel et al., 2006), with those 
engaged in either the fusion process (Mgm1) or nuclear-encoded protein translocation 
(Mia40p, TIM23) being preferentially placed in IBM. In contrast, proteins of the 
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OXPHOS system, iron-sulphur cluster biogenesis, as well as proteins involved in 
mitochondrial translation and transport of mtDNA-encoded polypeptides are in higher 
density located in the cristae membrane (Figure 1.2). However, the distribution of these 
proteins between the two compartments undergoes dynamic changes triggered by the 
physiological state of the cell.  
Nevertheless, it is accepted that the structure of the inner membrane is very 
dynamic, going through processes of fusion and fission during mitochondrial network 
reshaping, remodelling in response to the cellular conditions (Benard and Karbowski, 
2009). The structure and swift remodelling of mitochondrial compartments is of great 
importance for cellular homeostasis, and perturbations in morphology are seen in 
numerous human diseases including Alzheimer’s and Parkinson’s disease (Trimmer et 
al., 2000). Mitochondrial fission is crucial for growing and dividing cells to supply them 
with sufficient population of mitochondria (Youle and Van der Bliek, 2012). Moreover, 
fission allows segregation of damaged beyond repair mitochondria from the 
mitochondrial network in order to be degraded (mitophagy). In contrast, fusion is driven 
by energy demand in the face of stress; it allows mitochondria to exchange proteins, 
lipids, RNA, in order to compensate for one another’s defects and maintain energy 
output.  
 
1.1.2.1 Mitochondrial remodelling in cell death. 
Alterations in the morphology of mitochondria are also reported in apoptosis and 
necrosis, manifesting in the fragmentation of mitochondrial tubules and the reshaping of 
inner-membrane cristae (Itoh et al., 2013). Apoptosis is a programmed cell death that is, 
for example, responsible for separation of fingers and toes in a developing human 
embryo. Whereas necrotic cell death is distinct from the apoptotic signal transduction 
pathway, caused by factors external to the cell or tissue, such as extreme temperature 
changes or infections (Vanlangenakker et al., 2008). Mitochondria play an important 
role in the regulation of apoptosis via caspase-dependent or caspase-independent death 
pathways in response to diverse signals. Caspases are cysteinyl aspartate –directed 
proteases cleaving a broad range of cellular proteins (Kurokawa and Kornbluth, 2009). 
The caspases 9 and 3 cascade is activated by the release of cytochrome c from 
permeabilised mitochondria into the cytosol (Jiang and Wang, 2004, Frey and Sun, 
2008). Increased accessibility of cytochrome c, which is stored in the intracristal space, 
has been shown to occur upon extensive remodelling of the mitochondrial inner 
membrane (Zick et al., 2009). In the caspase-independent cascade an apoptosis-inducing 
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factor (AIF) is relocated to the nucleus from the IM (Dawson and Dawson, 2004). AIF 
is required for the maintenance of normal cristae structure (Cheung et al., 2006). The 
loss of AIF from mitochondria was proposed to cause disintegration of the IM topology 
(Zick et al., 2009). 
 
1.1.3. Functions of mitochondria. 
As already mentioned, a broad range of metabolic and bioenergetic pathways is located 
in mitochondria. These pathways include oxidative phosphorylation (OXPHOS), Krebs 
cycle, β-oxidation of fatty acids, iron-sulphur clusters biogenesis (Lill and Mühlenhoff, 
2006), certain amino acid metabolism as well as regulatory pathways, such the above 
mentioned programmed cell death or Ca
2+
 buffering and signalling (Glancy and 
Balaban, 2012). The long list of functions also needs tightly regulated transport 
machinery embedded in both of the mitochondrial membranes (Neupert and Herrmann, 
2007). 
Energy transduction is one of the most studied functions of mitochondria, as it is 
essential for cell survival and functionality. In order to sustain its homeostasis cells 
require a constant source of ATP, which is a carrier of energy locked in phosphate 
bonds (Koopman et al., 2012). There are two sources of adenosine triphosphate, first in 
cytosol through a purely anaerobic process called glycolysis, which produces two 
particles of ATP, NADH and pyruvate. The latter is then transported to the 
mitochondrial matrix, converted to acetyl coenzyme A and processed by Krebs cycle to 
yield NADH and FADH2 molecules that feed electrons into the oxidative 
phosphorylation pathway. Five protein complexes located in mitochondrial inner 
membrane take part in generating ~32 ATP molecules from one event of a glucose full 
oxidation to CO2 and H2O. 
 
1.1.3.1. OXPHOS system. 
Respiratory complexes I, II, III and IV transfer electrons from donors (NADH and 
FADH2) to an acceptor (O2), which releases energy used in transport of H
+
 protons from 
the mitochondrial matrix to the intermembrane space in order to create a pH gradient 
and electrical potential across the IM. The fifth complex, the FoF1- ATP synthase 
couples the flow of protons back to the matrix and converts this chemiosmotic energy 
into phosphate bonds, generating ATP from ADP (Mitchell, 2011). The OXPHOS 
machinery is a very complex and dynamic structure, consisting of ~ 92 subunits. 
Although mostly encoded by nuclear genes, genetic information for 13 of these 
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polypeptides (embedded in complex I, III, IV and V) is held in the mtDNA genome and 
the proteins are produced in the mitochondrial matrix. This is in contrast to complex II, 
which consists of polypeptides entirely encoded by the nDNA. Correct biogenesis of 
respiratory complexes also requires assembly factors, of which 35 are currently 
described (Koopman et al., 2012). It has been also proposed that complexes can create 
higher molecular structures named ‘respirasomes’ supporting their dynamic stability. 
The present view is that such supercomplexes are composed of CI, CIII and CIV. The 
newest publications in Science proposes a further two supercomplexes to be embedded 
in IM, the first composed of CI and CIII and second built of CIII and CIV (Lapuente-
Brun et al., 2013). 
 
 
Figure 1.3. Schematic representation of OXPHOS system embedded in the mitochondrial 
inner membrane. This illustrates the established electron movement in complexes I, II, III and 
IV of the OXPHOS system, which transduces energy, transformed by complex V into phosphate 
bonds of ATP molecules. Electrons extracted from NADH and FADH2 are passed to CI and CII 
respectively, and are transported by a chain of Fe-S clusters to CoQ10, which carriers them to 
CIII. Cytochrome c (cyt c) passes electrons to CIV. At CV, the chemiosmotic energy created by 
CI, III and IV by pumping H
+
 protons across the inner membrane from mitochondrial matrix to 
intermembrane space is released by controlled backflow and coupled to the formation of ATP 
from ADP and phosphate (Pi), (taken from Yu-Wai-Man et al., 2011).  
 
Different types of cells, their physiological demands and environmental conditions 
influence the balance between glycolytic and mitochondrial ATP production. Some, 
such as mature erythrocytes that lack nuclei and mitochondria depend completely on 
cytosolic ATP synthesis. Other cell types mostly rely on the complete oxidation of 
glucose (brain cells) or fatty acids (liver cells). Skeletal muscle cells switch from fatty 
acids to glucose oxidation during high activity events that provide them with the biggest 
ATP supply. Because of these differences in energy demand and its sources, cells and 
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tissues can be more or less severely affected by malfunction of the OXPHOS system 
(Smeitink et al., 2006). 
 
Nevertheless, as a major supplier of ATP produced from energy-rich molecules, 
influencing many other metabolic and signaling pathways, dysfunctions of OXPHOS 
machinery can cause many disorders, some of which are lethal in an early onset (Chan, 
2006, Nunnari and Suomalainen, 2012). Mitochondrial disorders can be caused by 
single deficiency of a specific complex, due to a defect in one of the subunits or 
assembly factor failure (Sugiana et al., 2008). In contrast, multiple deficiencies, 
affecting more than one of the complexes are often induced by mutations in mtDNA, or 
nuclear factors maintaining its expression (Shutt and Shadel, 2010, Rötig, 2011, 
Nicholls et al., 2013, Schon et al., 2012). Clinical presentation of OXPHOS impairment 
can include developmental regression, dystonia (neurological movement disorder), 
failure to thrive, ataxia and nystagmus (involuntary eye movement) (Koopman et al., 
2012) and commonly display neuromuscular defects. 
 
1.2    Mitochondrial DNA expression. 
1.2.1 The human mitochondrial genome. 
The 16.6 kilobase mitochondrial genome of humans encodes 13 subunits of the 
OXPHOS system, as well as 22 mitochondrial tRNAs and 2 mt-rRNAs that are crucial 
in translation mt-mRNA (Anderson et al., 1981). It lacks introns and the only long non-
coding region of the genome (1.1 kilobase), the D-loop, contains the majority of the 
control elements of transcription and replication (Taanman, 1999). 
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Figure 1.4. Human mitochondrial DNA map. 
The map depicts the positions of the 37 mitochondrial genes; 13 of which encodes polypeptide 
subunits of Complex I (red; ND1, ND2, ND3, ND4, ND4L, ND5, ND6), Complex III (orange; 
Cyt b), Complex IV (purple; COXI, COXII, COXIII) and Complex V (yellow; ATP6, ATP8) 
located on heavy DNA strand apart from ND6 based on light strand. 2 mt-rRNA (12S and 16S) 
species and 22 mt-tRNAs. OL and OH are the origins of heavy and light strand replication, 
respectively. HSP and LSP are the promoters of transcription for heavy and light chain DNA. 
Non-coding regions are indicated in grey, mt-tRNAs in dark blue. (Taken from Schon et al., 
2012). 
 
The mtDNA can be easly described as compact as it does not contain introns but 
harbours several overlapping genes and incomplete termination codons. Moreover, the 
mtDNA is not a diploid like nuclear DNA but a multicopy genome. Most human 
mitochondria accommodate approximately ten copies of maternally inherited mtDNA 
(Phillips et al., 2014), although the copy number depends on the cell type and demand 
for energy (Schon et al., 2012). A cell contains hundreds of mitochondria and 
depending on the tissue 500-10,000 mtDNA molecules. An exception is mature oocytes 
that have between 100,000 to 600,000 mtDNA copies. As mtDNA resides in the 
mitochondrial matrix in close proximity to the high concentration of reactive oxygen 
species (ROS) it is prone to damage-induced mutations that can remain and potentially 
propagate (Phillips et al., 2014). Since cells contain multiple mitochondrial genomes, if 
a mutation is present, it is possible to have a heterogeneous set of mtDNA in a cell, 
tissue or even organelle, a condition named heteroplasmy. The opposite is homoplasmy, 
where all mtDNA molecules are identical. 
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Heteroplasmy can be inherited by the fetus from a heteroplasmic mother, but the 
mutation load passed to the offspring depends on the mitochondrial bottleneck (Smeets, 
2013). The latter depends on clonal proliferation of mtDNA in the developing oocyte 
and mtDNA segregation among the cells of blastocyst (Poulton et al., 2010). 
Heteroplasmy can also be a result of somatic mutations contributing to the ageing 
process and degenerative diseases of ageing such as cancer (Ames et al., 1993, Lee et 
al., 2010). 
 
1.2.1.1. Replication of mtDNA. 
Mitochondrial DNA is organized in protein-rich structures called nucleoids that have 
been shown to be sites of replication (Spelbrink, 2009, Gilkerson et al., 2013). 
Strikingly, it has been reported recently that mitochondria in a single cell are organized 
in populations that differ in DNA processing activities like initiation of replication or 
the relative amount of transcripts expression (Chatre and Ricchetti, 2013). Current 
knowledge of the mitochondrial replication system is still incomplete and needs far 
more investigation in order to draw clear mechanistic schemes of this process. There are 
at least two major patterns of replication proposed (reviewed in Stumpf and Copeland, 
2011). First, the asynchronous strand displacement model, proposes that replication at 
OriH is initiated by transcription at the light strand promoter (LSP) producing a 
processed RNA primer, which is extended by mitochondrial DNA polymerase γ 
(POLG). When approximately two thirds of H strand replication is complete, the 
replication forks triggers synthesis of L-strand from OL in the opposite direction, by 
unfolding it to the single-stranded form (Xu and Clayton, 1996, Lee and Clayton, 1996). 
Second, the coupled replication model based on analysis of partially nuclease digested 
mtDNA by 2D gel electrophoresis, proposes the ribosubstitution pattern in coupled 
leading and lagging strand replication (Holt et al., 2000, Yang et al., 2002). In this 
model nascent L chains of mtDNA contain ribonucleotides patches, removed during the 
maturation step and converted to DNA. In contrast, the H strand contain only scattered 
ribonucleotides (Yang et al., 2002). The same research group in their next publication 
postulates also, that replication originates from multiple sites located in MTCYB, 
MTND5 and MTND6 genes. The replication fork arrests near the OH, and restricts 
replication to one direction only (Bowmaker et al., 2003). Recently, the strand-
displacement model has been supported with new evidence obtained by in vivo 
saturation mutagenesis indicating that OL is indispensable for mtDNA replication in the 
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mouse (Wanrooij et al., 2012). Moreover the biochemical and bioinformatic data 
presented in the report show that OL is conserved in vertebrates. 
Despite the lack of a final picture of how mitochondrial DNA replication 
proceeds, a few of the proteins taking part in this process have been identified and 
probably a lot more awaits description. Mitochondrial transcription factor (TFAM), 
mitochondrial single-stranded DNA binding protein (mtSSB), Twinkle helicase and 
POLG have been shown to colocalize in nucleoids (Garrido et al., 2003). Very recently 
it has been published that Twinkle helicase is firmly associated with IM, where it 
transiently interacts with mtDNA to facilitate replication and that nucleoids have 
dynamic composition and activity (Rajala et al., 2013).  
TFAM is a multifunctional protein taking part in the transcription initiation (Asin-
Cayuela and Gustafsson, 2007), packaging of mtDNA (Alam et al., 2003) and 
regulation of mtDNA copy number (Ekstrand et al., 2004). Overexpression of human 
TFAM in mice showed a slight increase in the steady state level of mtDNA, so it has 
been proposed as a main component of nucleoids wrapping and bending nucleotides 
chains; influencing the rate of replication (Ekstrand et al., 2004). Indeed, high-
resolution assessment with Chip-seq technique in HeLa cells revealed that TFAM binds 
to the whole mitochondrial genome (Wang et al., 2013), which confirms the recent 
super-resolution microscopy analysis of mitochondrial nucleoids (Kukat et al., 2011). 
Phosphorylation of TFAM within high-mobility-group box 1 (L-shaped three-helix 
domain that binds DNA in the minor groove) impairs its ability to bind mtDNA and 
triggers degradation by the Lon protease (Lu et al., 2012). Phosphorylation and 
proteolysis has been proposed to be a regulatory mechanism of TFAM function and 
abundance in mitochondria, which are essential in mtDNA maintenance and expression. 
Furthermore, TFAM dimerization increases mtDNA compaction by stimulating looping 
of the DNA (Ngo et al., 2014).   
POLG enzyme is a heterotrimer built of a 140 kDa catalytic subunit and two 
copies of a 55 kDa accessory subunit, which increases processivity. It has been reported, 
that POLG together with mtSSB and Twinkle proteins, are able to synthesise ssDNA of 
more than 15000 nt in vitro (Korhonen et al., 2004). Mutations in the POLG gene 
inhibiting its function have been identified in a subset of mitochondrial diseases 
(Stumpf et al., 2013). 
 
 
 
30 
 
1.2.2. Transcription of the mitochondrial genome. 
Maintenance and replication of mtDNA is of great importance for cell homeostasis. 
Mutations in POLG enzyme can cause many mitochondrially linked diseases (Milone 
and Massie, 2010, Cohen and Naviaux, 2010). The next step for the correct function of 
mitochondria is the expression of information coded in its genome. Transcription, 
delivers 11 mRNA species (as 2 are present as bicistronic RNA units: ATPase 8/6 and 
ND4L/ND4) to the mitoribosomes that contain two mt-rRNA molecules also transcribed 
from mtDNA, as are the tRNA species that are required for translation. The correct 
decoding of information prescribed by mtDNA and the processing of the resultant 
mtRNA is one of the main points of regulation in correct mitochondrial function 
(Mercer et al., 2011). 
Ten out of eleven mRNA containing transcripts and both rRNAs are transcribed 
from H strand DNA. Only MTND6 is decoded from the L strand. In contrast, tRNAs are 
quite evenly spread between both strands (Bonawitz et al., 2006). Promoters for heavy 
strand, HSP1 (H1) and HSP2 (H2) are located in close proximity, near the 5’end of 12S 
rRNA (Figure 1.4), but are differently regulated (Montoya et al., 1982). H2 promotes 
synthesis of a polycistronic molecule that covers almost the total H strand. Whereas, 
transcription initiated from H1 generates transcription units that harbour only two 
rRNAs and stops at a specific site in the tRNA
LEU
 (Asin-Cayuela and Gustafsson, 
2007). The existence of this mt-rRNA specific promoter has been much debated as has 
the termination function of mTERF. The generally accepted definitions are given here. 
This early termination of transcription from H1 is determined by a 34 kDa protein, 
mTERF1, binding to promoter-independent bidirectional termination site. The single 
promoter for the L strand is located in 7S DNA. Transcripts originating from HSP2 and 
LSP are transcribed in a polycistronic manner. These RNA transcription units are 
precursors that are processed to individual species where the extraction of tRNAs that 
flank most of the ORFs plays a major role (Ojala et al., 1981). This process takes place 
in the recently identified mitochondrial RNA granules (Jourdain et al., 2013). 
 
The final mechanism of transcription initiation is still not fully clarified. 
Recently published data, which will be addressed further in this subsection, suggest that 
the main proteins taking part in initiation are mitochondrial RNA polymerase 
(POLRMT), TFB2M and TFAM.  
Human POLRMT is a single subunit, phage-derived, 140 kDa enzyme, sharing 
common features with the bacteriophage T3, T7 and SP6 family of RNA polymerases. 
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It consists of two functional domains. The C-terminal region in eukaryotic and 
prokaryotic organisms retains high levels of conservation with the bacteriophage 
homologue, and it is the domain responsible for catalytic activity (Tiranti, 1997). The 
N-terminal domain, presenting lower similarity to bacteriophage RNA polymerases, is 
also less conserved in eukaryotes. In mammals it accommodates a PPR motif (Asin-
Cayuela and Gustafsson, 2007, (Ringel et al., 2011). This motif was originally identified 
in the plant kingdom, where it is a common motif in proteins that take part in RNA 
processing, editing and translation (Small and Peeters, 2000). 
In contrast to the yeast homologue, human POLRMT requires additional 
proteins in order to initiate the transcription process (Asin-Cayuela and Gustafsson, 
2007). The first of these is already mentioned TFAM, a high mobility group (HMG) 
family protein, which contains a 25 amino acid C-terminal tail crucial for DNA 
recognition (Dairaghi et al., 1995a). Removal of this tail does not affect unspecific 
binding ability to DNA. Its definite interaction upstream of transcription promoters is 
essential in the initiation stage (Dairaghi et al., 1995b). It has been proposed that TFAM 
can influence the structure of the promoter, which facilitates sequence-specific binding 
of the POLRMT/TFB2M complex at a start site for transcription (Gaspari et al., 2004). 
Mitochondrial TFB1 and TFB2 are the methyltransferase-related transcription 
factors (Falkenberg et al., 2002) that contain specific binding sites for S-adenosyl-L-
methionine, SAM, which acts as the methyl donor (McCulloch et al., 2002). These two 
proteins are homologues of the eubacterial RNA adenine dimethytransferase KsgA 
(Shutt, 2006, Cotney and Shadel, 2006), which introduces methyl groups in 
neighbouring adenine residues in the terminal stem-loop of 16S rRNA (helix 45). 
Although this modification is highly conserved in most metazoa, it is not significant for 
bacteria. The lack of methylation in E. coli 16S rRNA gives resistance to kasugamycin 
(Helser et al., 1971). Interestingly, this modification does not occur in mt-SSU rRNA of 
yeast, S. cerevisiae (Klootwijk et al., 1975) but it is present in human 12S mt-rRNA.  
Human mitochondrial TFB1 and 2 have both retained predicted 
methyltransferase ability (Cotney and Shadel, 2006), moreover it has been shown that 
both can bind POLRMT and activate transcription initiation in vitro (Cotney et al., 
2007). Further investigations of their functions in mitochondria clearly show that the 
first, TFB1M, is the primary methyltransferase influencing mitochondrial translation, 
metabolism and cell growth (Cotney et al., 2009,  Metodiev et al., 2009), whereas 
TFB2M is a main primary transcription factor (Shutt et al., 2010). 
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It is important to mention that all of the experimental approaches in investigating 
the initiation step of mitochondrial transcription, performed in vitro, failed to obtain 
RNA derived from the speculated HSP2 promoter, which might be due to additional 
involvement of as yet not described factors, or mismapped initiation start sites through 
methods that have now been refined and superseded. The HSP1 and 2 promoter sites 
will be discussed again later in the text. 
Experimental data published during the last few years concerning the process of 
transcription initiation, have presented so many opposing claims, that it is quite difficult 
to draw from these findings some consistent, even if not complete, picture. Shadel and 
colleagues showed stimulatory involvement of MRPL12 protein in LSP and HSP1 
transcription in vitro and an increase in the steady state levels of mitochondrial mRNAs; 
based on MTND2 and MTND6 in HeLa cells overexpressing FLAG-tagged MRPL12 
(Wang et al., 2007). In a later publication the same research group dismisses the 
necessity of any TFAM interaction with mtDNA in the process of promoter-dependent 
initiation from LSP and HSP1 and proposes instead the role of the activator for this 
protein (Shutt et al., 2010). In this study they use “a faithful, fully recombinant human 
mitochondrial transcription system with all proteins purified from E. coli”, in which the 
template for transcription is a linear DNA. 
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Figure 1.5. Representation of theoretical states of transcription initiation governed by 
the amount of mammalian TFAM interacting with mtDNA molecule. 
A. mtDNA associated with minimal amount of mtTFA (brown particle), demonstrates a basal 
level of transcription (indicated with arrows) from both promoters; HSP1 and LSP. B. Depicts 
mtTFA bound at the high-affinity LSP site where it preferentially stimulates transcription 
(thickness of the arrows refers to the level of transcription initiation). C. Higher amounts of 
mtTFA associated with mtDNA activate both promoters. D. Very high level of TFAM inhibits 
transcription. Image taken from Shutt et al., 2011. 
 
Interestingly, another research group published results presenting the ability of 
POLRMT to synthesize RNA in a promoter-independent manner on supercoiled circular 
double stranded DNA as a template in complex with TFB2M. The same capability was 
observed for transcription initiated from LSP promoter. Strikingly, in both cases TFAM 
presence was not required to obtain a strong signal from synthesised RNA in the in vitro 
reactions (Fukuoh et al., 2009). In the light of these findings Shadel and colleagues 
proposed a new model of transcription initiation, the schematic representation of which 
is shown in Figure 1.5, (Shutt et al., 2011).  
The dispute continued with the report from Temiakov and Gustafsson research 
group, which insists on a three factor (POLRMT, TFB2M and TFAM) dependent 
initiation of transcription in vitro, dismissing also stimulation of LSP transcription by 
MRPL12 and pointing out that TFB2M acts as an exclusive transcription stimulator in 
vitro (Litonin et al., 2010). Previous results showed this activity for both TFB1M and 
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TFB2M, although the latter had far greater activity (Falkenberg et al., 2002). In the next 
publication, Shadel and colleagues, present data that reinforces their previous 
publication, reporting a stimulatory effect of MRPL12 protein on promoter dependent 
and independent transcription in vitro (Surovtseva et al., 2011). Furthermore, they 
specify a pool of MRPL12 that is free and not bound to the mt-ribosome, as directly 
binding with POLRMT and distinct from complexes of the RNA polymerase/TFB2M. 
Interestingly, they also report that depletion of MRPL12 in HeLa cells causes a decrease 
in the steady state level of mitochondrial transcripts MTND1, MTND6, MTCO2, 12S 
and 16S. It is tempting to address the last finding and point out that northern blot 
analysis of mRNAs of MTND1 and MTCOI in immortalised, patient derived fibroblast 
with point mutation in MRPL12 gene, where free pool of this protein is undetectable in 
sucrose gradient fractions, did not show the same pattern. Indeed, in this report only 16S 
rRNA was modestly decreased to 68%, with 12S rRNA affected to a lesser extent 
(79.2%) (this thesis; Serre et al., 2013). The next publication regarding mitochondrial 
transcription machinery again addresses the requirement of TFAM in the initiation step, 
demonstrating its absolute necessity (Shi et al., 2012). The authors argue that the 
observations excluding TFAM from a core component of transcription initiation (Shutt 
et al., 2010) are due to incorrect experimental conditions, which allows DNA 
‘breathing’, such as low salt concentrations.   
The publications described above, although they do not draw the final 
mechanism of the transcription initiation step, definitely give an insight into the 
complicated mechanism of the human mitochondrial gene expression pathway. Clearly, 
the proteins described here, are only a few of those already reported, with many more 
still not identified. For example; recently TEFM protein, encoded by the C17orf42 gene 
was proposed as a significant factor in transcription elongation (Minczuk et al., 2011).  
 
1.2.3. Processing and maturation of mitochondrial RNA. 
Following completion of transcription, the three polycistronic primary transcripts 
(Montoya et al., 1983) are mostly processed into individual species by endonucleolytic 
cleavage of mt-tRNAs at their 5’ and 3’ends (Ojala et al., 1981) performed by RNase P 
(Holzmann et al., 2008) and RNase Z (ELAC2) (Brzezniak et al., 2011), respectively. 
Still, three of the mtORF junctions (MTND6-ncRNA, MTND5-MTCYB and RNA14-
MTCO3) that lack mt-tRNAs are not cleaved by RNase P/ Z (Brzezniak et al., 2011). 
Pentatricopeptide (PPR) RNA-binding protein, PTCD2 has been shown to take part in 
processing of MTND5-MTCYB (Xu et al., 2008). PPR motifs have been well 
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characterised in plants and take part in processing, editing and stability of transcripts in 
chloroplasts and mitochondria (Small and Peeters, 2000, Nakamura et al., 2012). 
Currently, six other mammalian mitochondrial PPR proteins have been characterised 
(reviewed in Lightowlers and Chrzanowska-Lightowlers, 2013).  
Recently, GRSF1 protein (first identified as cytosolic RNA binding protein with 
high affinity for G-rich sequences: Qian and Wilusz, 1994) has been reported to be 
required for the processing of MTND6-ncRNA and RNA14-MTCO3 precursors (Jourdain 
et al., 2013, Antonicka et al., 2013).  
Once mt-RNAs are processed to individual species they undergo 
posttranscriptional maturation and modification. The latter are important in their 
stability and function (Borowski et al., 2010). Free 3’ ends of mt-mRNAs, are 
polyadenylated by mitochondrial poly(A) polymerase, hmtPAP (Tomecki et al., 2004). 
The polyadenylation is necessary in seven transcripts to complete the UAA stop codon 
in the open reading frame by the addition of either one or two A residues. Further, a 
poly(A) extension of 50-60 nucleotides has been shown to influence stability of mt-
mRNAs (Nagaike et al., 2005, Wydro et al., 2010, Rorbach et al., 2011).  
A distinct difference between human mitochondrial mRNAs and those from the 
eukaryotic cytosol is that they are not 5’-capped and have no introns. In contrast to 
eubacterial mRNAs, mitochondrial RNA species lack Shine-Dalgarno sequences. Only, 
a limited 3’ oligoadenylation to mt-rRNAs and CCA addition to all 3’ends of mt-tRNAs 
has been reported (Gagliardi et al., 2004). Both RNA components of mitoribosome as 
well as tRNAs species require a number of base modifications (reviewed in Rorbach 
and Minczuk, 2012). 
 
 1.2.4. Turnover of mitochondrial RNA. 
The mechanism of mRNA degradation is still not well explored. Suv3 helicase has been 
reported as a decay regulator of correctly formed, mature mRNAs, aberrant transcripts 
and noncoding processing intermediates mostly originating from the L-strand transcripts 
(Szczesny et al., 2010). Another enzyme, polynucleotide phosphorylase (PNPase), 
which has both PAP and 3’ to 5’ phosphorolytic activities (uses phosphorolysis to 
degrade RNA), was suggested to take part in poly(A) tail removal and RNA turnover 
(Piwowarski et al., 2003). Curiously, subsequent studies of this protein showed its 
intermembrane space localisation (Chen et al., 2006) and a role in RNA transport into 
mitochondria has been postulated (Wang et al., 2010). The most recent publication, 
however, shows a subset of PNPase and Suv3 helicase in one complex, referred to by 
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the authors as a degradosome, which is co-localised in specific foci with RNA and 
nucleoids in the mitochondrial matrix (Borowski et al., 2013). Another protein, PDE12, 
was recently described as a 3’ to 5’ exoribonuclease. PDE12 (2’-phosphodiesterase) is 
located in the mitochondrial matrix and removes poly(A) tails from mRNA species in 
vitro and in vivo (Rorbach et al., 2011). Its overexpression depletes the poly(A) status of 
mt-mRNA, and has a transcript specific effect on stability. Finally, the first 
mitochondrial oligonuclease REXO2, capable of degrading short RNA species has been 
identified (Bruni et al., 2013). Intriguingly, it has dual localisation in mitochondria; it is 
found both in the intermembrane space and the matrix (Bruni et al., 2013). 
Disturbance of mt-RNA turnover deregulates mitochondrial functions as the 
above mentioned publications describe. Mitochondrial homeostasis strongly depends on 
balance between synthesis and stability/ degradation of RNA species. The keepers of 
this order are just emerging from the pool of more than 1000 proteins (Pagliarini et al., 
2008) involved in mitochondrial maintenance. Importantly, although originating from a 
common polycistronic RNA source, mitochondrial transcripts abundance varies 
significantly, which suggests involvement of complex posttranscriptional regulatory 
mechanisms (Mercer et al., 2011). On one pole can be placed proteins involved in the 
decay of RNA, on the other, protectors that guard these molecules from too early 
deterioration. 
 
1.2.5. Mitochondrial RNA binding proteins regulating mitochondrial RNA 
stability. 
Ten years ago, a number of unidentified proteins binding mitochondrial RNA were 
reported, ranging in molecular mass from 15 to 120 kDa, (Koc and Spremulli, 2003). 
Recently, a few of them have been described as factors playing significant roles in 
stability of mt-mRNAs and rRNAs. The first one, SLIRP (SRA – stem loop interacting 
RNA – binding protein) was characterised as crucial for OXPHOS function (Baughman 
et al., 2009). SLIRP is ~12 kDa protein containing one RNA recognition motif (RRM), 
and it is localized to mitochondria (Hatchell et al., 2006). Its depletion in immortalized 
human fibroblasts caused a global decrease in mt-mRNAs steady state levels, with the 
most affected being the bicistronic ND4/ND4L transcript, and mt-mRNAs encoding all 
three complex IV proteins. SLIRP has been reported to interact in high-molecular-
weight complexes with another RNA binding protein, LRPPRC (leucine-rich 
pentatricopeptide repeat motif containing protein) (Sasarman et al., 2010). The latter has 
16 PPR motifs and as the already mentioned PTCD2 (subsection 1.2.3.) belongs to the 
37 
 
family of mitochondrial PPR proteins (Sterky et al., 2010). Mutations in LRPPRC cause 
the French Canadian variant of Leigh syndrome (LSFC), which is usually fatal in an 
early onset neurodegenerative disease (Mootha et al., 2003). The majority of patients 
are homozygous for a single missense mutation changing A354 to V, leading to tissue-
specific decline in cytochrome c oxidase activity, which mostly affects brain and liver 
(Sasarman et al., 2010). Studies in fibroblasts, derived from the LSFC patients, show a 
decreased level of mutated LRPPRC that correlates with reduction in the levels of most 
mt-mRNAs, whilst rRNAs and tRNAs remain unchanged. This phenotype was 
reproduced in control cells depleted of LRPPRC with siRNA (Sasarman et al., 2010). 
Interestingly, maturation of primary transcripts was not affected, indicating involvement 
of this protein in the stability of processed mRNAs. Translation deficiency was most 
severe for mitochondrially encoded COX subunits, but further depletion of LRPPRC 
caused the global effect of deregulated assembly in all OXPHOS complexes containing 
polypeptide subunits produced in mitochondria, with all mRNAs severely decreased 
(Sasarman et al., 2010). Furthermore, the same research group confirmed co-
immunoprecipitation of LRPPRC with SLIRP and reported a decrease of the latter in 
LSFC patient fibroblasts. Cells that do not contain mtDNA, 143B rho
0
, and thus no mt-
mRNAs, show reduced level of both proteins but these are still able to remain in a 
complex (Sasarman et al., 2010). This last observation was challenged by another 
research group, which investigated further the functions of LRPPRC in a mouse model 
(Ruzzenente et al., 2011), proposing an RNA-dependent complex formation of both 
proteins. They propose that LRPPRC aggregates in the absence of RNA or interacts 
with another protein complex. Interestingly, they also show, using FLAG-tagged 
LRPPRC in complex with SLIRP, the presence of a wide spectrum of mt-mRNAs 
species in the immnuoprecipitated complexes. This is in contrast with the narrow 
substrate specificity described for plant PPR motifs (Nakamura et al., 2012). 
Furthermore, they also report an effect on polyadenylation, with only oligoadenylated 
mt-mRNAs present in its absence and a deregulation of translation. Studies in HeLa 
cells, also report a role for LRPPRC in mtPAP-catalyzed polyadenylation in vitro as 
well as providing a protective role for mt-mRNAs against PNPase mediated degradation 
when complexed with SLIRP (Chujo et al., 2012). 
 
A protein from the pool of mitochondrial RBPs that was reported to have RNA 
protective function is ERAL1. It is found in association with the small ribosomal 
subunit mt-SSU (Dennerlein et al., 2010). Crosslinking Immunoprecipitation (CLIP) 
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assay via the FLAG moiety was used to determine the ERAL1 binding on 12S-rRNA in 
vivo. CLIP analysis revealed that ERAL1 bound to defined region (Dennerlein et al., 
2010). The sequence mapped to 33 nucleotides that form part of helix 45, which is a 
stem-loop at the 3' terminus. The loop accommodates two dimethylated adenine 
residues (Seidel-Rogol et al., 2002). Hypermethylation of these residues was reported in 
patients with maternally inherited deafness (Cotney et al., 2009). Involvement of 
enhanced 12S rRNA methylation in loss of hearing was also investigated in a mouse 
model overexpressing TFB1M (Raimundo et al., 2012). This augmented modification 
was reported to cause ROS-dependent activation of AMP kinase and proapoptotic 
E2F1, nuclear transcription factor in patient-derived A1555G cells (Raimundo et al., 
2012). 
Depletion of ERAL1 in HEK293 cells caused severe decline in the nascent 12S 
rRNA steady state level (Dennerlein et al., 2010, Uchiumi et al., 2010). Interestingly, de 
novo translation appeared unaffected and steady state level of mt-mRNAs increased, 
although these observations are in contrast with another publication (Uchiumi et al., 
2010). Silencing of this protein caused growth arrest and induction of apoptosis (30% cf 
3% in controls) in cell population in a ROS-independent manner (Dennerlein et al., 
2010). 
This specific checkpoint in human mitoribosome biogenesis seems to play 
significant role in cell functionality, which is able to trigger programed death through 
two opposite pathways; ROS-dependent and independent. These recent findings show 
how complicated is the dependence between the cell and mitochondrion. Although this 
organelle contains a very minimalistic genome, somehow this limited information and 
its expression pathway is able to influence the host cell to a great extent. 
 
1.2.6.   The mitoribosome – a tool for translation. 
1.2.6.1. Structure of mammalian mitoribosome.  
The final stage of decoding mitochondrial genes and translating them from mt-mRNA 
ribonucleotides to polypeptides chains requires purpose-build machinery in the form of 
the mitoribosome. Through the evolutionary pathway, this highly organised structure 
has developed differently in different organisms. Here I describe the mammalian 
machinery that has unique features by which it differs from cytosolic ribosomes and 
although it shares some similarities of prokaryotic origin, the mammalian mitoribosome 
has its own exclusive structural and functional character. 
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The presence of mitoribosomes was first reported in rat liver (McLean et al., 
1958) but mammalian mitoribosomal particles were only isolated 10 years later 
(O’Brien and Kalf, 1967). The characterisation of mitoribosomes from different 
organisms showed their divergent structure and size, with sedimentation values ranging 
from 55S to 80S (Kitakawa and Isono, 1991). The mammalian ribosome (55S) is 
composed of two subunits; small 28S (mt-SSU) and large 39S (mt-LSU) (Figure 1.6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Cryo-EM structure of the bovine mitoribosome (55S) obtained at 13.5 Å 
resolution. Various features are indicated as follows, 12S rRNA is indicated in orange, 16S 
rRNA in purple, proteins in the SSU in yellow, LSU in blue. CP, central protuberance; L1, L1 
protein side of LSU; hd, head of the SSU; p, platform side of the SSU; mgt, mRNA-entry gate. 
The image was taken from Sharma et al., 2003. 
 
Each subunit includes an rRNA particle of mitochondrial origin and a set of 
proteins coded by the nuclear genome, produced in cytosol and imported to the 
mitochondrial matrix. The unique aspect of the mammalian mitoribosome starts with its 
weight ratio of RNA to protein content which is ~30%: 70%. This is in striking contrast 
to their eukaryotic cytosolic counterparts, which are built of ~60% RNA and eubacterial 
ribosomes, which contain 67% RNA (Mears et al., 2006, Koc et al., 2010). The small 
and large subunits of the mammalian mitoribosome are connected by 15 bridges. Nine 
of these contacts are distinct to the mitoribosome and the interactions are believed to be 
mainly via protein: protein or protein: RNA. Bacterial 70S particles by contrast are all 
RNA-RNA bridges (Koc et al., 2010). 
Mammalian 12S (950 nt) and 16S (1560 nt) rRNA of the small and large subunit 
respectively are dramatically shortened in comparison with the eubacterial 16S (1542 
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nt) and 23S (2904 nt) rRNAs. Alignment of the secondary structure of mammalian 
rRNAs with the bacterial counterparts shows precise deletion of specific helices and 
shortening of others, with the anti-Shine-Dalgarno sequence completely absent from the 
12S particle (Sharma et al., 2003). These reduced rRNA species influence the structure 
of the 55S, with it appearing to be highly porous in comparison with E. coli 70S. 
Interestingly, although the number of mitochondrial ribosomal proteins (MRPs) is 
increased and some that have eubacterial homologues are enlarged, many of them 
occupy new spatial positions in the mitoribosomes. These positions may potentially be 
compensating for missing rRNA segments, however they only occupy around 20% of 
space that is created by the relative loss of rRNA. In comparison, the subsequently 
obtained cryo-EM map of the protista (Leishmania tarantolae) mitoribosome shows 
more than 50% compensation by proteins (Sharma et al., 2009). 
A 13.5 Å resolution structure of highly purified bovine 55S mitoribosome 
obtained by cryoelectron microscopy revealed positions of many mitoribosomal 
proteins, coating almost entirely the rRNA molecules, possibly creating a shield against 
reactive oxygen species (Sharma et al., 2003). 
Twenty nine MRPs are located in the SSU of which 14 are homologues of 
eubacterial ribosomal proteins and 15 are ‘new’ specific mitoribosomal proteins. The 
small ribosomal subunit has a characteristic structure divided into three distinct parts 
named the body, head and platform. The mt-SSU accommodates the mRNA entry site, 
which in the mammalian ribosome has a distinctive triangular, possibly highly dynamic 
gate-like structure, built entirely of MRPs. These proteins cover part of the gate and 
may play a role in recruitment of the leaderless mRNAs to the mt-SSU (Agrawal and 
Sharma, 2012). A face of the small ribosomal subunit of the 55S also contains the A-
site. This decoding site of the mitoribosome accommodates conserved residues on the 
12S rRNA interacting with incoming tRNA species. These A-site retained contacts 
manifest similarities with the prokaryotic ribosome in the selection process of the 
tRNAs (Mears et al., 2006). The same conservation of rRNA segments was reported for 
peptide-bond formation (P) site on the 39S subunit. Interestingly, the interaction 
between tRNAs located in the P-site and the mitoribosome is strong enough to withhold 
several purification steps through sucrose gradients, as deacylated mt-tRNA still 
occupies the P site following purification. The most mysterious aspect of the 
mitoribosomal structure is the E-site, which in its eubacterial counterparts binds a de-
aminoacylated tRNA before it exits the ribosome. The mammalian 55S has lost 14 of 
the 38 potential sites of contact with tRNA that are present in prokaryotic 70S (Mears et 
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al., 2006). This finding together with inability to detect E-site-bound tRNA on the 
mammalian ribosome indicates its probable absence or significant alteration (Koc et al., 
2010).  
The LSU accommodates at least 50 proteins; 28 of them are characterised as 
eubacterial homologues (Koc et al., 2001) and 22 are specific to the mammalian 
mitoribosome. Only five or six of the eubacterial ribosomal proteins do not have 
equivalents in the mammalian 55S. Two of these, L5 and L25 are positioned in the 
central protuberance (CP) of the bacterial LSU and interact with 5S rRNA (Figure 1.7), 
which is considered as absent from mammalian mitoribosome. Depletion of L5 protein 
in E. coli causes accumulation of a 45S ribosomal LSU, which lacks the majority of the 
CP elements (5S rRNA and proteins L5, L16, L18, L25, L27, L31, L33 and L35) 
(Korepanov et al., 2012) and is unable to associate with SSU. Both L5 and 5S rRNA are 
proposed to play a role in the inter-subunit bridges between the 30S and the 50S central 
protuberance (Zhang et al., 2011). L5 protein is conserved in eubacteria, archaea and 
eukaryote ribosomes (Wool et al., 1995) and it has been shown to be crucial for the 
survival of E. coli (Korepanov et al., 2007). Bacterial L5 protein and 5S rRNA interacts 
with S13, also absent in mammalian mt-SSU. Another protein, L31 located in close 
proximity to 5S rRNA in bacteria also lacks a homologue in mammalian mt-LSU.  
 
Figure 1.7. Structural model of E. coli central protuberance (CP). Bacterial ribosomal 
proteins (L5, L16, L18, L25, L27, L30, L33, L35), 5S rRNA and helices of 23S rRNA (H38, 
H39, H83-87) are demonstrated. Image taken from Korepanov et al., 2012.  
 
Although cryo-EM structure of the bovine mitochondrial LSU is lacking a 5S 
rRNA particle, the central protuberance itself, which in bacteria contains the 5S rRNA, 
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is ~2-fold larger in the mitoribosome (Mears et al., 2006). Interestingly, it is partially 
replaced by MRPs. Moreover, a handle-like structure is noticeable in the cryo-EM 
model, connecting the central protuberance to the body of the LSU, possibly taking over 
some of the 5S rRNA role, present in cytosolic and prokaryote ribosomes.  
Whilst compiling this introduction, a new high resolution structure of the 
porcine mitoribosomal LSU was reported (Greber et al., 2013). This three-dimensional 
structure of the mt-LSU of the porcine mitoribosome determined by cryoelectron 
microscopy at 4.9 Å resolution reveals an additional RNA density at the central 
protuberance (CP), which resembles domain β of the eubacterial 5S rRNA (Greber et 
al., 2013). Still, the observed RNA density does not account for the full length 5S rRNA 
and does not reach to the main body of the 39S subunit. Instead a long α-helical protein 
density corresponding to mitoribosome specific MRPL52 protein connects the 
mitoribosomal central protuberance to the subunit body (Figure 1.8). It is important to 
mention another very recent publication presenting the structure of yeast mitochondrial 
large subunit obtained by single-particle cryo-electron microscopy at 3.2 Å resolution 
(Amunts et al., 2014). The CP of yeast 54S lacks 5S rRNA, is extensively remodelled 
with mitochondria specific proteins, the extensions of the five bacterial homologues, 
and RNA expansion clusters. Overall, in spite of the 5S rRNA absence, the yeast CP 
tripled the volume of the bacterial one. 
 
Figure 1.8. Structure of 39S mitoribosomal subunit with positioned unidentified second 
rRNA molecule and MRPL52 protein. Unidentified RNA (dark blue), MRPL38 protein 
(purple) positioned at the central protuberance, MRPL52 (gold) connecting central protuberance 
with the body of mt-LSU. Image taken from Greber et al., 2013. 
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The large subunit of bovine mitoribosome has three distinct structural units 
extending from the body; L1 stalk, L7/L12 stalk and the above mentioned central 
protuberance, which all are larger than their eubacterial homologues (Mears et al., 2006, 
Greber et al., 2013) (Figure 1.9). Most of the outer surface of bovine mt-LSU is covered 
with mitochondria specific MRPs.  
 
 
Their main mass is located in the central protuberance, mostly on the solvent side and in 
the lower portion of the body (Mears et al., 2006, Greber et al., 2013) (Figure 1.9). The 
cryo-EM map of 39S was updated with identified positions of mitoribosome-specific 
proteins MRPL38, mentioned already MRPL52, MRPL49 and ICT1 located at the CP 
(Greber et al., 2013).   
 
The most distinctive characteristic of mitochondrial LSU is the polypeptide exit 
tunnel. It has two openings on the solvent side. The first is similar to the conventional 
polypeptide exit site (PES) (Nissen et al., 2000). The second, around 25 Å ahead of the 
PES, has been called the polypeptide-accessible site (PAS). It arose from the loss of 
significant portion of domains I and III in the mt-LSU rRNA. It has been postulated that 
both of these exits can be functional and some of the nascent polypeptide chains emerge 
from the PAS opening. In general the presence of two exit sites is seen as an element of 
the ribosome that possibly allows monitoring of translation and inserting nascent 
polypeptides to specific locations in the IM (Koc et al., 2010). Moreover, hypothetical 
models have been proposed of the mammalian mitoribosome interplaying with the 
mitochondrial inner membrane based on the newest findings (Agrawal and Sharma, 
2012). Recently, a few proteins have been found to take part in coupling mitochondrial 
Figure 1.9. Cryo-EM structure of 
the porcine 39S mitoribosomal 
subunit obtained in a 4.9 Å 
resolution. Conserved elements of 39S 
are presented in blue, mitoribosome-
specific in red. L7/L12, L7/L12 stalk 
base; ; L1, L1 stalk; CP, central 
protuberance; PAS, polypeptide 
accessible site; PES, polypeptide exit 
site. Image taken from Greber et al., 
2013. 
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translation with assembly of respiratory complexes. Oxa1L was characterised as an 
integral inner membrane protein, in human mitochondria (Stiburek et al., 2007). Its 
depletion in HEK293 cells caused deregulation of F1Fo-ATP synthase and NADH: 
ubiquinone oxidoreductase biogenesis. The C-terminal ~100-amino acid tail of Oxa1L, 
which is exposed to the mitochondrial matrix was cross-linked with several proteins of 
the mitochondrial LSU (Haque et al., 2010). Intriguingly, none of these proteins belong 
to the conserved components of the conventional PES. In yeasts another inner 
membrane protein, Mba1, was defined as a ribosome receptor collaborating with the C-
terminal Oxa1 (yeast homologue of mammalian Oxa1L) tail in coordinating the 
insertion of nascent polypeptide species to the IM (Ott et al., 2006). Recently, new data 
were published concerning the role of two proteins, ObgH1 and Mtg1 in human 
mitochondria. Both were postulated to bind the mitochondrial inner membrane and 
associate with the mt-LSU and possibly play a role in correct insertion of mitochondrial 
subunits into OXPHOS complexes (Kotani et al., 2013). The most recent cryo-EM map 
of 39S again reveals more information about the structure of the PES, presenting new 
layer of proteins MRPL39, MRPL44, MRPL45 positioned on top of the conserved 
proteins surrounding the conventional polypeptide exit site (Greber et al., 2013). 
MRPL45 has been also proposed to take part in the interaction of mitoribosomes with 
the mitochondrial inner membrane.  
Features of the mammalian mitoribosome described above clearly show its 
divergence in comparison with cytosolic or eubacterial ribosomes. The unique aspect of 
the 55S complex manifests in a reversed RNA: protein ratio, a porous structure, 
enriched with new protein masses and specific appearance of an mRNA entry site and 
polypeptide exit tunnel. All of these characteristics evolved in order to create a highly 
specialised machinery, producing exclusively hydrophobic membrane proteins, 
responding to energy demands from the cell but also sensitive to intraorganellar 
homeostasis requirements. It can be easily hypothesised that the process of ribosome 
assembly must be complex and tightly regulated, considering the dual source of 
molecules that build it. 
 
1.2.6.2. Biogenesis of mitoribosome.  
Unfortunately, current knowledge about the assembly of the mitochondrial ribosome is 
poor. In yeast there are three G-proteins identified; two of them, Mtg1 (Barrientos et al., 
2003) and Mtg2 (Datta et al., 2005) are implicated in assembly of the LSU. One, Mtg3 
takes part in assembly of the SSU (Paul et al., 2012).   
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Also, in human, only a few proteins have been reported to take part in biogenesis 
of the mitoribosome. C7orf30 was described as an mt-LSU protein, as its depletion 
causes an impairment of mitochondrial translation (Wanschers et al., 2012), and 
abnormal assembly of mt-LSU, which leads to a decrease in monosome formation 
(Rorbach et al., 2012). Another protein C4orf14 (or NOA1), containing a highly 
conserved GTPase domain, has been reported to take part in assembly of the mt-SSU 
and was found associated with mitochondrial nucleoids (He et al., 2012). It has been 
proposed to participate in maturation of the small subunit and maintenance of mtDNA. 
Intriguingly, C4orf14 apart from interacting with proteins of mt-SSU and mtDNA 
binding proteins, also associates with MRPL12, which independently from being part of 
mt-LSU and fully assembled monosome, interacts with POLRMT, influencing the rate 
of transcription (Wang et al., 2007).  
ERAL1 is a protein that belongs to the family of GTP-binding proteins and has 
been reported to be an RNA chaperone as it directly binds with 12S rRNA (Dennerlein 
et al., 2010) and hence associates transiently with the mt-SSU. As already mentioned, 
the interaction site with 12S rRNA includes two dimethylated adenines. This post-
transcriptional modification is believed to be introduced into the 12S rRNA by TFB1M, 
which in organ specific depletion in mice has been shown to lead to impaired assembly 
of the monosome (Metodiev et al., 2009).   
Recently, a new publication has arisen, proposing a transcription-independent function 
of POLRMT in complex with TFB1M (Surovtseva and Shadel, 2013). The authors, 
using HeLa cells expressing hemagglutinin-tagged (HA) mitochondrial RNA 
polymerase, show an independent interaction of this enzyme with TFB1M and TFB2. 
Moreover, co-association of POLRMT and TFB1M with the small ribosomal subunit 
even in the absence of transcription apparently causes a minor increase in 12S rRNA 
methylation at the 3’end stem-loop. On the basis of this finding, the group led by Shadel 
propose a new function for POLRMT, co-operating with TFB1M, as a guard of SSU 
maturation and assembly into mitochondrial ribosome (Surovtseva and Shadel, 2013). 
Finally, it has been published that a non-ribosomal protein hMTERF4 (belonging to the 
mitochondrial termination factor (MTERF) family) complexes with ribosomal RNA 
methyltransferase NSUN4, recruits it to the LSU and thus influences mitochondrial 
ribosomal assembly and translation (Cámara et al., 2011). A following publication 
presents that MTERF4 strongly stimulates the specificity of NSUN4 in in vitro 
methylation experiment (Yakubovskaya et al., 2012).  
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Apart from all the factors described here, which play a role in the biogenesis of 
the mammalian mitoribosome as well as many more still awaiting identification, it has 
become clear that post-translational modifications of MRPs including phosphorylation 
and acetylation are of significant importance for translational regulation (Miller et al., 
2009, Koc and Koc, 2012). The modifications of ribosomal proteins in mitochondria 
and eubacteria are very well conserved and located in the regions essential for ribosome 
function, like L1 and L7/L12 stalks or near the sarcin-ricin loop (SRL) in the ribosomal 
RNAs. These alterations are thought to modulate various steps of protein synthesis, by 
affecting mt-mRNA interactions with mt-tRNA and translation factors binding to the 
mitochondrial ribosome. For example, phosphorylation of mitochondrial ribosomal 
proteins was proposed to inhibit the synthesis of the 13 mitochondrial subunits of 
OXPHOS system (Miller et al., 2009). The same was reported for NAD
+ 
dependent 
deacetylation of translational machinery components (Koc and Koc, 2012). 
 
1.2.6.3. Translation process in mitochondria.  
Although, research of the last 10 years has given an insight into the mitochondrial 
translation machinery, this system is still far from being well described and understood. 
Despite some striking similarities with bacterial counterparts, mammalian 
mitoribosomes have developed a range of unique features driven by evolutionary 
adaptations to cope with high demand for energy provision requiring precise regulation. 
Unfortunately, the mitochondrial research field still lacks techniques that allow the 
genetic manipulation of the mitochondrial genome and there is no in vitro system 
capable of synthesizing mitochondrial polypeptides, so the basic model of this process 
is copied from studies in bacteria supported with some mitochondria-specific 
observations. The translation process is divided into four major steps; initiation, 
elongation, termination and recycling. The first requires two mitochondrial initiation 
factors in vitro; IF2mt (Liao and Spremulli, 1990) and IF3mt (Koc and Spremulli, 2002). 
These proteins are essential in the initiation complex assembly, consisting of the 55S 
ribosome with fMet-tRNA
met
 located at the AUG start codon of mt-mRNA in the 
mitoribosomal P-site (Christian and Spremulli, 2010). It is important to mention that 
both of these factors are orthologous to bacterial IF2 and IF3 but there is no identified 
mitochondrial orthologue of prokaryotic IF1 (Spremulli et al., 2004). In the proposed 
model of initiation, IF3 assures that the mt-SSU and mt-LSU remains dissociated, 
preventing 55S formation. IF2-GTP stimulates binding of fMet-tRNA
met
 to the SSU 
followed by sequence - independent complex formation between 28S and a mt-mRNA 
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(Liao and Spremulli, 1989). Interestingly, the interaction between mt-SSU and mRNA 
does not require any additional factors, unlike the prokaryotic and cytosolic systems 
(Smits et al., 2010). Moreover, the leaderless nature of mt-mRNAs is essential in 
initiation complex formation, suggesting that processing of the polycistronic 
mitochondrial transcripts has to occur before translation can initiate (Christian and 
Spremulli, 2010).  
The polypeptide chain elongation step in mammalian mitochondria has more 
conserved features than either the initiation or termination stages in comparison to 
prokaryotes (Agirrezabala and Frank, 2009, Woriax et al., 1997). It requires the 55S 
complex to be associated with mt-mRNA and an fMet-tRNA
met
 located in the P site. 
Then GTP-bound elongation factor Tu (EF-Tumt) associates with aminoacyl-tRNA. This 
enters the A-site of mitoribosome. Positive recognition of a correct codon-anticodon 
match by the ribosome triggers hydrolysis of GTP, which frees EF-Tu. Elongation 
factor Ts (EF-Tsmt) reactivates EF-Tu-GDP by promoting the exchange of GDP to GTP. 
Peptide bond formation is catalysed by the mitoribosome itself, leaving a deacylated 
tRNA in the P-site and a peptidyl-tRNA enriched by one amino acid in the A-site. Next, 
mitochondrial elongation factor G1 (EF-G1mt) catalyses the removal of the deacylated 
tRNA from the P-site and the relocation of the peptidyl-tRNA from the A-site to the P-
site. As mentioned before, there is apparently no E-site identified in the cryo-EM 
structure of the bovine mitochondrial ribosome, so the exact mechanism of how the 
deacylated tRNA leaves the 55S complex is unknown (Sharma et al., 2003).  
The next step of translation, termination, starts when a stop codon either UAA or 
UAG is detected in the A-site (Christian and Spremulli, 2012). In human mitochondria 
two reading frames are followed by either an AGA or AGG triplet, each of which would 
code for arginine in the standard genetic code. In the mitochondrion, however, there are 
no tRNAs or proteins that recognise these triplets and so they remain unassigned. A -1 
frameshift is promoted, in part by the 3’ structure of the bound mt-mRNA, which 
creates a classical UAG in the A-site (Temperley et al., 2010a). Both the UAA and 
UAG stop codons are recognized by the release factor mtRF1a (Soleimanpour-Lichaei 
et al., 2007), which binds in the A-site of the mitoribosome and through the GGQ motif, 
causes hydrolysis of the ester bond between the nascent polypeptide chain and the mt-
tRNA (Lightowlers and Chrzanowska-Lightowlers, 2010). Three other proteins (mtRF1, 
C12orf65, ICT1) that contain GGQ motifs have been identified, and are classified as 
mitochondrial release factor family members and have been shown by my host lab to be 
localized to mitochondria (Antonicka et al., 2010, Richter et al., 2010b). The function of 
48 
 
mtRF1 is still unknown. Interestingly, the other two mt-RF family members lack the 
regions involved in codon recognition (Richter et al., 2010a). ICT1 in contrast to other 
family members is an integral member of the mitoribosome in the LSU (Richter et al., 
2010b). It has been proposed that it is a ribosome-dependent, codon-independent, 
peptidyl-tRNA hydrolase with activity that can play a role in rescuing stalled ribosomes. 
A quality control rescue function was also suggested for C12orf65 protein by other 
groups (Antonicka et al., 2010, Kogure et al., 2012).  
After departure of synthesized proteins from the mitoribosome, two recycling 
factors RRF1 (Rorbach et al., 2008) and RRF2 (Tsuboi et al., 2009,Christian et al., 
2009) bind to the A-site and induce mitoribosome subunit dissociation and release of 
the tRNA and the mRNA. The hydrolysis of GTP is not required for dissociation of 
subunits but is necessary for the release of recycling factors from the LSU.    
 
1.2.7. Significance of ribosomal 5S in human mitochondria.  
The reviews concerning one of the most sophisticated machineries found in all types of 
cells, the ribosome, usually starts with the basic description of it addressing the 
heterogeneity in its composition and asymmetry in the structure. The sentence that 
always is present in summaries of established knowledge confirmed through analysis of 
the crystal structures of LSUs and complete ribosomes from different organisms inform 
that a 5S rRNA is present in virtually all ribosomes except mitoribosomes of some 
fungi, mammals and most protists (Barciszewska et al., 2001, Szymański et al., 2003). 
Interestingly, the function of eubacterial and eukaryotic cytosolic 5S rRNA despite 
years of research remains unclear. Published results on studies in bacteria localise 5S 
rRNA in the central protuberance of LSU, where it interacts with three proteins L5, L18 
(the bacterial homologue of eukaryotic L5) and L25. However, in eukaryota this 
interaction is limited only to L5 protein. Structural analyses of ribosomes from many 
species, positions 5S rRNA in the junction between small and large subunit, which 
allows it a broad interaction with many centres crucial for translation (Kiparisov et al., 
2005, Kouvela et al., 2007). Indeed, its absence causes a decline in protein synthesis in 
both bacterial and eukaryotic cells (Ciganda and Williams, 2011). Furthermore, the 
most recent publication, presenting cryo-EM structures of the final-stage assembly 
precursors of the bacterial LSU shows involvement of 5S rRNA in the maturation 
process of 50S (Li et al., 2013). In addition, data on silencing of TFIIIA in human 
U2OS cells reports an inhibition of 5S rRNA transcription and impairment of ribosome 
biogenesis (Donati et al., 2013).  
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The 5S rRNA is the smallest ribosomal RNA molecule, built of 120 nt (40 kDa), 
with a secondary (Figure 1.10) and tertiary structures largely preserved across 
phylogeny (Ciganda and Williams, 2011, Cheng et al., 2012).  
 
 
Figure 1.10. Secondary structure of human 5S rRNA.  Evolutionary changes in the 
sequence of the 5S rRNA are indicated with yellow, green and purple. Image taken from Cheng 
et al., 2012. 
 
Intriguingly, the 5S gene is present in a different number of tandem or multiple repeats 
spread throughout the genome. Recently, it has been shown that each mammalian 
species has a greatly conserved 5S rRNA type and many variable ones (Vierna et al., 
2013). In eukaryotic cells, 5S rRNA is synthesized by RNA polymerase III, is 
transported from the nucleus to the cytosol in a complex with TFIIIA (transcription 
factor), and then re-enters the nucleus in the complex with protein L5. It is the only 
reported RNA species that creates complexes with ribosomal proteins before 
incorporation into the ribosomes in prokaryotes and eukaryotes (Szymański et al., 
2003). Furthermore, it has been already reported that 5S rRNA plays roles outside the 
ribosome. The most recent publication, shows this small RNA particle in a complex 
with L5 and L11 protein implicated in p53 level regulation (Donati et al., 2013). This 
pre-ribosomal complex is redirected from assembly into nascent 60S ribosomes to 
Hdm2 inhibition, which activates p53, as a result of defective ribosome biogenesis. 
These intriguing data implicate 5S rRNA in very complicated and still elusive processes 
of carcinogenesis, as p53 is known as a tumour suppressor, which is lost or mutated in 
over 50% of all human tumours (Cairns and White, 1998). The role, if any, of 5S rRNA 
in mitoribosomes is even more mysterious. There are very limited data available 
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concerning the function of this molecule in mammalian mitochondria. As already 
mentioned it was not detected in a 13.5 Å resolution structure of bovine 55S obtained 
by cryoelectron microscopy (Sharma et al., 2003). However, this observation was 
challenged in a recent publication, showing its presence in mitoribosomes 
immunoprecipitated via either overexpressed FLAG tagged ICT1 or MRPS27 (Smirnov 
et al., 2011). The ratio of mitoribosomes to bound 5S rRNAs was reported as 1:1. This 
astonishing result needs further investigation as it is the first reported finding, standing 
against very strongly established dogma in mitochondrial research. There are no more 
publications supporting it directly, but there are at least a few that strongly suggest the 
presence of 5S rRNA in mammalian mitochondria. Two of the first reports shows the 
presence of this particle in stringently purified mitochondria and mitoplasts of bovine, 
chicken, rabbit, rat and human cells (Yoshionari et al., 1994, Magalhães et al., 1998). 
However, since the cytosolic ribosomes co-purify with mitochondria it is very difficult 
to eliminate contamination. It is important to underline, that the new mammalian 39S 
structure has an RNA fragment present that is not the 16S but has not been identified 
(Greber et al., 2013). 
 
Structural analysis of 5S rRNA suggests two distinct regions, α- and γ- domains 
as critical for its mitochondrial targeting in vitro, confirmed by decline of import in vivo 
(Smirnov et al., 2008). The same research group, point out two proteins, mitochondrial 
enzyme rhodanese and MRPL18, as involved in 5S rRNA transport into mammalian 
mitochondria (Smirnov et al., 2010, Smirnov et al., 2011). There are also two 
independent publications showing involvement of PNPase (polyribonucleotide 
nucleotidyltransferase) in mitochondrial RNA import. This protein has a 3’ to 5’ 
exoribonuclease and poly(A) polymerase activity. As mentioned before it has a dual 
location in mitochondria; inner membrane and matrix. PNPase has also been shown to 
enhance transport of RNase P RNA, 5S rRNA and MRP RNAs into the mammalian 
mitochondrial matrix (Wang et al., 2010). These results were reinforced with a recent 
report, describing two patients with homozygous missense mutation in the PNPase gene 
who presented with severe encephalomyopathy, choreoathetotic movements (irregular 
involuntary movements that may involve the face, neck, trunk, limbs or respiratory 
muscles) and respiratory chain deficiencies (Vedrenne et al., 2012). The analysis of 
patient 1 fibroblasts showed a reduction in 5S rRNA and MRP RNA import into 
mitochondria, and a decrease in translation. Overexpression of the wild type PNPase 
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cDNA enhanced 5S rRNA transfer to mitochondria and rescued the translation 
deficiency.  
 
Overall, the significance and functions of 5S rRNA in human cells is far from 
defined. Presented in this subsection publications clearly show how incomplete is our 
knowledge about this 120 nt RNA species especially in regard to its mitochondrial 
appearance. Although, few published findings suggest that 5S rRNA is a part of 
mitochondrial ribosome in human cells with the most recent cryo-EM structure of the 
porcine 39S at 4.9 Å resolution presenting additional density of unidentified short RNA 
fragment positioned in the CP, the only strong conclusion which can be made at this 
stage is that the 5S rRNA is present in human mitochondria. Beyond this conclusion 
there is not enough experimental evidence deciphering its exact location or functions.  
 
1.3 Aims of this study. 
As can be seen from the introduction, many of the processes regulating post 
transcriptional gene expression are still poorly characterised. My PhD project is focused 
on three proteins SLIRP, MRPL12 and RBFA to identify if they are involved, and if so 
what is their role, in different aspects of this regulation. During the course of my study I 
have undertaken numerous experimental approaches to investigate and define the 
precise functions of these proteins in mitochondrial gene expression.  
 
Regarding SLIRP, my project aimed to: 
 assess the ability of this protein to bind the mitochondrial RNA in vivo 
 identify interacting RNA species and  
 specify the location of binding.  
Further investigation was not undertaken due to publications that arose during my 
studies, describing SLIRP function in mt-mRNAs maintenance and turnover. 
 
The second part of my project was focused on one of the mitoribosomal proteins of the 
LSU, MRPL12. This protein is highly conserved throughout phylogeny, however, the 
role of MRPL12 in mitochondrial gene expression is still enigmatic. Available data 
suggest involvement of MRPL12 protein not only in the mitochondrial translation but 
also in modulation of the transcription process.  
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Immortalised fibroblasts from a patient harbouring a mutated form of MRPL12 caused 
by homozygous c.542C to T transition in exon 5 changing a highly conserved alanine 
into a valine were obtained from a collaborating laboratory and allowed me to study its 
function in human mitochondria. 
 
My experimental investigation aimed to establish: 
 the role of MRPL12 protein in mt-LSU and mitoribosome assembly  
 the influence of MRPL12 on the steady state level of mt-RNA species 
 the impact of MRPL12 on mitochondrial translation. 
 
The third part of my study was concentrated on RBFA. Preliminary data gathered in my 
host laboratory by Joanna Rorbach and Ricarda Richter identified RBFA as a 
mitochondrial protein interacting with the small subunit of the mitoribosome. The 
eubacterial orthologue of this protein also named RbfA is a cold shock protein, taking 
part in the maturation of the 5’ end of pre-16S rRNA. When associated with the 
bacterial small ribosomal subunit it interacts directly with numerous sections of 16S. 
Moreover some of these sections are binding sites of another protein Era, participating 
in maturation of the 3’end of pre-16S rRNA. Interestingly, bacterial cells lacking RbfA 
protein can be partially rescued by overexpression of Era. As I already mentioned in the 
introduction, the mitochondrial counterpart of Era; ERAL1 was investigated in my host 
laboratory. The CLIP assay analysis for ERAL1 protein that I performed clearly showed 
direct interaction with the 12S mt-rRNA 3’end.  
 
The experiments with RBFA that I have undertaken were designed to answer: 
 whether RBFA interacts directly with 12S mt-rRNA of SSU and if so what is the 
location of binding? 
 Can RBFA and ERAL1 reciprocally compensate for each other’s function 
following siRNA silencing in human cells? 
 what is the role of RBFA in the maturation and/ or assembly of mt-SSU and 
formation of the mitoribosomes? 
 
Each of the results chapters that follows reports the progress I made with respect to each 
of these sets of aims. 
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2.      Chapter 2: Materials and Methods. 
 
2.1    Cell culture.  
         2.1.1 Human cell lines used in the project: 
 HEK293T FLP-IN TRex (Invitrogen) 
 HEK293T inducibly expressing FLAG tagged SLIRP 
 HEK293T inducibly expressing FLAG tagged RBFA 
 HEK293T inducibly expressing FLAG tagged ERAL1 
 Immortalised Control skin fibroblasts 
 Immortalised Patient skin fibroblasts with point mutation in MRPL12 gene 
changing A181 to V in polypeptide chain. 
 
2.1.2 Cell culture maintenance. 
HEK293T cells and HEK293T expressing C-terminal FLAG tagged versions of SLIRP, 
RBFA and ERAL1 protein were grown in DMEM medium (Sigma D6429, 4500 mg/L 
glucose, 1 mM sodium pyruvate, 2.5 mM L-glutamine) supplemented with 10% FCS, 
non-essential amino acids (1x) and uridine (50 µg/ml). During every third passage cells 
were treated with Blasticidin
S
 (10 µg/ml final concentration) to retain the tetracycline 
repressor, and Hygromycin
B 
(100 µg/ml final concentration) to avoid growth of 
construct-free cells. Immortalised fibroblasts were grown in DMEM medium (Sigma, 
4500 mg/L glucose) supplemented with 10% FCS, 100IU Penicillin, 100 µg 
Streptomycin, non-essential amino acids (1x), 1 mM sodium pyruvate, 0.2 mM uridine. 
Cells were kept in a humidified Sanyo Incubator, at 37C with 5% CO2 and passaged 
twice per week at ~80% confluency. In order to remove cells from the surface of the 
flask HEK293T were incubated in 1mM EDTA/PBS for ~2 - 3 min at 37 C. 
Fibroblasts were harvested with 1x Trypsin (Sigma) in 1mM EDTA/PBS. After 
pelleting at 230 g (bench centrifuge) for 4 minutes, cells were resuspended in fresh 
media and for general maintenance 1/10 of HEK293T cells were transferred to a new 
flask containing 15ml of fresh media. Fibroblasts were split 1:6. 
 
2.1.3 Cells storage. 
Cells of ~ 80% confluence, grown in 75 cm
2
 flasks were stripped, pelleted and 
resuspended in ice-cold FCS. Equal volume of 20% DMSO in FCS was added drop-
wise to the cells suspension. Cells in 10% DMSO were kept on ice for ~5 min. Next 
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transferred to pre-cooled cryopreservation tubes. Placed in polystyrene container, 
overnight at -80C, and afterwards transferred to liquid nitrogen. 
 
2.1.4 Mycoplasma detection. 
Cells were kindly tested for Mycoplasma infection every 3 months by Mrs Debra Jones. 
MycoAlert® Mycoplasma Detection Kit (Lonza) was used following the 
manufacturer’s instruction. In case of an infection, cells were discarded or treated with 
Plasmocin following the manufacturer’s instruction. 
 
2.1.5 Cells counting. 
Cells counting were performed with haemocytometer; Hawksley, depth 0.1 mm, 
1/400mm
2
. Directly before pipetting cells suspension to microscope counting chamber, 
Trypan Blue (0.4% solution, Sigma) was added in ratio 1:1, in order to distinguish dead 
cells and eliminate them from counting pool. In order to estimate the number of cells in 
1 ml of medium, the average counted in 4 large squares was multiplied by 10
4
.  
 
2.1.6 Transfection of HEK293T cell lines using siRNA. 
HEK293T cell lines seeded in 6-well plates, 25 cm
2
 or 75 cm
2
 flasks (Corning) were 
reverse transfected with a final concentration of 33.3 nM siRNA, apart from RbfA 
siRNA for which 50 nM concentration was applied, using Lipofectamine RNAiMAX 
(Invitrogen). Lipofectamine (2 µl/ well, 4 µl/ 25 cm
2
, 12 µl/ 75 cm
2
 flasks) was mixed 
with siRNA in Opti-MEM® I+Glutatmax™I (Gibco) (250 µl/ well, 500 µl/ 25 cm
2
 flask, 
1.5 ml/ 75 cm
2
 flasks) and incubated for 10-20 min at RT. Next it was added to the cells 
suspended in growing medium (1.25 ml/ well, 2.5 ml/ 25 cm
2
, 7.5ml/ 75 cm
2
 flasks), 
described in 2.1.2. Cells were grown in the presence of siRNA for 72 hr and if required 
re-transfected with the same amount of siRNA and kept in the culture for additional 48-
72. All siRNAs were custom synthesised by Eurogentec and stored as 20 μM or 100 μM 
stocks in RNase free water at -20°C/-80˚C.  
 
Table 2.1.Sequences of siRNA used in transient transfections of HEK293T cell lines. 
Name of the siRNA Sequence (sense strand) 
si-RBFA-ORF A (481) 5’ GGA GCU GUA UGA CCU UAA C dTdT 3’ 
si-ERAL1-ORF1 5’ GUG UCC UGG UCA UGA ACA A dTdT 3’ 
si-non-targetting control 
(NT) 
siRNA negative control duplex OR-0030-NEG05 
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2.1.7 Stable Transfection of control and patient immortalized fibroblasts. 
Fibroblasts (20 000 per well) of 6-well plate were transfected with 2 µg of pcDNA3.1 
plasmid containing MRPL12 open reading frame, linearized with BsmI restriction 
enzyme (NEB), re-suspended in TE buffer. Transfection was performed using 
SuperFect® Transfection Reagent (Qiagen) according to the manufacturer protocol. 
The selection of cells was started after 72 hr with Geneticin G-418 Sulphate (400 µg/ml 
final concentration). During second attempt, transfection was repeated twice with a 4 hr 
interval. 
 
2.2    Bacterial culture and manipulations. 
              2.2.1 Bacterial strains and plasmids. 
Bacterial strains used in this study are:  
 for CLIP method, TOP10 Chemically Competent cells transfected with pCR®4-
TOPO
®
 (Invitrogen) 
 for generation of MRPL12 protein (antibody purification) E. coli expression 
strain Rosetta (DE3 cells, Novagen) 
 for amplification of pcDNA3.1 plasmid containing MRPL12 gene used in stable 
transfection of patient and control fibroblasts, bronze α-select chemically 
competent cells (Bioline). 
 
2.2.2 Transformation. 
Transformations of chemically competent bacterial cells were performed according to 
manufacturers’ protocols. 
 
2.2.3 Isolation of plasmid DNA and insert screening.  
Following transformation, Bioline α-select bacterial cells were seeded on selective agar 
plates (containing ampicillin 100µg/ml, LB with 2% agar) and grown overnight at 37°C. 
Single colonies were moved to 5 ml of LB medium (1% Bacto-tryptone, 0.5% yeast 
extract, 1% NaCl) with antibiotics and again grown overnight in the incubator at 37°C, 
200 rpm. Afterwards bacteria were harvested and plasmids were extracted with 
GeneJET
TM
 Plasmid Miniprep Kit (Fermentas). 
In each case 5 colonies transformed with pcDNA3.1 were sequenced as described in 
subsection 2.3.5. CLIP tags were analysed as described in 2.6.1. 
 
 
57 
 
2.3    DNA manipulation. 
2.3.1 DNA electrophoresis. 
DNA samples were mixed with loading dye (bromophenol blue, xylene cyanol FF, 3% 
(v/v) glycerol) and separated on agarose gels in 1x TAE buffer (40mM Tris acetate, 
1mM EDTA pH 8.0). Solution of ethidium bromide (0.5μg/ml final concentration) was 
added to dissolved agarose in 1xTAE buffer in order to visualise DNA with UV light, 
before casting the gel and electrophoresis in the 1xTAE running buffer. 
 
2.3.2 Measurement of nucleic acid concentration. 
The concentration of samples diluted in ddH2O or TE buffer was measured with Nano-
drop Spectrophotometer ND-1000, using a millimolar extinction coefficient of 33 for 
single stranded DNA and 50 for double stranded DNA and 40 for RNA. 
 
2.3.3 Polymerase Chain Reaction (PCR). 
All PCRs were performed with Taq DNA Polymerase (Thermo Scientific), Taq 
Polymerase (Fermentas) or KOD hotstart polymerase (Novagen). The latter was used as 
a proofreading polymerase where amplification of fragments for cloning was required. 
Reactions were performed in 25 to 50 µl volumes according to suppliers’ protocols 
unless otherwise specified in the subsections.  
 
2.3.4 PCR product purification. 
PCR products were purified either directly from PCR reaction (if there was single DNA 
product of the correct size when analysed by agarose gel electrophoresis) with 
QIAquick PCR Purification Kit (QIAGEN) or excised from 4% low melting agarose 
gels and extracted with phenol-chloroform, followed by ethanol precipitation (used in 
CLIP method; 2.6.1).  
 
2.3.5 DNA Sequencing. 
The MRPL12 gene sequence in pcDNA3.1 plasmid was determined with CMV Forward 
(5’CGC AAA TGG GCG GTA GGC GTG3’) and BGH Reverse (5’TAG AAG GCA 
CAG TCG AGG3’) primers, which have sites in the recipient vector. The detailed 
protocol of sample preparation for sequencing with Genetic Analyzer 3130xI (Applied 
Biosystems) is given in CLIP method subsection. 
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2.3.6 Restriction digest. 
Restriction enzymes used in this study are; EcoRI, Xho1 and BsmI (NEB). 
Digestion reactions were carried in 10 or 50 µl volumes and 1 or 10 µg of DNA 
respectively according to the suppliers’ protocols. 
 
2.4    RNA manipulations. 
2.4.1 Trizol extraction. 
Total RNA extractions from cell pellets were carried with TRIzol Reagent (Invitrogen) 
according to supplier protocol. TRIzol LS Reagent (Ambion) was used to extract RNA 
from sucrose gradient fractions.  
 
2.4.2 Northern blot. 
RNA samples (2-8 µg) extracted from cells or sucrose gradient fractions were prepared 
in total volume of 20 µl containing 1x MOPS, 35 % (v/v) formamide and 5.5 % (v/v) 
formaldehyde. Samples were incubated for 15 min at 55C. Ethidium bromide (0.1 μg/ 
μl final concentration) and RNA loading buffer (to 1x final; 10% (v/v) glycerol, 0.01% 
(w/v) bromophenol blue, 0.01% (w/v) xylene cyanol FF) were added before loading the 
samples on the 1.2% (w/v) denaturing agarose gel containing 1x MOPS and 0.9% 
formaldehyde. RNA was separated through the gel at 80 Volts (in 1x MOPS). After ~3 
hr electrophoresis, the separation was assessed by exposure to UV light, if separation 
was sufficient the gel was rinsed 3x in DEPC dH2O. The RNA was transferred to 
GeneScreen Plus membrane by capillary transfer overnight in 10x SSPE buffer and the 
efficiency of transfer assessed with the UV light. The membrane was rinsed in 2x SSPE 
and vacuum baked at 80°C for 2h followed by prehybridisation in 10ml of 50 % (v/v) 
formamide, 5x SSPE, 1% (w/v) SDS and 5x Denhardt’s solution for minimum 2 h at 
42°C.  
The radiolabeled probes were prepared with specific DNA fragments (50-100 ng) in 
total volume of 9 µl in DEPC ddH2O, denatured at 95°C, 4 min. After cooling on ice, 
DNA was mixed with random hexamers (3µl/sample; mix also contained 5x buffer, 
dATP, dGTP, dTTP), 2.5U Klenow DNA polymerase I (Promega) and 2 μl of 32P dCTP 
(~10-20 μCi, PerkinElmer NEG513H). After 1 hr incubation at 37°C, the probe was 
purified to remove free nucleotides on a NICK
TM
 Column, Sephadex
TM
 G50, DNA 
Grade (GE Healthcare). The activity of the probe in 400 µl of DEPC ddH2O was 
measured by a Cerenkov counter and minimum of 500,000 cps were added to 10 ml of 
hybridisation buffer. The incubation with the membrane was carried over-night at 42°C. 
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The membrane was washed twice with 20 ml of 2x SSPE in DEPC dH2O for 15 min at 
RT and once with 2x SSPE/2% SDS at 65°C. Next it was placed in SARAN Wrap and 
exposed to a screen in Phosphor-Imager cassette. Detection of signal was performed 
with a Storm PhosphorImager and analysed with Image-Quant software (Molecular 
Dynamics, GE Healthcare). If the membrane had to be re-probed, the signal was 
stripped by 3x washes in boiling 0.1x SSC for 15 min and once with 0.1x SSC/0.1% 
(w/v) SDS. New hybridisation buffer would be applied for at least 2 hr and required 
probe added. 
 
2.4.3 Reverse transcription. 
RNA obtained from TRIzol extractions was reverse transcribed to cDNA with Super 
Script VILO 
TM
 Mastermix (Invitrogen) according to the supplier’s protocol. Random 
hexamers were used in the 20 µl RT reactions, containing 100 ng of RNA.  
 
2.4.4 Real time PCR. 
1:100 or 1:1000 dilutions of cDNA were used in real time PCRs. Fast start DNA Master 
SYBR Green I - kit (Roche) and the Roche Lightcycler (capillary system) were used. 
All reactions were made up in 20 μl volume with the following components: 2 µl of the 
template (cDNA), ddH2O, forward and reverse primer (concentration given in Table 
2.2), MgCl2 (concentration dependent on pair of primers used, given in Table 2.2) and 
1µl of SYBR green mix (Roche). 
 
Table 2.2. Sequences of primers used in Real Time PCRs. 
Primer Sequence from 5’ to 3’ [MgCl2] Ta [Primer]  
12S forward ACA CTA CGA GCC ACA G  
3 mM 
 
59C 
 
1 µM 
12S reverse ACC TTG ACC TAA CGT C 
16S forward CCA ATT AAG AAA GCG TTC AAG  
4 mM 
 
57C 
 
0.5 µM  
16S reverse CAT GCC TGT GTT GGG TTG ACA 
5S forward GTC TAC GGC CAT ACC ACC CTG  
3 mM 
 
59C 
 
1 µM 
5S reverse AAA GCC TAC AGC ACC CGG TAT 
28S forward TCA TCA GAC CCC AGA AAA GG  
3 mM 
 
60C 
 
1 µM 
28S reverse GAT TCG GCA GGT GAC TTG TT 
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2.5    Protein manipulation. 
2.5.1 Isolation of mitochondria from human cell lines. 
Cells grown in 75 or 300 cm
2
 flasks were harvested at ~80% confluence, if required the 
cell lines with FLAG-tagged proteins were induced as indicated with either 1 µg/ml 
tetracycline (SLIRP and ERAL1) or 1 ng/ml doxycycline (RbfA) for 2-3 days. Pelleted 
cells were washed once with ice-cold Dulbecco’s PBS and re-suspended in 
homogenisation buffer (0.6 M Mannitol, 10 mM Tris; pH 7.4, 1 mM EGTA) adjusted 
with 1mM PMSF and 0.1% BSA. The homogenisation step was repeated three times, 
each time followed by centrifugation at 400g, 10 min, 4C in order to separate 
mitochondria from unbroken cells. Obtained supernatants containing mitochondria were 
centrifuged at 11000g, 10 min, 4C. Pelleted mitochondria were washed in 1 ml of 
homogenisation buffer (lacking BSA) and lysed (Sigma lysis buffer, FLAG-IP kit with 
EDTA-free Roche Protease Inhibitor Cocktail, and 1 mM PMSF, 10 mM MgCl2 and 
RNase inhibitor if required).  
For the Real Time PCR assessment of monosomes immunoprecipitated from cells that 
over-expressed FLAG-ICT1, a further treatment to more stringently purify 
mitochondria was applied. Around 100 µl of mitochondrial pellet (~2.5 mg proteins) 
was incubated in 1 ml of 1x homogenisation buffer supplemented with 10 mM MgCl2, 
1mM CaCl2 and 1.2 µl DNase I for 15 min on ice. After washing with 10 mM Tris-HCl; 
pH 7.4 mitoplasts were obtained by 30 min incubation (Thermomixer; 16C, 1000 rpm 
every 3 min for 15 sec) in 500 µl 10 mM Tris-HCl pH 7.4, adjusted with 10 mM MgCl2, 
1mM CaCl2 and Proteinase K; Invitrogen (5 µg/1 mg of proteins). Proteinase K was 
inactivated by addition of 1mM PMSF, mitoplasts were washed twice with 5 mM Tris-
HCl; pH 7.4 containing PMSF. Next, the pellet was re-suspended in 500 µl of 
homogenisation buffer (with 10 mM MgCl2, 1mM CaCl2) and treated with RNase A (5 
µl of 10 mg/ml stock) for 20 min in Thermomixer (the same program as described 
above). Afterwards, mitoplasts were washed once with 1 ml of 10 mM Tris-HCl; pH 7.4 
containing 10 mM EDTA, 1 mM PMSF and 5 µl SUPERase In and once with Tris 
without EDTA. Each incubation or wash was followed by centrifugation at 6000g, 4 
min, 4C. 
 
2.5.2 Preparation of cell and mitochondrial lysates. 
Harvested cells were pelleted and rinsed once with ice-cold PBS (tissue culture grade; 
Dulbecco’s A lacking Mg2+ and Ca2+). Cell and mitochondrial (obtained as described in 
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the subsection 2.5.1) pellets were re-suspended in lysis buffer from the FLAG 
Immunoprecipitation Kit (Sigma), adjusted according to requirements of a technique 
used and analysis performed, which are specified in subsections of methods. Cells or 
mitochondria were incubated in the buffer for 30 min, at 4C, on a rotating wheel. 
Obtained lysates were centrifuged for 10 min at 12000g, 4C (unless stated otherwise). 
Supernatants were used for further analysis.   
 
2.5.3 Protein concentration - Bradford Assay. 
Protein concentration was measured by Bradford Assay. 1μl of cell or mitochondrial 
lysate was added to 799 μl of ddH2O. Dilutions of BSA ranging from 0, 2, 5, 10, 15 to 
20 mg/ml were prepared in the same volume. 200 µl of Bradford Reagent (BioRad) was 
added to each sample and mixed. BSA standard samples were loaded in duplicate, the 
lysates four times in 200 µl aliquots onto 96 well-plate to be measured in Microplate 
Reader (Elx800) at the absorbance of 595 nm. 
 
2.5.4 SDS-PAGE. 
Proteins from mitochondria and cell lysates as well as fractions from sucrose gradient 
fractionation (as described) were mixed with loading buffer (1x final concentration: 
62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% Glycerol, 0.01% Bromophenol Blue and 50 
mM DTT) incubated at 95C, 3 min and separated on 10%, 12%, or 14% Tris-glycine 
SDS/PAGE, alongside Spectra Multicolour Broad Range Protein Ladder (Thermo 
Scientific). 
 If required for western blot analysis the proteins were transferred on to PVDF 
membranes (Millipore, activated with 100 % methanol) by wet transfer where the gel 
and membrane were assembled between Whatman paper and sponges in a cassette that 
was then placed in the TE22 Apparatus from Hoefer. The transfer was performed for 2 h 
in case of one gel or 2.5 hr (two gels) at constant 100 Volt, at 4˚C, with agitation of the 
buffer.  
2.5.5 Staining of polyacrylamide gels. 
Gels for Coomassie Brilliant Blue (CBB) staining were incubated for 15 min in CBB 
solution (45% (v/v) methanol, 10% (v/v) glacial acetic acid and 0.2% (w/v) Coomassie 
Blue R) then destained for 2x 10 min in the CBB destaining solution (45% (v/v) 
methanol and 10% (v/v) acetic Acid).  
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2.5.6 Immunodetection of proteins. 
Proteins of interest were visualized by membrane incubation with primary antibody 
(Table 2.3), followed by appropriate secondary antibody conjugated to horseradish-
peroxidase (Dako), and using ECL Plus reagent (GE Healthcare) and Storm 860 (GE 
Healthcare) PhosphorImager or by standard autoradiography. For the detection of signal 
with ChemiDoc MP Imaging System (BioRad), ECL Prime Reagent (GE Healthcare) 
was used. 
 
   Table 2.3. Description and details of primary antibodies used. 
 
 
2.5.7 
35
S metabolic labelling of mitochondrially encoded proteins. 
Control and patient fibroblasts were grown in 25 cm
2
 flasks to ~70% confluence. Cells 
were then incubated twice with methionine/cysteine free DMEM supplemented with L-
glutamine, 1 mM sodium pyruvate, 0.2 mM uridine for 10 min, 37˚C. This was 
followed by 10 min incubation in 1.5 ml of the same medium containing 10% dialysed 
FCS and emetine dihydrochloride (100 µg/ml final). Next, 0.5 ml of medium was 
removed from each flask and 20 µl of 
35
S- methionine/cysteine mix (PerkinElmer; 125 
µCi/ml EasyTag
TM
 express 
35
S protein labelling mix NEG-772, 73% L-met, 22% L-cys) 
was added. After 1hr incubation, the medium was removed, cells were washed twice 
with standard growth medium (subsection 2.1.2) without antibiotics but supplemented 
with additional 7.5 µg/ml of cold methionine. Cells were harvested in 1mM EDTA/PBS 
and centrifuged at 250g, 4 min. Pellets were washed 3x with ice-cold PBS and re-
suspended in ice-cold PBS containing EDTA-free, Protease Inhibitor Cocktail (Roche) 
and 1mM PMSF. Cell pellets were snap frozen and stored at -80C. When required 
aliquots were thawed on ice, protein concentration estimated and equal protein amounts 
Protein Size (kDa) Antibody information 
COXII ~20 Molecular Probes (A6404), mouse, 1:1000 
Cyt c ~11.5 MitoSciences, mouse (MSA06), 1:2000 
DAP3 ~46 Abcam  (ab11928), mouse, 1:1000 
ERAL1 ~48 Protein Tech Group (11478-1-AP), rabbit, 1:1000 
FLAG    - Sigma (F1804), mouse, 1:1000 
ICT1 ~20 Protein Tech Group (10403-1-AP) rabbit, 1:750 
MRPL3 ~35 Abcam (ab39268), goat, 1:2000 
MRPL12 ~19 Custom made Affinity purified, rabbit, 1:1000 
MRPS18B ~29 Protein Tech Group (16139-1-AP), rabbit, 1:4000 
NDUFB8 ~20 MitoSciences (MS105), mouse, 1:1000 
RbfA ~42 Custom made Affinity purified, rabbit, 1:800 
POLRMT ~140 Abcam, rabbit (ab32988), 1:300 
Porin ~39 Molecular probes (A31855), mouse, 1:10000 
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(50 µg) were mixed with 2x dissociation buffer (20% glycerol, 4% SDS, 250 mM Tris-
HCl pH 6.8, 100 mM DTT). Samples were incubated 1 hr at RT with 12 U Benzonase® 
nuclease (Novagen) and electrophoresed in 15% (w/v) SDS-PAGE.  
Gels were fixed over-night (fixer: 3% (v/v) glycerol, 10% (v/v) glacial acetic 
acid, 30% (v/v) methanol) after which they were vacuum dried at 60 C, 2 hr. Nascent 
proteins were visualized with PhosphorImager and analysed using Image-Quant 
software (Molecular Dynamics, GE Healthcare). 
  
2.5.8 Isokinetic sucrose gradient. 
Linear sucrose gradient was prepared in Centrifuge Tube (11 x 34 mm; Beckman 
343778) as follows: 
 10% and 30% sucrose solutions in gradient buffer (0.05 M Tris, pH 7.2, 
0.01 M MgOAc, 0.4 M NH4Cl, 1 M KCl, 1 mM PMSF, 50 µg/ml 
chloramphenicol, 0.5µl RNase inhibitors/1 ml were prepared 
 0.5 ml of 30% sucrose solution was injected under 0.5 ml of 10% sucrose 
solution and mixed by Gradient Masterip 107 (BIOCOMP) for 55 seconds 
using programme for TL55, 10-30% S1/1 0:55/85.0/22 and incubated for ~1 
hr at 4C in the Ultra Clear plastic tube (for 1ml volume with an open top, 
Beckman). 
 Cell (700 µg) or mitochondrial (300 µg) lysate (max 100 µl volume) was 
pipetted on top of the gradient, directly before centrifugation. 
The lysates were prepared with Sigma lysis buffer adjusted with Protease Inhibitor 
Cocktail, EDTA-free (Roche), 1 mM PMSF, 10 mM MgCl2 and 3 µl of SUPERase In™ 
RNase Inhibitor (Ambion)/500 µl of buffer. 
 
 
 
 
 
Figure 2.1. Schematic illustration of cell lysate fractionation in the sucrose gradient. 
The percentage of sucrose is indicated showing where light and heavy particles would 
be expected, and the positions of the fractions (numbers within tube). 
 
      10%                            30% 
      Light                          Heavy 
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Cell or mitochondrial lysates were loaded on to a linear sucrose gradient (1ml, 10-30% 
[v/v]), and fractionated by centrifugation in Beckman OptimaTLX ultracentrifuge, 
TLS55 rotor at 39000 rpm/min for 135 min at 4C. (acceleration and deceleration rate 
settings were 1 and 4 respectively). Fractions (100 l) were collected and analysed by 
western blot or treated with TRIzol LS Reagent (Ambion) in order to extract RNA for 
northern blot. 
 
2.5.9 Affinity purification of antibody. 
I. Expression and purification of MRPL12 protein. 
One litre of LB medium (supplemented with 100µg/ml ampicillin) was inoculated with 
two 5 ml cultures of Rosetta cells transformed with the plasmid (pTYBII) containing 
sequence of self-cleavable intein fusion with the chitin binding domain and ORF 
MRPL12 protein. Cells were grown at 37C, 200 rpm in a floor standing orbital shaker 
until the culture reached OD600 0.6. Next, flasks with liquid culture were transferred to 
16C and after 30 min, production of MRPL12 protein was induced with IPTG (1.0 mM 
final concentration) for 18 hr. Bacteria were centrifuged at 5000 rpm (Sorvall GSA 
centrifuge, rotor code 10) for 15 min at 4C and the pellet was frozen at -80C. Next, 
cells were thawed on ice, and resuspended in 20 ml of 1x Intein Buffer (IB: 20 mM 
Tris-HCl; pH 7.9, 500 mM NaCl, 1mM EDTA) containing Protease Inhibitor Cocktail, 
EDTA-free (Roche), 1 mM PMSF, 2 µl Benzonase® nuclease (Novagen) and sonicated 
for 20 min (30 seconds on; 18 microns amplitude, 30 seconds off; Soniprep 150; 
(SANYO)). Afterwards this was centrifuged at 15000g, 20 mins, at 4C. The 
supernatant was loaded onto equilibrated chitin beads (2 ml of slurry was twice washed 
in 50 ml of IB and centrifuged at 2000g, 2 min) and incubated 1 hr on a rotary shaker. 
Next, the supernatant was discarded and beads were washed twice with 50 ml of IB 
(containing Protease inhibitor Cocktail, EDTA-free (Roche), 1 mM PMSF) 
supplemented with 1 M NaCl for 40 min, at 4C, on the rotary shaker. The beads, re-
suspended in 10 ml of IB were moved to an empty Sephadex® G25 column. The 
flowthrough was discarded, and beads were washed 3x with 10 mls IB and further 3x 
with IB containing 50 mM β-Mercaptoethanol. During the last wash the flow was 
stopped and beads were incubated for 24 hr in remaining 4 ml of IB with 50 mM β-
Mercaptoethanol. The target protein was eluted by continuing the column flow. The 
eluate was dialysed twice overnight, at 4C against 1 L of 50 mM NaCl and 10 mM β-
Mercaptoethanol. The eluate (20 µl) before and after concentration (with Aquacide II, 
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Calbiochem), alongside sample obtained by boiling a small amount of chitin beads in 20 
µl elution buffer with loading dye, were separated by 12% SDS-PAGE and stained with 
CBB (as described in subsection 2.5.4 and 2.5.5) in order to determine the cleavage 
efficiency. 
 
II. Antibody purification using NHS- activated Sepharose
TM
 4 Fast Flow, (GE 
Healthcare). 
An aliquot of packed beads (0.6 ml volume) was added to 10 ml BioRad column and 
washed 3x with cold 1 mM HCl followed by overnight incubation with 1 mg of purified 
MRPL12 protein. After removing the flowthrough, beads were blocked with 0.1 M Tris-
HCl, pH 7.4, over-night at 4C. Next, the beads were washed 5x with PBS and 
incubated over-night with 7 ml of filtered (0.45 µm filter) serum from the immunized 
animal [sample identification number: ZGB08099, R0906, SAB: 26/11/08, Eurogentec 
(6)] and 3 ml PBS on the rocker, at 4C. The flowthrough was saved and beads were 
washed 2x with PBS, 1x with Tris-buffer, pH 8.0 (50 mM Tris-HCl pH 8.0, 0.1% Triton 
X-100, 0.5 M NaCl), 1x with Tris-buffer, pH 9.0 (50 mM Tris-HCl pH 9.0, 0.1% Triton 
X-100, 0.5 M NaCl), 1x with Na-phosphate buffer, pH 6.3 (50 mM Na-phosphate pH 
6.3, 0.1% Triton X-100, 0.5 M NaCl). Two types of elution buffers were applied. First, 
an acid elution with 5 ml Glycine-buffer, pH 2.5 (50 mM Glycine pH 2.5, 0.1% Triton 
X-100, 0.15 M NaCl). Each 850 µl of eluate were collected in 1.5 ml eppendorfs 
containing 150 µl Tris-HCl pH 9.0. Afterwards 1 ml of Tris-HCl pH 9.0 was added to 
the beads and the flowthrough was collected. The protein concentration in each fraction 
was assessed with Bradford Reagent (BioRad). Positive antibody fractions were 
dialyzed against 1L of PBS, with stirring, at 4C, over-night, at least twice. The volume 
of dialyzed IgG was reduced to 1 ml with Aquacide II, Calbiochem. 
To store antibody long term, glycerol (10% final volume), BSA (2% final volume) and 
sodium azide (0.02% final volume) were added. Aliquots were frozen in -20C. 
 
2.5.10 Immunoprecipitation of endogenous proteins. 
Immunoprecipitation of MRPL12 protein was performed with affinity purified antibody 
(technique described above, subsection 2.5.9), coated on magnetic Dynabeads® Protein 
G (Invitrogen). 20 µl of beads were washed 3x with 0.1M Na-phosphate, pH 8.1, and 
resuspended in 60 l of 0.1M Na-phosphate pH 8.1 and 20 l of antibody added, 
followed by incubation on a rotating wheel at RT for 45 min. After the incubation, 
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beads were pelleted and washed 3x with lysis buffer (Immunoprecipitation Kit, Sigma 
adjusted with EDTA-free Protease Inhibitor Cocktail (Roche), 1 mM PMSF, 10 mM 
MgCl2, 3 µl of SUPERase In™ RNase Inhibitor (Ambion)/500 µl of buffer). 
Mitochondria were isolated (according to protocol described in 2.5.2) from 
immortalised control and patient fibroblasts grown to ~80% in 300 cm
2
 flasks. These 
were then lysed in the buffer described above, according to the subsection 2.5.2. Control 
and patient fibroblast lysates, of equal protein amount (830 µg) were incubated with 
beads for 1 hr on the rotating wheel, at 4C. Removal of supernatant was followed by 
three washes with lysis buffer. The pull-down was eluted from beads with 25 µl of 1x 
sample buffer (described in 2.5.4) diluted in lysis buffer during 3 min incubation at 
95C, 1000 rpm in Thermomixer. Supernatants were analysed by western blot. 
 
2.5.11 Immunoprecipitation of FLAG tagged proteins. 
Immunoprecipitation of FLAG tagged ICT1 and MRPS27 were performed with 
FLAG® Tagged Proteins Immunoprecipitation Kit (Sigma) according to the suppliers’ 
protocol with a minor modification to the buffer. Sigma lysis buffer was adjusted with 
Protease Inhibitor Cocktail, EDTA-free (Roche); 1 tablet/10 ml, 1 mM PMSF, 10 mM 
MgCl2, 3 µl of SUPERase In™ RNase Inhibitor (Ambion)/500 µl of buffer) was used. 
Sigma 1x wash buffer prepared from 10x concentrated stock with DEPC ddH2O was 
adjusted the same as lysis buffer except the volume of SUPERase In, which was 
lowered to 0.5 µl/ml. Cell or mitochondrial lysates (preparation: subsection 2.5.1) were 
incubated with anti-FLAG M2-Agarose Affinity Gel for 3 hr on the rotating wheel, at 
4C. Pull-downs from ¼ of the resin were eluted as described in subsection 2.5.10. The 
rest of the resin was re-suspended in 250 µl of TRIzol reagent (Ambion) and RNA 
extractions were performed following the supplier protocol. In case of mitoplasts pellets 
(~50 µl volume, obtained according to the subsection 2.5.2), 200 µl of lysis buffer was 
used with 3 µl of SUPERase In. Lysed mitoplasts were incubated 2 hr with Sigma resin, 
followed by 3 washes with buffer described above, except that first wash contained 10 
mM EDTA.   
 
2.6    CLIP Technique. 
2.6.1 CLIP of endogenous protein. 
The protocol for CLIP assay was followed as described in Ule et al., 2005. Below are 
presented only main steps of the method, followed by a detailed protocol used to 
investigate MRPL12 and RBFA proteins. 
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The steps illustrated in Fig. 2.2 are briefly described below.  
I. Cells grown in 150 mm plates were UV-irradiated on ice leading to formation of a 
covalent bond between protein and RNA. 
II. Partial digestion of RNA after cell lysis.  
III. Immunoprecipitation of protein-RNA complexes.   
a) Dephosphorylation of RNA.  
b) 3’-RNA linker ligation.  
c) Radioactive labelling of RNA by γ 32P on the 5’ terminus.  
IV. SDS-PAGE electrophoresis of protein-RNA complexes and transfer to 
nitrocellulose. 
V. Thin region of the membrane corresponding to protein–RNA complexes of 
appropriate size was localized by expose to X-ray film and cut out. 
VI. Protein was digested by proteinase K and 5’ RNA linker was ligated to free RNA.   
VII. CLIP tags were then amplified by RT-PCR, cloned, sequenced and analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Schematic representation of main steps in CLIP method. 
Detailed description is given in the text. 
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Solutions: 
 
Lysis Buffer 
From FLAG Immunoprecipitation Kit cat no. FLAGIPT1 
Adjusted with: 
 0.1% SDS 
 Protease Inhibitor Cocktail, EDTA-free (Roche) 
 RNAsin (Promega)  
 
1xPNK buffer 
50 mM Tris-HCl pH 7.4 
10 mM MgCl2 
0.5% NP-40 
 
1xPNK+EDTA buffer 
50 mM Tris-HCl pH 7.4 
20 mM EDTA 
0.5% NP-40 
 
1xProteinase K (PK) buffer  
100 mM Tris-HCl pH 7.4 
50 mM NaCl 
10 mM EDTA 
 An adequate number of cells were seeded into 150 mm dishes to achieve a culture of 
about 70-80% confluence on the day of UV treatment. 
 The cells were fed the day before the experiment or split if needed. 
UV cross-linking 
 The cells were rinsed once with Dulbecco’s PBS (Ca2+, Mg2+ free). Enough of cold PBS 
was added to keep the cells moist (~10ml/ plate area). Next, the plate was placed on the 
tray with ice on the bottom of the Stratalinker 2400 (STRATAGENE) and cells were 
irradiated one time for 400mJ/cm
2
.  
 The cells were harvested and pelleted at 4C, the pellet was washed with ice-cold PBS, 
snap -frozen at -80˚C until use (each eppendorf contained ~200 µl of cells). 
Bead Preparation 
 20 l of Dynabeads protein G (Invitrogen) was used for each eppendorf of cross-linked 
material. Beads were washed 3x with 0.1 M Na-phosphate, pH 8.1. 
 These were re-suspended in 60 l 0.1 M Na-phosphate pH 8.1 and 20 l of antibody.    
 This was rotated at room temperature for 30-45 min. 
 Next, beads were washed 3x with lysis buffer. 
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Cell lysis and partial RNA digestion 
 Each of cell pellets was resuspended in 1ml of lysis buffer (FLAG IP kit, Sigma), 
containing proteinase inhibitor cocktail, EDTA-free (Roche), 0.1% SDS and 
supplemented with 15ul RNAsin (Promega). 
 Cells were lysed for 30 min on the rotating wheel at 4C. 
 50 µl of DNAse I (RNase free, 1U/µl, Epicentre Biotechnologies) was added to each 
eppendorf, followed by incubation at 37C for 5 min, 1000 rpm in Thermomixer. 
 Dilutions of RNase T1 (Ambion, 1000U/µl) at 1/100 (overdigested sample) and at 
1/5000 (underdigested sample) were prepared in the lysis buffer. 
 20 µl of each RNase T1 dilution was added to one of the duplicate eppendorfs, and 
incubated at 37C for 10 min. 
 Next, 3 µl of SUPERase In (Ambion, 2U/µl) was added to each duplicate, in order to 
inhibit RNase T1. 
 Lysates were centrifuged at 20800 g in Eppendorf centrifuge 5414R for 20 min at 4C. 
 Supernatants were transferred onto Invitrogen magnetic Dynabeads protein G coated 
with specific antibody. 
 Beads/lysate mix was rotated for 1 hr at 4C. 
 Next, the supernatants were removed and beads washed twice with 1 ml of lysis buffer 
and twice with PNK buffer, the over-digested sample was resuspended in PNK buffer. 
 
    Next two steps: CIP treatment and 3’ RNA linker ligation are performed only with 
sample treated with low RNase concentration (1:5000). The over-digested sample is 
left at 4C in PNK buffer until PNK treatment step. 
 
CIP treatment (on beads) 
 CIP mix (total volume: 80µl): 
8 µl 10x dephosphorylation buffer (Roche) 
3 µl alkaline phosphatase (Roche, 10713023), kept at 4C 
69 µl H2O 
 The last 1x PNK wash was removed from the beads and CIP mix was applied. 
 Beads were incubated at 37C for 10 min; 1000 rpm every 3 min for 15 s. 
 Next, the beads were washed twice with 1 ml of 1x ‘PNK+EDTA’ buffer and twice 
with 1ml of 1xPNK buffer. 
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3’ RNA Linker ligation 
 Linker mix (40 µl): 
8 µl   L3 3’ RNA Linker at 20 pmol/µl 
32 µl DEPC H2O 
The 1x PNK buffer was carefully discarded from the beads and 40 µl of the linker mix 
was added to each tube of beads. Followed by 40 µl of ligase mix (with final L3 conc. at 
2 pmol/µl). 
 
 Ligase mix (40 µl): 
8 µl 10x buffer (NEB, contains ATP) 
1 µl T4 RNA ligase I (20U, NEB M0204S) 
31 µl DEPC H2O 
Beads were incubated in the Thermomixer at 16C over-night (1000 rpm every 5 min 
for 15 s). 
 
PNK treatment on beads 
  The beads were washed 3 times with 1ml of 1x PNK buffer. 
 PNK mix (total volume 80 µl): 
8 µl 10x buffer (NEB) 
1 µl 32P (ATP) 
4 µl T4 PNK enzyme (NEB, M0201S) 
67 µl DEPC H2O 
 80 µl of the mix was added to each sample and incubate in Thermomixer at 37C for 10 
min (1000 rpm every 4 min for 15s). 
 Next, 1 µl of 10 mM ATP was added to each sample and the reaction mix was 
incubated for an additional 5 min. 
 The beads were washed 3x with 1 ml ‘PNK+EDTA’ buffer.  
 
Elution 
 After the third wash the beads were resuspended in 25 µl of 1x ‘PNK+EDTA’ buffer 
with 1x Novex loading dye (containing reducing agent in case of RbfA), Invitrogen, 
incubated in Thermomixer at 70C for 10 min (1000 rpm), and the supernatant taken for 
loading. 
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SDS- PAGE and BA-85 nitrocellulose transfer 
 Samples were loaded on 10 well Novex NuPAGE 10% Bis-Tris gel, Invitrogen. 
 Separated under reducing conditions in case of RBFA (for MRPL12 protein no reducing 
agent was used) according to the manufacturer protocol (Novex Pre-Cast Gel 
Electrophoresis Guide). 
 RNA-protein complexes were transferred to BA-85 nitrocellulose (PerkinElmer) using 
the Novex wet transfer system according to the manufacturer protocol (Novex Pre-Cast 
Gel Electrophoresis Guide).  
 After the transfer, the nitrocellulose was rinsed in 1x PBS and wrapped in SARAN film.   
 This was exposed to the x-ray film for few hr or O/N at -80C with an intensifying 
screen. 
 
RNA isolation and purification 
 A 4 mg/ml Proteinase K solution was made in 1x Proteinase K buffer; pre-incubated at 
37C for 20 min. 
 A fresh stock of 100 mM PMSF was made up in isopropanol. 
 The autoradiogram was matched with the membrane. 
  The over-digested sample, was used to determine the specificity of the RNA-protein 
complexes according to the following requirements: 
1. In the over-digested sample lane, the band should be localized ~7 kDa above 
the expected MW of the investigated protein.             
2. The distance from the closest contaminating band, should not be less than 10 
kDa, it guarantees the specificity of purified RNA.     
3.  The RNA-protein complexes that were treated with a low concentration 
RNase T1 will appear as a diffuse radioactivity around 15-20 kDa above the 
expected MW of investigated protein (average MW of 50 nucleotides long RNA 
is ~16 kDa, plus attached 20 nucleotides long linker L3).  
4. The band cut out from the membrane should be as thin as possible (~3 kDa 
wide) approximately 20 kDa above the expected MW of the protein. 
 The excised nitrocellulose piece or pieces were incubated in 200 µl of Proteinase K 
solution each, for 20 min at 37C at 1000 rpm (Thermomixer). 
 200 µl of 1x Proteinase K buffer with 1 mM PMSF was added; incubated for 5 min, 
37C at 1000 rpm. 
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 RNA was extracted by addition of 400 µl of RNA - phenol pH 6.7 and 130 µl of 
chloroform 49:1 with isoamyl alcohol; incubated for 20 min at 37C at 1000 rpm. 
 Next, this was centrifuged at 17900 g for 5 min, at 4C. 
 The aqueous phase was mixed with 50 µl 3 M NaOAc, pH 5.2, 0.5 µl glycoblue 
(Ambion, 9510), 1 ml of 1:1 EtOH : Isopropanol. 
 RNA was precipitated O/N at -20C. 
 Next, this was centrifuged for 20 min at maximum microfuge speed, at 4C. 
 Pellet or pellets were washed twice with 200 µl ice-cold 75% ethanol and air dried 
briefly. 
 RNA was resuspended in 8 µl RNase free water. 
 
5’RNA Linker Ligation 
 Ligation mix (total volume: 10 µl) 
1 µl 10x T4 RNA Ligase buffer (NEB, contains ATP)  
1 µl L5 RNA linker 20 pmol/µl 
7 µl RNA 
1 µl T4 RNA ligase, diluted first 1:5 to give 4U/µl 
 Reaction was incubated for 5 hr at 16C. 
 Next, volume of the ligation reaction was increased to 200 µl with DEPC ddH2O. 
 RNA was extracted with 200 µl phenol pH 6.7 and 65 µl chloroform; vortexed and 
centrifuged at 13000 rpm (microfuge), 5 min at 4C.  
 The RNA from aqueous phase was precipitated O/N with 50 µl NaOAc pH 5.2, 0.5 µl 
glycoblue and 1 ml 1:1 EtOH: Isopropanol at -20C. 
 RNA was centrifuged for 20 min at maximum speed, at 4C. 
 Pellet was washed twice with 200 µl ice-cold 75% ethanol and air dried briefly. 
 RNA was resuspended in 9 µl RNase free water (not treated with DEPC). 
 
Reverse Transcription  
 The reaction was set up as follows: 
9 µl of RNA solution mixed with 1 µl P3 primer (10 pmol/µl) was incubated at 65C for 
5 min. Next the master mix was added. 
Master mix: 
1 µl 10 mM dNTPs 
4 µl 5x 1st strand buffer 
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2 µl 0.1 DTT 
1 µl SUPERase In 
1.5 µl RNase free water 
Sample was incubated for 5 min at 42C, followed by the addition of 0.5 µl Superscript 
II (Invitrogen). The final reaction mix was incubated for 1 hr at 42C, 15 min at 70C. 
 
PCR reaction 
 Total volume: 30 µl 
3 µl  10x Reaction Buffer IV (Thermo Scientific)  
1.5 µl  10 mM dNTPs mix        
2.4 µl  25 mM MgSO4                
1 µl  P5 primer (10 pmol/µl)    
1 µl  P3 primer (10 pmol/µl)    
17.5 µl  ddH2O                                
0.6 µl  Taq DNA Polymerase (Thermo Scientific)                  
3 µl of Reverse Transcription Reaction (cDNA) was used as a template. 
 
PCR settings: 
95C 5 min 
 
95C 20 s                         
67C 30 s                     35 cycles 
72C 30 s 
 
72C 5 min 
 
Separation of the PCR product on agarose gel and product extraction.
 Entire PCR reaction was separated on 4% low melting agarose gel, against 50 bp 
molecular weight marker (NEB).  
 The gel piece with DNA of 80-90 bp length of ~100 µl volume was cut out. 
 DNA from the crushed gel was phenol/chloroform extracted  
 First, ddH2O was added up to 400 µl to the excised gel. 
 Sample was incubated at 65C for 10 min at 1000 rpm. 
 DNA was purified by:  
 2x extraction with 400 µl phenol (pH) 
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 1x 200 µl phenol/200 µl chloroform 
 1x 400 µl chloroform 
 
 DNA was precipitated 3h at -80C or O/N at -20C with 40 µl 3 M NaOAc, 1 µl 
glycoblue, 1 ml 100% ice-cold ETOH. 
 Next, this was centrifuged at maximum speed for 15 min at 4C.  
 Pellet was washed twice with ice cold 75% ETOH.  
 Air dried DNA pellet was resuspended in 10 µl ddH2O. 
 
Re-amplification of DNA: 
PCR reaction 
 Total volume: 50 µl 
5 µl 10x Reaction Buffer IV (Thermo Scientific)  
2 µl 10 mM each dNTPs mix         
3 µl 25 mM MgSO4                 
5 µl P5 primer (10 pmol/µl)    
5 µl P3 primer (10 pmol/µl)    
27 µl H2O                               
1 µl Taq DNA Polymerase (Thermo Scientific)                                  
2 µl of first PCR reaction was used as a template 
 DNA was reamplified with the same thermal program but with 20 cycles and 63C 
annealing temperature. 
 The PCR product was again separated on an agarose gel and extracted according to the 
required size of ~ 80-90 bp as previously described by phenol/chloroform extraction. 
 Obtained DNA pellet was resuspended in 12 µl of ddH2O. 
 
Examination of CLIP tags 
 Amplified CLIP tags were cloned with TOPO TA Cloning KIT (Invitrogen: following 
the manufacturer’s protocol) and transformed into One Shot TOP10 Chemically 
Competent E. Coli cells (Invitrogen; procedure performed according to manufacturer 
protocol). 
 Bacterial colonies were grown on agar plates with 100 µg/ml of ampicillin, were 
screened by colony PCR 
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 Single colonies were resuspended in 50 µl of 10% Triton X-100 and then frozen 
at -80C, followed by thawing. 
 Standard 25 µl PCRs were set up with M13 primers as follows: 
2.5 µl 10x Reaction Buffer (Fermentas)  
0.5 µl dNTPs mix         
0.5 µl M13 forward primer (50 µM)   
0.5 µl M13 reverse primer (50 µM)    
19.625 µl ddH2O                    
0.125 µl Dream Taq Polymerase (Fermentas)  
1.25 µl Triton X-100/colony lysate was used as a template 
PCR settings: 
95C 3 min 
 
95C 45 s 
48C 1 min                   30 cycles 
72C 30 s 
 
72C 7 min 
 5 µl of PCR product was separated on 2% agarose gel, chosen clones that contained 
CLIP tags of expected size were sequenced. 
 Steps ahead of CLIP tags sequencing procedure with Genetic Analyzer 3130xI  
(Applied Biosystems) are as follows: 
 5 µl of colony PCR performed with Dream Taq Polymerase was mixed with 
TSAP Thermosensitive Alkaline Phosphatase (Promega) and incubated: 
15 min at 37C 
15 min at 80C 
 2 µl of above reaction was mixed with: 
7 µl ddH2O 
3 µl sequencing buffer (Applied Biosystems) 
1 µl M13 forward primer 
2 µl Big Dyes v3.1 (Applied Biosystems) 
The reaction mix was amplified in the sequencing PCR. 
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Cycle sequencing settings: 
95C 5 min 
 
95C 30 s 
48C 10 s                   30 cycles 
72C 4 min 
 
4C                              
Precipitation of samples was kindly performed by Charlotte Alston. 
 
Table 2.4. Linkers and primers sequences used in CLIP method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 In order to obtain more comprehensive data, CLIP tags were sequenced with the 
IonTorrent. The final PCR products were prepared, following manufacturer’s 
instructions. Reads were collected and aligned to mtDNA as a reference sequence using 
the Torrent Suite software on the IonTorrent server. 
 
2.6.2 CLIP of FLAG tagged protein. 
CLIP assay was performed according to the protocol described in 2.6.1 apart from few 
modifications in following steps: 
 HEK293 cell line expressing FLAG tagged SLIRP (provided by Dr Paul Smith) 
was treated with UV two days after induction of the protein with tetracycline at 
1 µg/ml final concentration. 
Name of the 
primer 
Sequence 
L5 RNA linker 
(Thermo Scientific) 
5’-OH AGG GAG GAC GAU GCG G 3’-OH 
L3 RNA linker 
(Thermo Scientific) 
5’-P GUG UCA GUC ACU UCC AGC GG 3’-puromycin 
P5 DNA primer 
(Operon) 
5’-AGG GAG GAC GAT GCG G-3’ 
 
P3 DNA primer 
(Operon) 
5’-CCG CTG GAA GTG ACT GAC AC-3’ 
 
M13 Forward (-20) 
5’-GTAAAACGACGGCCAG-3’ 
 
M13 Reverse 
5’-CAGGAAACAGCTATGAC-3’ 
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 Immunoprecipitation step was performed with beads from FLAG Protein 
Immunoprecipitation Kit, Sigma. 
 Beads were equilibrated by 5 washes in 1x wash buffer (prepared in DEPC 
ddH2O, from 10x concentrated stock (FLAG Protein Immunoprecipitation Kit, 
Sigma) 
 After immunoprecipitation, beads were washed 3 times with 1 ml of 1x wash 
buffer, 2x with 1 ml of 1x PNK buffer. 
 RNA/FLAG-protein complexes were removed from beads by incubation in 
Thermomixer at RT for 45 min (1000 rpm) with elution mix: 
5 µl 3x FLAG peptide (IP kit, Sigma) 
45 µl 1x wash buffer 
 
2.7 Primer extension assay. 
In this study a primer extension assay was used in order to investigate the relative 
amounts of modified, methylated bases on 12S rRNA. The RNA-dependent DNA 
polymerase (M-MLV, Promega) extends a cDNA chain from the annealed radiolabelled 
primer. A limited nucleotide concentration and lowered amount of enzyme in the 
reverse transcription reaction was applied to determine the location of modified bases. 
The reduction in these parameters is designed so that the elongation process stops at the 
site of modification. To exclude confusion with pause sites caused by secondary 
structure of RNA enforcing the reverse transcriptase to pause, the negative control of 
un-methylated in vitro synthesized RNA was used in a parallel reverse transcription 
reaction, and was electrophoresed on 10% sequencing gel alongside investigated 
samples. The nucleotide dGTP was excluded from RT reaction mix. This limited the 
DNA strand from being extended beyond the position of the first ‘C’ nucleotide where a 
dGTP would need to be inserted. This restricted the full length readthough product to 23 
nucleotides. This allowed a comparison of the readthrough signal with the methylation 
site induced stop signal.  
The steps in primer extension assay are as follows: 
1. Primer radiolabelling reaction: 1 hr at 37C, stopped by 15 min incubation at 65C. 
 Total volume: 10 µl 
3.4 µl ddH2O 
0.8 µl 100 µM primer 
1 µl 10x buffer (NEB) 
0.8 µl T4 PNK enzyme (NEB, M0201S) 
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4 µl 32P (ATP) 
Radiolabelled primer was purified on Illustra™ MicroSpin™ G-25 column (GE 
Healthcare) and eluted in 50 µl of ddH2O. 
4 µg of total RNA or 800 ng extracted from beads after immunoprecipitation of 
monosome through FLAG tagged MRPS27 or FLAG-ICT1 in 3 µl of ddH2O were 
mixed with 3 µl diluted 
32
P-primer (1 µl of primer + 2 µl of ddH2O) and incubated 2 
min, at 95C, centrifuged and left at room temperature for 10 min in order to annealing 
process occur. Next RNA was transcribed into cDNA. 
2. Reverse Transcription Reaction: 45 min, at 37C, stopped by addition of 2x 
loading buffer (80% (v/v) formamide, 1 mM EDTA, 0.1% (w/v) BFB, 0.1% (w/v) 
XCFF). 
 Total volume: 12 µl 
6 µl annealing mix 
2.93 µl ddH2O 
2.4 µl M-MLV RT 5x Buffer (Promega) 
0.24 µl M-MLV Reverse Transcriptase (Promega) 
0.4 µl SUPERase In (Ambion) 
0.024 µl 20 mM dNTPs mix without dGTP (final concentration: 0.04 mM) 
3-5 µl of samples were separated on 10% polyacrylamide / 8 M urea sequencing gel, at 
50 W in 1x TBE buffer. Afterwards the gel was removed from the glass plates and dried 
for 2 hr, at 80C. Next it was placed in a SARAN wrap and exposed to a screen in 
Phosphor-Imager cassette. Detection of signal was performed with Typhoon FLA9000 
and analysed using Image-Quant software (Molecular Dynamics, GE Healthcare). 
 
10% polyacrylamide / 8 M urea sequencing gel (55 ml) 
27 g  Urea 
5.5 ml  10x TBE 
18.33 ml  Acrylamide / Bis-Acrylamide (30% Ratio 29:1, NBS Biologicals) 
Up to 55 ml ddH2O 
90 µl  TEMED 
400 µl  10% APS 
 
10x TBE (1 L) 
108 g Tris Base 
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55 g Boric Acid 
20 ml 0.5 M EDTA, pH 8.0 
 
The preparation of the un-methylated in vitro synthesized RNA used in reverse 
transcription reaction as a negative control. 
100 ng of total DNA extracted from HeLa cells were used in 50 µl PCR reaction with 
12S rRNA primers (Table 2.5). Taq DNA Polymerase (ThermoScientific) was used in 
order to generate template with a site to initiate transcription with SP6 RNA polymerase 
using AmpliScribe SP6 Transcription Kit (Epicentre Technologies). The PCR product 
was purified by phenol-chloroform extraction, followed by ethanol precipitation. 3 µl of 
sample was separated on 1% (w/v) agarose gel in order to confirm the size of the 
product.  800 ng of DNA was used in the following transcription reaction: 
 
 Total volume: 20 µl 
2.5 µl RNase-free water 
1.5 µl 100 mM ATP 
1.5 µl 100 mM CTP 
1.5 µl 100 mM GTP 
1.5 µl 100 mM UTP 
2    µl 100 mM DTT 
2    µl 10x Reaction Buffer 
5    µl SP6 DNA template (800 ng) 
0.5 µl SUPERase In (Ambion)  
2   µl AmpliScribe SP6 Enzyme Solution 
 
The above reaction was incubated for 2 hr, at 37C. In order to remove DNA template, 
the sample was treated with 1 µl of RNase-free DNase (1U/ul, Epicentre 
Biotechnologies) for 15 min, at 37C. RNA was purified by phenol-chloroform 
extraction, followed by precipitation in 1:1 isopropanol:ethanol. RNA was air-dried and 
resuspended in RNase-free water. Again the size of the product was checked on 1% 
agarose gel. 
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Table 2.5. Sequences of oligonucleotides used in primer extension assay. 
 
 
 
 
 
 
The sequence in red indicates the SP6 promoter, in green is presented a fragment of 12S mt-
rRNA. AA primer was used in the primer extension assay for investigating di-methylation of 
two adjusted adenines near the 3’end of 12S. 
 
5’CCAGTTGACACAAAATAGACTACGAAAGTGGCTTTAACATATCTGAACACACAATAGCTAAG
ACCCAAACTGGGATTAGATACCCCACTATGCTTAGCCCTAAACCTCAACAGTTAAATCAACAAAACTGCT
CGCCAGAACACTACGAGCCACAGCTTAAAACTCAAAGGACCTGGCGGTGCTTCATATCCCTCTAGAGGAG
CCTGTTCTGTAATCGATAAACCCCGATCAACCTCACACCTCTTGCTCAGCCTATATACCGCCATCTTCAG
CAAACCCTGATGAAGGCTACAAAGTAAGCGCAAGTACCCACGTAAAGACGTTAGGTCAAGGTGTAGCCCA
TGAGGTGGCAAGAAATGGGCTACATTTTCTACCCCAGAAAACTACGATAGCCCTTATGAAACTTAAGGGT
CGAAGGTGGATTTAGCAGTAAACTAAGAGTAGAGTGCTTAGTTGAACAGGGCCCTGAAGCGCGTACACAC
CGCCCGTCACCCTCCTCAAGTATACTTCAAAGGACATTTAACTAAAACCCCTACGCATTTATATAGAGGA
GACAAGTCGTAACATGGTAAGTGTACTGGAAAGTGCACTTGGACGAAC3’ 
Figure 2.3. Sequence of 12S mt-rRNA.  
The 2 adenosine residues that are modified by dimethylation are indicated in red. Positions of 
both primers (AA primer (blue); used in the primer extension assay and SP6 primer (green) used 
in the synthesis of unmethylated RNA control with AA primer) are also specified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Name of the primer Sequence 
AA primer 5’GGT TCG TCC AAG TG3’ 
SP6 primer 5’ATT TAG GTG ACA CTA TAG A AC ACA CAA TAG CTA3’ 
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3.  Chapter 3: Investigating the sequence specificity of the mitochondrial     
RNA binding protein SLIRP using 
Cross-linking Immunoprecipitation - CLIP. 
 
3.1 Introduction.  
SLIRP (SRA stem-loop interacting RNA binding protein) was originally reported to 
bind STR7, which is a functional substructure of SRA (steroid receptor RNA activator) 
(Hatchell et al., 2006). The latter is a complex RNA molecule anticipated to contain 
numerous stable stem-loop structures of which STR7, an 89 nt sequence, is the largest 
and one of the most stable (Lanz et al., 2002). SRA serves as a catalytic RNA transcript, 
regulating eukaryotic gene expression via the nuclear steroid receptors. The predicted 
SLIRP structure is almost exclusively built of an RRM motif as seen in figure 3.1 
(Hatchell et al., 2006), which is present in nearly all cellular compartments that contain 
RNA of animals, plants, fungi, and bacteria.  
 
 
 
This extensive conservation suggests its early evolution and the importance of its 
functions (Burd and Dreyfuss, 1994). A specific element of the RRM motif is its 
consensus sequence that is built of two short, canonical sequences, RNP1 and RNP2. 
These sub-motifs contain highly conserved amino acids crucial for RNA binding, and 
positioned on the two central β-strands (Nagai et al., 1990) of RRM βαββαβ secondary 
structure. However, the specificity of binding is determined by the most variable 
regions of the RRM motif. In general, the domain of the RRM responsible for 
interacting with the RNA structure, is composed of a conserved β-sheet, the specificity 
of which is modulated by more changeable residues located in the loops and the C-, N-
terminal regions of RNA binding domain (Bentley and Keene, 1991,Görlach et al., 
1992).  
Figure 3.1. Structural model of 
SLIRP protein. Mitochondrial 
signal sequence and RNA binding 
domain are indicated. Image 
adapted from Hatchell et al., 2006. 
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SLIRP has been proposed to repress nuclear receptors trans-activation in a SRA- 
and RRM-dependent way. The highest levels of SLIRP among human tissues were 
detected in heart, liver, skeletal muscle, and testis. Furthermore, over 90% of 
endogenous SLIRP was detected in mitochondria suggesting dual function of this 
protein. The location of SLIRP in mitochondria is in agreement with the presence of the 
N-terminal mitochondrial targeting sequence visible in the predicted structural model of 
this protein as an independent α-helix linked to the RRM that defines its cellular 
distribution (Figure3.1). 
 
3.2 SLIRP binds mt-RNA in vivo. 
Prior to published data, the mitochondrial location of SLIRP was confirmed and 
specified to the matrix by Dr. Paul Smith in my host laboratory. This preliminary data 
suggested its involvement in maintenance of mt-mRNAs. As a part of the project I 
performed CLIP assay (cf subsection 2.6.2), using a HEK293T cell line designed to be 
able to inducibly overexpress FLAG tagged SLIRP (generated by Dr. Paul Smith) in 
order to identify the specific binding sequences on mt-RNA. The CLIP tags obtained 
were initially cloned and sequenced and later the generated tags were IonTorrent 
sequenced by Dr. Helen Tuppen. Reads were collected and aligned to mtDNA as a 
reference sequence using the Torrent Suite software on the IonTorrent server. The 
alignment is presented in the form of a graph in Figure 3.2, where the x axis is a linear 
representation of the human mtDNA. The peaks indicate the locations of SLIRP binding 
sites and the number of ‘hits’ for which more than 50 CLIP tags were identified.  
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Figure 3.2. Alignment of SLIRP CLIP tags on mtDNA sequence. Human Cambridge 
reference sequence of mtDNA is presented as the x-axis and the number of CLIP tags in each 
position is given on the y-axis. Using IonTorrent derived data for CLIP on FLAG tagged SLIRP 
protein the threshold for the minimum number of hits at one site was set up at 50. Thus the 
peaks indicate only genes for which the number of CLIP hits exceeded 50. Y-axis starts from 
the nucleotide for which at least one hit was detected. 
 
The positions where the number of hits exceeded this threshold were located in six mt-
mRNAs: MTND2, MTCO1, MTATP8/6, MTATP6, MTND3 and MTND4. The highest 
number of CLIP tags was identified for the mtTF1 binding site (~600 hits), MTND2 
(~87 hits), MTCO1 (~ 160 hits), MTATP8/ATP6 (~150 hits), MTATP6 (position I: 
almost 700 hits, position II: over 600 hits), MTND3 (over 60 hits), MTND4 (over 200 
hits). Locations of binding sites with reads lower than 50 were also identified 
(Appendix 1.4). These were found in MTCOI, MTCOII, MTCOIII, MTCYB, MTND1, 
MTATP8, MTND4L, and MTND5. The last four had only one binding site mapped with 
approx. 12, 29, 16, 26 hits respectively. Whereas two sites were identified in MTCOII 
(approx. 40 and 30 hit) and MTCYB (approx. 37 and 28 hits) and three binding sites 
mapped to MTCOIII each with 30, 26 and 20 hits. The number of binding sites in 
MTCOI was the highest among all identified mt-mRNAs with five locations mapped. 
The first binding site had approximately 30 hits, second 40, third 160, fourth 20 and 
fifth 20. The only mRNA for which no CLIP sequences were found was MTND6. 
Interestingly, mt-rRNA was also targeted, although minimally, with 20 hits located at 
the 3’end of 12S rRNA. Intriguingly, one of the highest number of CLIP tags are 
positioned at the H strand origin, where binding sites of mtTF1 are assigned. Analysis 
of SLIRP RNA binding sites in vivo did not show any discernible specificity of the 
sequence or structure, which would be shared by all RNA fragments. Still the sequences 
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with the highest number of hits are rich in A and T(U) residues (Appendix 1.4). 
Moreover 12 out of 25 identified binding sites contain CGC or CTG sequence. Seven of 
the binding sites contain both CGC and CTG sequences. Ten binding sites contain GAG 
sequence.  
Further investigation was not pursued because of publications arising in the 
literature concerning SLIRP function in mitochondria and characterising aspects of this 
protein (described in Introduction), (Baughman et al., 2009, Sasarman et al., 2010, 
Ruzzenente et al., 2011, Chujo et al., 2012). All of the now available data show an 
important function of SLIRP in maintenance of mt-mRNA species. Moreover, the last 
three of the publications cited above, present an interacting partner of SLIRP, LRPPRC. 
This protein was initially characterised as mutations were found to cause the French 
Canadian variant of Leigh syndrome, as described in the introduction (Sasarman et al., 
2010). SLIRP and LRPPRC are found in complexes with mature mt-mRNAs and their 
precursors. Furthermore, both are implicated as playing a role in the polyadenylation 
status of mt-mRNAs, potentially by suppressing 3’deadenylation (Chujo et al., 2012). 
These proteins not only play an important function in stabilizing RNA but their steady 
state levels appear to be dependent on it (Sasarman et al., 2010). Further, there appears 
to be a mutual reliance between these two proteins; depletion of one has been shown to 
cause a decrease of the other (Sasarman et al., 2010). Although recently published data 
reveal a lot of interesting information about the functional implications of the 
ribonucleoprotein complex in which SLIRP is a significant participant, none of them 
specify whether this protein binds mitochondrial RNA directly in vivo and what are the 
positions of these binding sites. This chapter specifically identifies the RNA species 
present physiologically in ribonucleoprotein complexes that were immunoprecipitated 
with SLIRP-FLAG.  
 
3.3 Discussion. 
The CLIP data presented here show that there is direct binding of SLIRP to all mt-
mRNA species, apart from MTND6. Particular transcripts had two binding sites 
(MTCOII, MTATP6, MTND4, MTCYB), three (MTCOIII) or even five in case of MTCOI 
(Appendix 1.4). The number of hits per transcript for specific mRNAs including 
MTCOII, MTATP8, MTCOIII, MTCYB, MTND1, MTND4L and MTND5 were specific 
but not abundant. This could have been due to the low level of SLIRP-FLAG expression 
in the HEK293T cell line, allowing the endogenous protein to occupy the sites on the 
RNA and thus, although binding the RNA, these species would not be 
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immunoprecipitated via the anti-FLAG antibody. The preferential amplification of some 
CLIP tags during sample preparation for IonTorrent analysis also cannot be ruled out. It 
is important to underline that SLIRP protein was reported to be in large molecular 
complexes with LRPPRC protein, however, the CLIP sequences reported here are 
exclusively bound by SLIRP protein. The specificity of the complex excised from the 
nitrocellulose membrane corresponded to migration of SLIRP/RNA and not to a higher 
molecular weight complex that could have represented LRPPRC/SLIRP/RNA. It is 
highly possible that the number of hits is lower than might be expected because a 
significant amount of mRNA species was bound in complexes that contained both 
proteins rather than SLIRP alone. In order to further validate the broad range of binding 
sites by SLIRP protein on mt-mRNA species at least one more repeat of the CLIP assay 
would be required. However, this data fits well with findings published during last few 
years showing interaction of LRPPRC/SLIRP complex with all mt-mRNA species 
(Chujo et al., 2012, Ruzzenente et al., 2011) but with very low abundance of interaction 
with MTND5 and MTND6. The former, has been described as having only A5-8 as a tail 
(Temperley et al., 2010b), whereas, MTND6 is not routinely found as polyadenylated 
(Slomovic et al., 2005). So the complex does not appear to be necessary for their 
elongation or protection, which is in line with CLIP data. Moreover, the very low 
number of hits located on MTND1 could be due to its short half-life, estimated to be 
only 74 min in HeLa cells (Chujo et al., 2012). Surprisingly, there was also evidence of 
limited binding to the 12S rRNA in the CLIP sequences. This could be explained as a 
side effect of interaction between mRNA in complex with LRPPRC/SLIRP and the 
small subunit of the mitochondrial ribosome. In general the steady state levels of 
mitochondrial COX polypeptides were shown to be most affected in SLIRP depleted 
HeLa cells (Chujo et al., 2012). This is in agreement with the CLIP data that I obtained, 
which showed high binding to MTCOI (with four more sites of interaction below 50 
hits) and multiple binding sites to MTCOII and MTCOIII, although for the last two the 
number of hits in a single position did not exceed 50 reads. The high number of hits 
recorded for RNA14 (MTATP8/6) and MTND4 is also supported by the reported 
outcome of SLIRP silencing, which caused a significant decrease in the steady state 
levels of these subunits (Chujo et al., 2012). The possibility of multiple binding sites on 
mt-mRNAs was also suggested in the most recent publication, postulating high 
abundance of LRPPRC in mitochondria, with 7 molecules of this protein per 1 molecule 
of mRNA (Chujo et al., 2012). As SLIRP is proposed to be in complex with LRPPRC, 
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again the CLIP data confirmed this assumption showing that for most of mt-mRNAs 
there is more than one binding site. 
In summary, the CLIP assay result clearly states direct interaction of SLIRP-
FLAG with all mt-mRNAs apart from MTND6, which correlates with published data 
concerning the role of LRPPRC/SLIRP complex. 
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4.   Chapter 4: Characterization of the effect of the p.Ala181Val mutation   
in MRPL12 protein. 
 
4.1 Introduction. 
The mt-LSU of the mammalian mitochondrial ribosome has a distinct structure called 
the L7/L12 stalk (Sharma et al., 2003). It is a highly conserved element of ribosomes in 
all three kingdoms: prokaryote, archaea and eukaryote (Wahl and Möller, 2002). The 
prokaryotic proteins are designated as L7/L12 and the eukaryotic, cytosolic as P1/P2. 
L7/L12 are identical in amino acid sequence, differentiated only by acetylation of the N-
terminus converting L12 to L7. P-proteins can be phosphorylated, and this alteration 
regulates interaction of the polypeptides with the ribosome in vitro (Vidales et al., 
1984). These are the only RPs bound to the large subunit through an interaction with 
other protein, L10 or P0 respectively, thus creating the stalk protuberance. L7/L12 and 
P1/P2, are acidic in character and occur on large subunits in dimers or multimers of 
dimers. They have a distinctive amino acid composition due to the large number of 
alanines, few aromatic residues and hardly any arginine, cysteine, or tryptophan. Acidic 
ribosomal proteins of archaea and eukaryotes are analogues of bacterial L7/L12, with a 
conserved functional domain organization (Rich and Steitz, 1987, Wool et al., 1991). In 
contrast to other RPs that are almost exclusively found complexed with translational 
machinery, the acidic ribosomal stalk proteins of both prokarya and eukarya have also 
been found in free cytosolic pools in E. coli (Ramagopal, 1976), S. cerevisiae, A. salina, 
and HeLa cells (Rich and Steitz, 1987). The studies on Saccharomyces cerevisiae 
showed that the amount of P-protein bound to a ribosome is changeable and depends on 
the metabolic state of the cell (Saenz-Robles et al., 1990). Approximately 40% more of 
it interacts with ribosomes in exponentially growing cultures than in stationary phase. 
Furthermore, the cytosolic pool is significant and can be comparable to the number of 
these molecules associated with ribosomes. It is important to mention interesting data 
concerning studies of four acidic proteins in yeast classified in two groups, YP1α/β and 
YP2α/β, corresponding to P1 and P2 mammalian cytosolic ribosomal proteins 
(Remacha et al., 1995). The analysis of translation rates in strains deprived of ribosome-
bound acidic proteins show only 30% activity compared to WT strains and a changed 
pattern of protein expression, but had no effect on the translational accuracy of the 
ribosomes. The authors propose that the alterations in translation rate of different 
mRNAs can be caused by aberrant ribosomes that are less efficient at disruption of 
some particular complex RNA structures of the messengers. Thus the lower level of 
protein synthesis on particular templates would not be specific but dictated by 
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incompetence of ribosomes from mutant strains to resolve the unique motifs of some 
templates. Interestingly, bacterial ribosomes lacking L7 and L12 proteins remain active 
under particular in vitro conditions (Koteliansky et al., 1977). However, this 
experimental approach was dismissed as incorrect by another research group, who 
showed a strong dependence of the translation rate on the presence of L7/L12 in 
prokaryotic ribosomes in vitro (Pettersson and Kurland, 1980). Moreover, removal of 
L7/L12 from the ribosome was reported to reduce significantly the accuracy of protein 
synthesis (Kirsebom and Isaksson, 1985) but no in vivo data has yet been published to 
show that translation can occur in the absence of L7/L12. 
 
E. coli L7/L12 protein is one of the most studied r-proteins. Four copies of L12 
are present in the E. coli ribosome (Brot and Weissbach, 1981). Some of which are 
modified post-translationally by acetylation of the N-terminal serine, to form L7 with a 
molecular mass increase of 42 Da (Terhorst et al., 1973). Interestingly, this modification 
is very common among eukaryotic proteins but in prokaryotes there are only four 
known polypeptides with N-terminal acetylation (Polevoda and Sherman, 2002). Two 
of these are SSU proteins, S18 and S5, and the third is L7. In contrast to S18 and S5, 
which are always present in the bacterial cells as acetylated, the ratio of L12 to L7 is 
changeable and depends on growth phase as well as nutrient availability (Subramanian, 
1975, Gordiyenko et al., 2008). The N-terminal domain of L12 is responsible for strong 
dimer interaction via methionine residues (Gudkov, 1997) and their oxidation causes 
disconnection of the dimers. Monomers are unable to bind L10 protein, which anchors 
the dimers to the ribosome. Mass spectrometry studies have shown that the N-terminal 
methionine promotes helical folding of NTD and thus binding to L10, which is 
enhanced by presence of acetyl group in L7 (Gordiyenko et al., 2008). In general this 
modification was proposed to increase stability of the L7/L12 stalk on the ribosome 
under stress conditions. Detailed structural studies of L7/L12 polypeptide are available 
and present this molecule as composed of two distinct organized domains linked by a 
flexible hinge (Dey et al., 1995,Dey et al., 1998, Wahl et al., 2000, Diaconu et al., 
2005). The helical, N-terminal domain of elongated shape, the function of which was 
described above, is connected by a short region to a globular C-terminal domain built of 
three α-helices and three β-sheets. The latter can take different conformations, from a 
compact helix to an extended random coil (Wahl et al., 2000, Moens et al., 2005). The 
flexible hinge gives the C-terminal domain a high freedom of movement, which 
contributes significantly to its ability to span a volume with a radius of 45 A. It is 
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proposed that this dynamic feature of L12 facilitates the recruitment of translation 
factors and also regulates the different states of the ribosome during the translation 
process (Berk and Cate, 2007). Indeed, the conserved region of the L12 C-terminal 
domain has been found to interact directly with initiation factor; IF2, elongation factors; 
EF-Tu (which brings the aa-tRNAs to the A-site of the ribosome), EF-G (which 
translocates peptidyl-tRNAs from the A-site to the P-site) and release factor RF3 
(recycles release factors RF1 and RF2 after removal of the nascent peptide) (Helgstrand 
et al., 2007). All of these factors catalyse the main steps of protein synthesis in a GTP-
dependent manner. Two of these factors, elongation factors Tu and G, together with 
L7/L12 proteins have been shown to activate GTP hydrolysis (Mohr et al., 2002) and 
take part in the rapid subunit association into the 70S initiation complex (Huang et al., 
2010). This process requires specific interaction between L7/L12 stalk present on the 
50S and IF2-GTP on the 30S subunit, although L7/L12 is not the GTPase activator for 
IF2 protein in contrast to elongation factors Tu and G.  
 
A broad range of L12 studies have also included experiments investigating the 
reasons for multiple L12 dimers presence on the bacterial ribosome. There are data 
showing that the activity of a single L12 dimer associated through a truncated L10 
protein with the ribosome was almost equal to two-dimer particles in an in vitro 
polyphenylalanine synthesis assay (Griaznova and Traut, 2000). Another publication, 
using the same assay presented high activity of chimeric molecules composed of two 
monomers of L12 in which one was lacking the C-terminal domain (Oleinikov et al., 
1998). Although interesting, these two articles present activity of L12 molecules in very 
simplified conditions, which cannot be easily compared to complex process of 
translation in vivo. In a recent publication, the E. coli strain JE105 with only a single 
dimer was reported to have a significant growth defect (Mandava et al., 2012). 
Moreover, ribosomes isolated from this strain showed lower efficiency of initiation and 
elongation steps involving IF2 and EF-G factors in vitro. The authors propose that the 
activity of bacterial ribosomes can be modulated by altering the number of L12 dimers 
bound to them in response to the growth conditions. This variation is seen in mesophilic 
archaea, Methanococcus vannielii and Methanosarcina barkeri, in which ribosomes 
with two L12 dimers are predominant at the early stages and during the lag phase of 
growth, whereas three dimers are most abundant in the exponential growth phase 
(Gordiyenko et al., 2010). In E. coli the stability of stalk is regulated by acetylation of 
the L12 protein (Gordiyenko et al., 2008). It has been also shown that the L7 content on 
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ribosomes changes according to the growth stage, with the highest abundance of the 
acetylated form in the stationary phase (Ramagopal and Subramanian, 1974), but the 
average number of L7 and L12 per ribosome remaining constant. Moreover, once 
integrated into the ribosome L7/L12 proteins do not undergo acetylation or 
deacetylation. Recently, the mechanism of L7/L12 monomer and dimer exchange 
between ribosomes was proposed based on kinetic analysis (Deroo et al., 2012). It has 
been also shown that binding of elongation factor EF-G decreases the rate of exchange 
via dimers by 47% and monomers by 27%. These new data fit well with previous 
observations and assumptions that in the bacterial cell a few populations of ribosomes 
can coexist with different ratios of L7 to L12 polypeptide, which can modulate the pace 
of translation in response to changing cellular requirements.  
 
The gene of human mitochondrial MRPL12 protein was identified almost 10 
years ago, as a delayed-early response. The protein has been shown to accumulate in the 
G1 phase of growth-stimulated cells (Marty and Fort, 1996) and described as a 
homologue of chloroplastic and bacterial L12 protein. Expression of the truncated form 
of MRPL12 lacking 76 amino acids from the CTD in HeLa cells, caused cell growth 
inhibition and ATP production impairment. Wild type (WT) and mutant were found to 
localize in mitochondria and co-fractionate with ribosomes (Marty and Fort, 1996). 
More recently, two pools of MRPL12 have been identified in mammalian mitochondria, 
ribosome-bound and free (Surovtseva et al., 2011). The free pool was shown to 
selectively interact with the mitochondrial RNA polymerase and stimulate 
mitochondrial transcription in vitro and in vivo (Wang et al., 2007, Surovtseva et al., 
2011). Interestingly, in human cells MRPL12 was identified as one of the interacting 
partners of NOA1 (C4orf14), which is postulated to be involved in 28S subunit 
biogenesis and mtDNA maintenance (He et al., 2012). The authors proposed that the 
free pool of MRPL12 interacting with POLRMT may play a role in the handover of 
mRNA from the transcription to the translation machinery, the assembly of which is 
believed to start from association of mt-SSU with mt-mRNA. Interestingly, MRPL12 
has been also identified in a complex of 200 kDa with MRPL10, MRPL53, MRPL45, 
MRPS21, LRPPRC, SLIRP and COX7A2, in a mitochondrial fraction obtained from 
HEK293 cells (Wessels et al., 2013). 
 
MRPL12 was also reported to be phosphorylated in mammalian mitochondria 
(Koc and Koc, 2012). A study using hybrid E. coli ribosomes carrying chimeric L7/L12 
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proteins that consist of the E. coli N-terminal domain and the mitochondrial C-terminal 
domain showed their ability to trigger the GTPase of elongation factor EF-G, interact 
with EF-Tu and support the translation activity (Terasaki et al., 2004). In other studies, 
applying core bacterial ribosomes stripped of L7/L12 stalk and replaced with 
mitochondrial MRPL10-MRPL12 complex in the presence of eight fold excess of 
recombinant MRPL12, the translation ability of these hybrid particles was restored to 
80% in comparison to the bacterial system, reconstituted with recombinant bacterial 
L10 and L7/L12 in vitro (Han et al., 2011). These last two publications described give 
at least partial evidence for a conserved function of MRPL12 protein in the translation 
process, with the ability to bind elongation factors and support protein synthesis on 
hybrid ribosomes. Han et al., 2011, present evidence partially confirming the structural 
and functional organisation of the stalk in mammalian mitochondria showing that both 
MRPL12 and MRPL10 are necessary for reconstitution of translational activity. In 
bacteria L12 dimers are linked to the ribosome via L10 protein. The high-resolution 
crystal structure of a complex consisting of L10 and 6 L12 NTDs from T. maritima 
determined the α8-helix at the C-terminus of protein L10 as a site for L12 dimers 
attachment (Diaconu et al., 2005). 
 
The available data concerning the role of mammalian mitochondrial MRPL12 
are still insufficient to draw sound conclusions of its functions. The relatively 
superficial information suggests that this is a highly conserved protein, which apart 
from taking part in the translation process as a ribosomal component, may also be 
involved in the modulation of the transcription process. So it could be that MRPL12 is a 
multifunctional factor of mammalian mitochondria with a range of regulatory functions 
linking different steps of mtDNA expression pathway. 
 
Immortalised fibroblasts with a mutated form of MRPL12 were made available 
to my host lab allowing us to study its function in human mitochondria. The cells 
originate from a patient with a severe clinical presentation consistent with mitochondrial 
disease (dysmorphy, growth retardation, lactic acidosis, hyperlactatemia, epilepsy). The 
measurements of the mitochondrial respiratory chain enzyme activities were performed 
by our collaborators and showed decreases in CI and CIV activities in the patient 
muscle biopsies, confirming a mitochondrial defect (Serre et al., 2013). The mutation 
was found to be a homozygous c.542C to T transition in exon 5, changing a highly 
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conserved alanine into a valine, p.Ala181Val (Figure 4.1; received from collaborators), 
which was identified and predicted by Polyphen2 software to be potentially damaging. 
Genome wide sequencing of the patient’s DNA failed to detect any other pathogenic 
mutations. It is important to underline that this mutation was absent from over 100 
sequenced controls. Both parents were heterozygous and a healthy girl sibling were wild 
type homozygous. Affected twin foetuses were homozygous the same mutation as the 
sibling from whom the fibroblasts originate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Fragment of sequenced MRPL12 gene with point mutation in patient 
compared with mother and control. The arrow shows the position of the mutation. Below, 
alignment of the CTD fragment of L12 protein containing the conserved A (alanine) in 
eukaryote and prokaryote, substituted in the patient gene to encode V (valine).  
 
The three dimensional structure of the human MRPL12 was modelled on the 
crystallized L12 protein from Thermotoga maritima. Based on this, the amino acid 
change in the mutant polypeptide chain was located in the highly conserved α-helical 
fragment of MRPL12 C-terminal domain (Serre et al., 2013). 
 
mother controlpatient
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Figure 4.2. The structural model of the human MRPL12. Polypeptide chain of human 
MRPL12 (residues 64 to 198) was modeled using the Swiss-Model on the L12 from 
Thermotoga maritima as a template. The model of MRPL12 contains just residues 64 to 
198 as the homology between human MRPL12 and the prokaryotic L12 does not extend 
across the entire length of the protein sequence. The A181 residue is indicated in red. CTD, 
C-terminal domain; NTD, N-terminal domain. Image adapted from Serre et al., 2013. 
 
Although substitution of alanine by valine is classified as a conservative 
mutation, it has been reported to cause changes in helix propensity (Gregoret and Sauer, 
1998). Alanine is considered as one of the best helix-forming residues in contrast to 
valine, which is a poor helix former. As the C-terminal domain of MRPL12 is 
putatively involved in translation factor interactions with the ribosome, this substitution 
could affect mitochondrial polypeptides synthesis.  
 
4.2 Point mutation in the MRPL12 gene affects steady state level of the  
protein and other proteins of the mt-LSU. 
In order to assess the influence of the mutation in the MRPL12 gene on the steady state 
level of the protein, western blot analysis of immortalised control and patient fibroblast 
lysates (50 µg) was performed (Figure 4.3). Membranes were incubated with antibody 
against MRPL12 as well as two other mt-LSU proteins MRPL3 and ICT1. The levels of 
three mt-SSU proteins, DAP3, MRPS18B and MRPS25 were also assessed. Figure 4.3 
is a representative western blot of a minimum of at least three independent samples for 
each protein. 
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Figure 4.3. Steady state levels of selected mt-LSU and mt-SSU proteins in immortalised 
MRPL12 patient fibroblasts are affected compared to control. Cell lysates (50 μg) were 
resolved on 12% SDS-PAGE gel. Antibodies for mt-LSU proteins: MRPL12, ICT1, MRPL3; 
mt-SSU proteins: DAP3, MRPS18B, MRPS25; and porin used as a loading control were 
detected via Storm PhosphoImager. Quantification of steady state levels of presented proteins   
(table) was performed with Image-Quant software (Molecular Dynamics, GE Healthcare). 
 
The steady state level of MRPL12 in patient fibroblasts was decreased by 70% versus 
control. Two other mt-LSU proteins were also reduced; ICT1 (by 70%) and MRPL3 (by 
40%). The levels of mt-SSU proteins were only modestly decreased to 70.7% (DAP3), 
74% (MRPS18B), and 56% (MRPS25) of control value. The reduction in mitochondrial 
large subunit proteins in the subject’s fibroblasts suggested destabilization of 
mitoribosome or its assembly. So, next the steady state levels of chosen respiratory 
chain proteins were assessed in order to confirm the results of the collaborating 
laboratory who presented a reduction of complexes I and IV by BN-PAGE of 
mitochondria prepared from fibroblasts of patient and control (Appendix 1.5, Figure 
1B).  
 
4.3 Steady state levels of respiratory chain proteins are selectively affected  
by the decrease in MRPL12 steady state level. 
Western blots were performed to analyse steady state levels of COX2, NDUFB8 and 
cytochrome c (cyt c) presented in Figure 4.4 as described in the previous subsection. 
The mitochondrially encoded subunit of complex IV, COX2 showed a significant 
 Patient % relative to 
Control 
MRPL12 32.5% 
ICT1 26.8% 
MRPL3 63.0% 
DAP3 70.7% 
MRPS18B 74% 
MRPS25 56.0% 
 
MRPL12 
MRPL3 
ICT1 
DAP3 
MRPS18B 
MRPS25 
Porin 
 
 
mt-LSU 
mt-SSU 
Patient Control 
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reduction in the steady state levels. This was also true for NDUFB8, which although not 
mitochondrially encoded is used as a marker for complex I as it is sensitive to 
degradation in the absence of assembled complex I. These data confirm the results of 
BN-PAGE analysis that showed a decrease of both of these complexes in patient 
fibroblasts versus control. The level of cytochrome c was also determined, as a control 
for the respiratory chain and porin was used as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Steady state levels of selected respiratory chain proteins in immortalised 
MRPL12 patient and control fibroblasts. Patient and control fibroblasts lysates (50 µg) were 
separated by 12% SDS-PAGE followed by western blot analysis with antibodies against COX2 
and NDUFB8. Cyt c level was determined as a control for the respiratory chain. Porin was used 
as an indicator of mitochondrial mass. Antibodies for presented proteins were detected via 
Storm PhosphoImager/ImageQuant. 
 
The significant reduction in the steady state level of MRPL12 protein as well as two 
other proteins of the ribosomal mt-LSU, ICT1 and MRPL3 seen in Fig 4.3, suggested 
possible deregulation in mitoribosome assembly. In conjunction with the decreases seen 
in subunits of complex I and IV (Fig 4.4) this strongly supported an aberrant function of 
the translational machinery in patient fibroblasts. To identify whether these changes had 
an impact on cell viability, the growth rate of immortalised patient fibroblasts versus 
control was also assessed. 
 
4.4 Patient fibroblasts have a decreased rate of growth. 
In order to assess the influence of the mutated form of MRPL12 on patient derived 
fibroblast viability, cells (10 000) were seeded in 6-well plates. Control and patient 
fibroblasts were plated in triplicate on day 0. Cells were counted three times at 48 hours 
intervals as described in subsection 2.1.5. Each point on the graph (Figure 4.5) 
NDUFB8 
COX2 
Cyt c 
respiratory chain proteins  
Porin 
Control Patient 
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presenting the growth curves for control and patient fibroblasts, is the mean number of 
cells from three independent wells. 
 
 
Figure 4.5. Cells growth analysis of patient and control fibroblasts. Cells were grown in 6 
well plates in glucose containing media. On “day 0” 104 cells were seeded and counted every 
second day in triplicates. n = 3 control (blue) and patient (red). Error bars are +/- SD. 
 
The growth rate of patient fibroblasts was reduced in comparison with the control cell 
line, which is in agreement with data showing disruption of OXPHOS complexes. All of 
the preliminary data described so far prompted further investigations aiming to specify 
the molecular basis of step or steps of mitochondrial gene expression where mutated 
MRPL12 failed to function correctly. In order to determine whether the mutation in 
MRPL12 affected integration into the ribosome, sucrose gradient fractionation of 
mitochondrial lysates was performed. 
 
4.5 Analysis of mt-SSU, mt-LSU and monosome location in isokinetic    
     sucrose gradients of mitochondrial lysates of patient fibroblasts. 
Isokinetic sucrose gradient fractionation allows for the separation of particles according 
to their molecular mass. Thus, if the assembly of either the mt-LSU or the complete 
mitoribosome was altered, the distribution of individual MRPs would be expected to 
differ for the subject’s gradient profile versus the control. Mitochondrial lysates (300 
µg; prepared as in subsection 2.5.1 and 2.5.2) of control or patient fibroblasts were 
independently loaded onto 10-30% isokinetic sucrose gradients and separated by 
centrifugation (described in subsection 2.5.8). Fractions of 100 µl were collected and 10 
µl aliquots were analysed by western blotting (Figure 4.6). 
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Figure 4.6. Isokinetic gradient centrifugation to analyse MRPs distribution in patient 
samples. Mitochondrial lysates (300 µg) from control (C) and patient (P) immortalised 
fibroblasts were loaded on 10-30% sucrose gradients. Fractions were collected for each sample, 
where sample 1 corresponds to the top and fraction 11 the bottom of the gradient. 15 µl of each 
fraction was separated on 12% SDS-PAGE gel and proteins of mt-LSU: MRPL12, ICT1, 
MRPL3, mt-SSU: DAP3, S18B and POLRMT were detected via western blot analysis using 
Storm PhosphoImager and ImageQuant software. Mitochondrial ribosomal subunits (28S, 39S) 
and monosome (55S) are depicted above the fractions in which they would be expected to 
migrate. 28S: boxed fractions 4 and 5, 39S: boxed fractions 6 and 7, 55S: fraction 8. 
 
Surprisingly, analysis of the gradients did not show any significant changes in 
location of 28S, 39S or 55S as can be seen by the similar migration of control and 
patient proteins in the boxed regions, showing the position of the mt-SSU (fractions 4 
and 5) and mt-LSU (fractions 6 and 7) on the gradient. The most significant difference 
in the patient can be observed in the overall strength of the MRPL12 signal, reflecting 
both the lack of detectable signal in fractions 1 and 2 (the free pool) and also 
substantially decreased amounts in mt-LSU fractions. Since it has been published that 
the free pool of MRPL12 interacts with POLRMT (Surovtseva et al., 2011), this 
redistribution of MRPL12 may have influenced the distribution of POLRMT. The 
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distribution of mitochondrial RNA polymerase in sucrose gradient fractions and its 
steady state level was therefore analysed (Figure 4.6 and 4.8). Although steady state 
level of POLRMT was decreased to 63% in patient fibroblasts versus control, the 
position of the signal within the gradient did not differ, suggesting that the physiological 
interactions had not been affected. The abundance of patient MRPL3 was slightly 
reduced in fractions 5, 6, 7 and 8, but there was no significant shift in the migration 
pattern in the patient fibroblast sample. The position and strength of the ICT1 signal 
was very similar in subject cells versus control, apart from fraction 11, where a clear 
decrease in the amount of this protein occurs. The same reduction in amount of protein 
present in fraction 11 is also seen for MRPL12. The small subunit proteins, DAP3 and 
MRPS18B, were affected to an even lesser extent. The distribution of their signals in 
the sucrose gradient of patient fibroblasts was comparable with control. The biggest but 
nevertheless modest difference is in MRPS18B, where there is a reduced abundance in 
patient fractions 4 and 5. Both of the mt-SSU proteins assessed were reduced in fraction 
11 in subject fibroblasts in comparison with control. It was necessary to determine 
directly whether these relatively minor changes seen on the gradient analyses, had an 
impact on mitochondrial translation. 
 
4.6 De novo mitochondrial proteins synthesis in patient fibroblasts versus 
control. 
To further characterise the effect of mutated MRPL12 on mitoribosomes analysis of 
mitochondrial translation was performed. Metabolic labelling with 
35
S-met/cys of de 
novo synthesised mitochondrial proteins under conditions of inhibited cytosolic 
translation was performed in immortalised control and patient fibroblasts together with 
Dr. Francesco Bruni. 
 
Cultured immortalised control and patient fibroblasts of ~70% confluency were 
preincubated in methionine/cysteine free DMEM, followed by incubation with emetine 
to inhibit cytosolic translation (cf 2.5.7). Radiolabel was added for 1 hour and chased 
for the same period of time. Samples were prepared and separated on 15% SDS-PAGE. 
A generalised decrease in signal for almost all mt-encoded proteins was seen in patient 
fibroblasts compared to control (Figure 4.7) indicating a global decrease in 
mitochondrial translation. Densitometric evaluation of the signals revealed that in 
particular, translation of COXI, COXII and COXIII subunits of complex IV were 
significantly reduced, as was ATP6 of complex V. Mitochondrial polypeptides of 
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complex I were also decreased but to a lesser extent and cytochrome b was not affected. 
Following analysis, the gel was rehydrated and Coomassie blue stained to confirm equal 
loading. 
 
 
Figure 4.7. In vivo 35S-met/cys metabolic labelling of mitochondrial proteins. Whole cell 
lysates (50µg) from immortalised control and MRPL12 patient fibroblast following metabolic 
labelling were separated by 15% SDS-PAGE. 
35
S-methionine/cysteine incorporated into de novo 
synthesized mitochondrially encoded OXPHOS subunits were visualised after overnight 
exposure of the dried gel to a PhosphorImage screen, analysis with Typhoon FLA900 and 
Image-Quant software (Molecular Dynamics, GE Healthcare). Coomassie blue staining of the 
rehydrated gel is shown in the lower panel. To the right of the autoradiograph are presented 
densitometric profiles of control (black trace) and patient (blue trace). The figure was provided 
by Dr. Francesco Bruni. 
 
The result of the de novo mitochondrial translation assay is in agreement with western 
blot analysis of COXII and NDUFB8, where both techniques demonstrate a significant 
reduction in the steady state levels (subsection 4.4). Moreover, our collaborators BN-
PAGE analysis of OXPHOS complexes also presented a significant decrease in complex 
I and IV with no change in complex III level in subject fibroblasts. Despite publications 
suggesting a potential role for MRPL12 in translational accuracy, there were no aberrant 
polypeptides detected in the analysis of the patient cell line. There is, however, evidence 
Coomassie blue 
staining 
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of malfunction of the mitoribosome. Although the pattern of protein synthesis is clearly 
changed in patient fibroblasts, a particular feature is the inequality of translational 
efficiency for different mitochondrially encoded subunits. Intriguingly, mitoribosomes 
in fibroblasts with the mutated form of MRPL12 are capable of producing cytochrome b 
with the same efficiency as control, but fail most profoundly in synthesis of COX 
subunits. In order to clarify whether the MRPL12 defect had its effect at the 
transcriptional rather than translational level the steady state levels of mt-rRNA; 16S, 
12S and selected mt-mRNA species: MTCO1, MTND1 and MTCYB were assessed.  
 
4.7 The effect of mutant MRPL12 on 16S, 12S and mt-mRNAs levels. 
Diversity in translational efficiency and lowered signal of POLRMT in fraction 11 of 
sucrose gradients (Figure 4.6), which was confirmed by western blot analysis of 
POLRMT steady state levels presented in figure 4.8, dictated assessment of 
mitochondrially encoded RNAs in patient fibroblasts. 
 
 
Figure 4.8. The steady state level of POLRMT in patient fibroblasts. Western blot analysis 
of immortalised patient and control fibroblast lysates (50µg) was performed with antibodies 
against POLRMT. Porin was used as a loading control. The blot is representative of 3 
independent repeats. 
 
Northern blot analysis of MTRNR1, MTRNR2 and mt-mRNAs steady state levels was 
performed (cf subsection 2.4.2.). Different amounts of RNA from the same sample were 
loaded to improve the quantification in case signals were weak or saturating. RNA 
species were visualised with radiolabelled probes and indicated that MTRNR2 level was 
lowered by 32.5% in subject fibroblasts and MTRNR1 was decreased by 20% (Figure 
4.9). 
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Figure 4.9. Northern blot analysis of control and patient total RNA.  
A. RNA was extracted and separated on 1.2% agarose gel under denaturing conditions, 
transferred to the GeneScreen Plus membrane and probed for MTRNR1, MTRNR2 and MTCO1, 
MTND1, MTCYB, and 18S cytosolic rRNA as a loading control. B. Tables containing the 
densitometric quantification of signals derived for mt-rRNAs and mt-mRNAs. C. Immortalised 
patient and control fibroblasts lysates (50 µg) were separated by 12% SDS-PAGE and the 
subsequent western blot was decorated with antibodies against SLIRP protein, and with -actin 
as a loading control. Signals were detected via Storm PhosphoImager and analysed by Image-
Quant software. 
 
The data for the 2 ribosomal RNAs shows that the mutation in MRPL12 affects the 
large ribosomal subunit to a higher extent than mt-SSU. This is in agreement with the 
results of steady state ribosomal proteins levels and sucrose gradient fractionation of 
mitochondrial lysates, which also showed a greater reduction in amounts of mt-LSU 
proteins than in mt-SSU proteins, in the patient samples. The levels of MTCO1 and 
MTCYB in patient fibroblasts were not affected, but MTND1 was elevated by ~38% 
comparing with control. SLIRP protein is part of the ribonucleoprotein complex that is 
dependent on the presence of mt-mRNA (Sasarman et al., 2010). Therefore,  it was 
appropriate to see if the change in mt-mRNA levels have an effect on the steady state 
RNA 
amount 
MTCO1 
Patient/Control 
MTND1 
Patient/Control 
MTCYB 
Patient/Control 
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5µg 98% 153% 100% 
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RNA 
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10µg 70% 80% 
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level of SLIRP in patient fibroblasts compared to control. Western blot analysis was 
performed and showed that there was no change in the steady state level (Figure 4.9C), 
which is consistent with the lack of reduction in mt-mRNAs. 
 
The reduction of MTRNR2 and the lower signal for MRPL12 in sucrose gradient 
fractions (Figure 4.6) both of which are components of the mt-LSU (fraction 6 and 7) 
and fully assembled mitoribosome (fraction 8) suggested a protective function of this 
protein on the 16S rRNA.  This could be indirect by affecting 39S assembly or integrity, 
or directly by specific interactions with the rRNA. In order to investigate this potential 
ability of MRPL12 to bind rRNA in vivo and map the location of interaction if any, the 
CLIP method was used (protocol is provided in subsection 2.6.1). The assay was 
performed with endogenous protein for which an affinity purified antibody was 
generated (described in subsection 2.5.9). CLIP sequences were analysed by IonTorrent 
and aligned to a linear map of mtDNA. As expected the highest number of hits was 
identified in 16S rRNA. The specific position of binding was between nucleotide  
~1750-1790, with almost 500 reads for control fibroblasts and 570 for patient 
fibroblasts (data presented in Appendix 1.2). There were three more positions identified 
that suggested direct binding to 16S but each with a lower number of reads. Overall, the 
number of CLIP sequences identified as 16S rRNA was considered as too low in order 
to unequivocally confirm a close and direct interaction with MRPL12, when compared 
with another ribosome interacting protein, RBFA, where over 3000 hits were mapped to 
one position on the 12S rRNA. The MRPL12 data also included a high number of reads 
for 18S rRNA, which was used as one of controls, (data presented in Appendix 1.1; 
Table 1). It would be interesting to repeat the CLIP for MRPL12 with HEK293 lysate in 
order to clarify its ability to bind rRNA directly. It has to be taken in consideration that 
fibroblasts have a lower mitochondrial mass comparing with HEK293 (used in CLIP for 
RBFA protein) so it could be the reason for the lower number of hits on 16S rRNA and 
18S sequences amplified preferentially. Interestingly, some mt-tRNA species were also 
identified among the CLIP tags in the patient sample. Although patient and control 
exhibited the same pattern of possible binding to 16S rRNA, the interactions with 
tRNA
Glu
 (over 200 reads) and tRNA
Met
 (100 reads) are specific for mutated form of 
MRPL12. 
 
Because the levels of mt-mRNA species were not decreased, even elevated in 
case of MTND1, but the steady state level of POLRMT was reduced (Figure 4.8) and 
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free pool of MRPL12, which interacts with POLRMT, was not detected in subject 
fibroblasts (sucrose gradient fractionation; Figure 4.6), the stability of a subset of mt-
messenger RNAs was assessed to check if the half-lives were extended to compensate 
for a possible lowered transcription rate.  
 
4.8 Stability of mt-mRNAs in patient fibroblasts versus control.  
The stability of transcripts was determined by exposing patient and control fibroblasts 
to ethidium bromide, which selectively inhibits mt-transcription at a final concentration 
of 250 ng/ml, and isolating and analysing RNA taken at time points thereafter. 
A 
 
 
    B 
 
Figure 4.10. Stability of mt-mRNA species in control and patient fibroblasts. 
Cells were grown in 6-well plates in presence of transcription inhibitor and harvested at 0, 1, 2, 
4, 8 and 16 hr post ethidium bromide addition (n = 2). A. Northern analysis was performed 
probing for mt-mRNA species MTCO1 and MTND1. B. The rate of decay is plotted for each 
transcript in each sample. Signals were detected via Storm PhosphoImager and analysed by 
Image-Quant software (Molecular Dynamics, GE Healthcare). 
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Fibroblasts were collected for each time point (n=2 for both control and patient cells). 
RNA was isolated and analysed by northern blot (Figure 4.10 A) and the quantification 
of the half-lives for MTCO1 and MTND1 shows elevated stability of transcripts in 
patient fibroblasts (Figure 4.10 B). Especially MTND1 appears to be stabilized, this 
might compensate for the decrease in the level of POLRMT (Figure 4.8). Since, the 
steady state levels of mt-mRNAs are not reduced but the translation efficiency is 
decreased for most of the mitochondrial transcripts (Figure 4.7; de novo mitochondrial 
translation) further investigation of ribosome assembly was undertaken. RNA from 
isokinetic gradient fractions of fibroblast lysates was analysed by northern blot to assess 
the location of 12S and 16S mt-rRNA as well as selected mt-mRNAs. This was 
performed as a more sensitive technique than western blot to determine whether mt-
rRNA was protected and subunits were assembled.  
 
4.9 Location of 16S, 12S and mt-mRNA in sucrose gradient fractions. 
In order to determine potential, subtle changes in mitoribosome assembly, cell lysates 
(700 µg; cf 2.5.1) of control and patient fibroblasts were loaded on the 10-30% 
isokinetic sucrose gradient (cf 2.5.8). Fractions (100 µl) were collected and 90% used 
for LS Trizol RNA extraction (cf 2.4.1). 
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Figure 4.11. Northern analysis of mitochondrial RNA species extracted from sucrose 
gradient fractions of cell lysates. Patient and control RNA from gradient fractions analysed by 
northern blot with probes for mt-rRNAs; MTRNR1, MTRNR2 and mt-mRNAs; MTCO1, 
MTND1 as indicated. The positions of the 28S mt-SSU, 39S mt-LSU and 55S monosome are 
indicated above the fraction numbers, where 1 is top of the gradient and 11 the bottom. Signals 
were detected via Storm PhosphoImager/ ImageQuant software. 
 
Northern analysis (cf 2.4.2, Figure 4.11) revealed the distribution of MTRNR1and 
MTRNR2 in sucrose gradient fractions. This was consistent with the position within the 
gradients of the mt-SSU and mt-LSU obtained by western blot (Figure 4.6), which 
showed no major relocation of ribosomal subunits in patient fibroblasts. Although the 
location of mt-mRNAs (MTND1 and MTCO1) was not changed, the MTND1 signal is 
stronger in patient fraction 8 in contrast to control fraction 9, but clearly decreased in 
patient fraction 4. The strong signal of precursor (higher band from the doublet) of 
MTCO1 is located in patient fraction 6. There is also reduced signal of MTCO1 in 
patient fractions 9 and 10. The precursors were not detected for any other mt-RNA 
species described. 
 
4.10 Further investigation of mitoribosome assembly in patient fibroblasts. 
The western and northern blot analysis of sucrose gradient fractions did not 
unequivocally answer whether ribosome assembly is altered in subject fibroblasts. One 
question that remained unanswered was whether the MRPL12 mutation affected 
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dimerization or multimerisation, which in turn could affect binding to the monosome 
and translation efficiency.  
 
 
Figure 4.12. Immunoprecipitation of mitoribosomes via MRPL12 protein. A. 
Mitochondrial lysates (830 µg) from control and patient were incubated for 90 min with protein 
G beads (Dynal Invitrogen), coated with MRPL12 antibody. Half of the elution and 
mitochondrial lysate (input: 15µg) was analysed by western blot. Mt-SSU (DAP3, S18B) and 
mt-LSU (MRPL3, ICT1, MRPL12). In case of the mitochondrial lysate (input) β-actin was used 
as a loading control. B. Steady state level of mt eF-TS (mitochondrial elongation factor). 
Western blot analysis of immortalised patient and control fibroblast lysates (50µg) was 
performed with antibodies against mt eF-TS. Porin was used as a loading control. Proteins 
levels were visualised by Storm PhosphoImager. 
 
Immunoprecipitation of monosomes from patient and control mitochondrial lysates was 
performed to determine if it was possible to distinguish whether less monosome was 
formed or whether monosome was formed but had less MRPL12 associated. Affinity 
purified antibodies to MRPL12 were used and relative amounts of co-
immunoprecipitating MRPs were analysed. 
 
The immunoprecipitation experiment was performed (cf subsection 2.5.10) with 
830 µg of mitochondrial lysate. After incubation (1hr) with protein G/ MRPL12 beads, 
supernatant was removed from pelleted beads and the pull-down was eluted from 
washed beads with 25 µl of 1x sample buffer (described in 2.5.4). After 3 min 
incubation at 95C eluates from control and patient were analysed by western blot. Half 
of the obtained samples were separated on 14% SDS-PAGE alongside 15 µg of 
fibroblast mitochondrial lysates (input) (Figure 4.12 A). In order to assess monosome 
 
A 
B 
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abundance antibodies for mt-SSU (DAP3, MRPS18B) and mt-LSU (MRPL12, ICT1, 
MRPL3) proteins were used. Western blot analysis of the eluates shows equal levels of 
mt-SSU proteins but decreased MRPL12 and ICT1 relative to approximately control 
levels of MRPL3 in subject eluate versus control (Figure 4.12 A). As the 
immunoprecipitation was performed with MRPL12 antibody, the eluates contained not 
only fully assembled mt-ribosomes, but also mt-LSU and free fraction of MRPL12. 
Similar levels of mt-SSU (DAP3, S18B) proteins in patient and control samples suggest 
that the mutated form of MRPL12 has no influence on the assembly of monosomes. 
This is in agreement with western and northern analysis of sucrose gradient fractions 
(Figures 4.6 and 4.11). The level of mt-LSU protein MRPL3 is unchanged in contrast to 
MRPL12, whereas ICT1 appears to be modestly decreased. The control eluate also 
consists of a free pool of this MRPL12 as well as mt-LSU and monosomes, so the signal 
is a sum of three pools; free, 39S and 55S. In the case of the patient sample most of the 
signal consists of two pools; mt-LSU and monosome bound, as the free pool of 
MRPL12 was below detection in sucrose gradient fractions (Figure 4.6). A substantial 
part of the decrease in the level of MRPL12 in patient cells may potentially be 
accounted by the loss of a fraction interacting with POLRMT, independent of the 
ribosome bound protein. It can not be excluded, however, that some portion of decrease 
in the signal detected for mutated form of MRPL12 is caused by partial loss of this 
protein bound to mt-LSU as the sucrose gradient analysis show clearly a reduction of it 
in fractions of mt-LSU and monosome. 
Overall, the immunoprecipitation result stays in agreement with previous 
experiments, confirming the presence of fully assembled monosomes in subject 
fibroblasts, but with decreased contribution from MRPL12.  
The MRPL12 was shown to interact with translational elongation factors. As its 
mutant form is substantially decreased, the steady state level of mteF-Ts was checked in 
order to assess if there is any correlation in the levels of these possible interactors 
(Figure 4.12B). Western blot analysis of mt eF-Ts did not show any reduction in the 
steady state level of this protein. Further investigation would be necessary to clarify 
how the mutated form of MRPL12 deregulates the process of translation in subject 
fibroblasts. In order to clarify whether any disruption occurs in the interaction between 
subject monosomes and translation factors, location of those proteins in sucrose 
gradient fraction could be analysed as well as their level in the eluate of 
immunoprecipitates obtained from immunoprecipitation of MRPL12 from patient and 
control mitochondrial lysates.  
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4.11 Discussion. 
The point mutation in MRPL12 gene that changes A181 to V causes a significant 
decrease in the steady state level of this protein by 70% in patient fibroblasts versus 
control (Figure 4.3). This reduction influences other proteins of mt-LSU including ICT1 
steady state level decreased to 26.8% and MRPL3 to 63% of control value. Whereas 
proteins of mt-SSU are affected to lesser extend with DAP3 reduced to 70,7%, 
MRPS18B to 74 % and MRPL25 to 56% versus control. As expected the decrease in 
the abundance of ribosomal proteins had an effect on the steady state level of OXPHOS 
subunits with COXII and NDUFB8 clearly reduced in subject fibroblasts (Figure 4.4). 
This observation is in agreement with Blue-Native analysis of mitochondrial complexes 
(performed by collaborating laboratory), which revealed a substantial decline in the 
amount of CI and CIV (Serre et al., 2013). In order to establish whether the mutated 
form of MRPL12 influences assembly of the mt-LSUs and/or monosomes, 
mitochondrial lysates of patient and control were separated in isokinetic sucrose 
gradients. Western blot analysis of the sucrose gradient fractions showed no significant 
changes in location of mt-LSU, mt-SSU or monosome in subject versus control (Figure 
4.6), which strongly suggest that mutated form of MRPL12 does not influence mt-
ribosome biogenesis. However, using antibodies to MRPL12 (Figure 4.6) clearly 
showed the lack of a free pool of MRPL12 in patient fibroblasts and a decreased signal 
in fractions assigned to mt-LSU and monosome. Interestingly, all of the MRPs detected 
in the sucrose gradient fractions are visibly reduced in patient fraction 11, apart from 
MRPL3. The final fractions harbour the heaviest particles, which may represent non-
translating aggregated ribosomes. The presence of a ribosomal pool that is not 
participating in protein synthesis has been acknowledged in publications (Remacha et 
al., 1995). Whatever the role of this subset is, the source of molecules that could be 
reused to generate newly formed monosomes or the reserves waiting to increase the 
translation process as required is distinctly reduced in patient fibroblasts.  
It is difficult to draw final conclusions regarding the number of MRPL12 
molecules per monosome in human mitochondria. In bacteria there are two or three 
dimers associated with 70S, but the dimerization status and the number of dimers in 
human mitochondrial monosomes is unknown. Although published results concerning 
the use of chimeric ribosomes composed of core bacterial ribosomes stripped of L7/L12 
stalk and replaced with mitochondrial MRPL10-MRPL12 complex showed the 
necessity of eight fold excess of recombinant MRPL12 to restore their activity to 80% 
of bacterial system in in vitro translation reactions (Han et al., 2011). 
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In order to elucidate if the stoichiometry of patient MRPL12 per mt-LSU was adjusted, 
I performed the immunoprecipitation on patient and control mitochondrial lysates using 
antibody against MRPL12 (Figure 4.12). Western blot analysis of the eluate clearly 
demonstrated reduction in the mutated MRPL12 as well as ICT1 although to a lesser 
extent. This reduction had no influence on MRPL3 protein assembled into the 
mitochondrial LSUs. Overall, the amount of mutated MRPL12/39S appears to be 
reduced. The level of mt-SSU proteins in fully assembled monosomes appears to be 
unaffected. The immunoprecipitation of subject and control monosomes via 28S protein 
could clarify whether the reduction in MRPL12/39S influences assembly of mt-SSUs. 
Unfortunately this approach had to be excluded from the experimental investigation as 
the antibody that would immunoprecipitate endogenous mt-SSU proteins was not 
available. 
Summarizing, immunoprecipitation of MRPL12, which collects free MRPL12, 
mt-LSUs and monosomes shows no detectable difference in the amount of proteins of 
mt-SSU in patient fibroblasts versus control in contrast to proteins of mt-LSU, where 
MRPL12 and ICT1 signal is clearly decreased. This observation strongly supports both 
western and northern blot analysis of sucrose gradient fractions confirming presence of 
assembled monosomes and mt-LSUs possibly lacking at least partially MRPL12. It has 
to be underlined that in the control fibroblasts the free fraction of MRPL12 represents a 
significant subset of this protein, which is absent in patient cells and may account for 
the reduced signal in the immunoprecipitation. 
Free MRPL12 was reported to be associated with mitochondrial RNA 
polymerase and thereby to have an influence on the transcription process. Although the 
steady state level of POLRMT is modestly reduced (Figure 4.8) in subject fibroblasts, 
the location in sucrose gradient fractions is not changed (Figure 4.6). This suggests that 
the distribution and by extrapolation the activity of POLRMT is not affected by the loss 
of free MRPL12. This is further supported by the northern blot analysis of mt-mRNAs 
steady state levels, which are not decreased. However, in order to determine if 
transcription was affected with a downstream consequence on transcript stability, the 
half-lives of two mt-mRNAs were analysed (MTCO1 and MTND1). In this preliminary 
analysis, the stability was found to be elevated, which might be a compensatory 
mechanism for a decrease in the transcription rate caused by the absence of MRPL12 
free pool. An alternative hypothesis that can not be excluded is that the stability of mt-
mRNAs species is increased because the rate of translation is lowered and the templates 
stay associated with monosomes longer. This possibility is supported by northern blot 
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analysis of fibroblast sucrose gradient fractions where the MTND1 signal is stronger in 
patient fraction 8 (assigned to the monosome) compared to control fraction 9 (Figure 4. 
11). In contrast, the signal of MTCO1 appears to be equal in patient and control fraction 
8 but the accumulation of MTCO1 precursor is clearly visible in patient fraction 6. 
There is also reduced signal of MTCO1 in patient fractions 9 and 10. It is vital to 
underline that although in patient fibroblasts translation of all species takes place, it 
does not appear to do so to a uniform extent (Figure 4.7). Some transcripts are 
synthesized in patient fibroblasts equally to control such as cyt b, some are modestly 
decreased including subunits of CI or others are markedly decreased (CIV subunits). It 
is tempting to speculate that the variations present in the above mentioned northern blot 
analysis as well as divergence in the level of translation could be of dual source; 1) lack 
of the free pool of MRPL12, and/ or 2) dysfunctional monosomes (mutated 
MRPL12/39S appears to be reduced).  
First, the free pool of MRPL12 was recently identified to be enriched at the 
nucleoids foci where mt-RNA processing begins. That could be justified by the 
interaction of MRPL12 with POLRMT and its role in transcription process (Surovtseva 
et al., 2011). However, taking into consideration the presence of MTCO1 precursor in 
fraction 6 of patient sucrose gradient allows to hypotheses that MRPL12 could 
influence the processing of some mt-mRNAs. Moreover, the free pool interacting with 
POLRMT (Surovtseva et al., 2011), potentially takes part in the assembly of monosome 
which starts by association of mt-SSU with mt-mRNA (He et al., 2012). Furthermore, 
as the mutated MRPL12/39S appears to be reduced and the accumulation of the MTND1 
signal in patient monosome fraction of sucrose gradient is enhanced it is possible that 
the ribosomes with a mutated form of this protein are not capable of performing 
translation as efficiently as the control. The lower rate of translation could be due to 
disturbance of interactions between MRPL12 and translation factors. The eubacterial 
L12 homologue has been shown to interact with range of translation factors that affect 
participation in all stages of translation; initiation, elongation and termination of protein 
synthesis. Human MRPL12 shares 27.5% identical amino acid sequence to its T. 
maritima counterpart (Serre et al., 2013) and the substitution of alanine to valine is 
located in an α-helix of the C-terminal domain (Figure 4.2) where sequence and 
structural similarity are shared. Importantly loss of this CTD has been shown in 
eubacterial ribosomes to cause a decrease in GTPase activity, which is driven by the 
interaction with various translation factors. It can, therefore, be proposed that the 
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MRPL12 mutation found in this patient results in the failure of the monosome to 
interact efficiently with translation factors. 
However, as mentioned before, de novo protein synthesis performed in subject and 
control fibroblasts clearly present variations in the level of mitochondrially translated 
proteins. If the source of decreased translation would be caused by deregulation of 
interactions between mutated MRPL12 and translation factors, one could easily assume 
a global, equal decrease in 13 mitochondrial subunits of OXPHOS system which is not 
seen in de novo mitochondrial proteins synthesis assay (Figure 4.7). However if the free 
pool of MRPL12 influences the rate of processing of some mt-mRNA species and their 
availability for the monosomes, then both disruption of posttranscriptional events and 
reduced efficacy of mitoribosomes could result in this mixed pattern of mitochondrial 
protein synthesis in patient fibroblasts. The pattern of distribution for other mt-mRNAs 
could be checked in sucrose gradient fractions to clarify if processing is affected. 
MTND1 and MTCO1 were chosen for this analysis as they co-build complex I and IV 
respectively, which presented highest deficiency in patient fibroblasts (Appendix 1.5; 
Table 1, Figure 1). 
It can not be excluded that the variations in patient mitochondrial protein 
synthesis can at least partially be due to the specificity of the transcribed template or 
synthesised polypeptide. It has been shown in numerous publications concerning 
bacterial L12 that this protein is enormously flexible and the CTDs of dimers interacting 
with translation factors (Helgstrand et al., 2007) are in close proximity to many strategic 
sites of ribosome including the sarcin-ricin loop (SRL) of 23S rRNA, which is a factor-
binding site essential for GTP-catalyzed steps in translation, the peptidyl-transferase 
domain, and the head of the 30 S subunit (Dey et al., 1998). It is tempting to speculate 
that these putative interactions in patient mitochondrial ribosomes are disrupted because 
of a decreased number of MRPL12 molecules per ribosome or by physical steric 
hindrance caused by the amino acid substitution. Again the enriched signal of MTND1 
in monosome fraction of sucrose gradient could be the result of mt-ribosomes stalling. It 
is, therefore, tempting to propose that human MRPL12 possibly influences correct 
conformation of ribosomes in order to efficiently disrupt the secondary structures of mt-
mRNAs. Indeed, some proteins of eubacterial mt-SSU (S3 and S4) were postulated to 
take part in its mRNA helicase activity influencing ribosome processivity (Takyar et al., 
2005). S3 protein was shown as one of interacting partners with L7/L12 (Dey et al., 
1998), the same as L2 protein implicated in peptidyl-transferase activity (Diedrich et al., 
2000). Interestingly, elongating ribosomes are able more readily to melt mRNA 
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secondary structures (Qu et al., 2011). It is possible that human MRPL12 also interacts 
with numerous parts of the mitoribosome influencing its velocity. Since the 
conformations of the templates differ it can not be excluded that ribosomes with 
mutated form of MRPL12 can stall on some specific structures of mRNAs as they are 
unable to promptly unwind them and therefore translate some species at a lower rate. 
The other source of mt-ribosomes stalling could be caused by distinct sequence motifs 
in the already translated polypeptides. Recently, it has been published that bacterial 
ribosomes stall on diprolyl motifs and are rescued by the EF-P (translation elongation 
factor) (Peil et al., 2013). Then, in the case of monosomes containing mutated MRPL12 
the possible altered interaction with some translation factors can stall some of them 
depending on the polypeptide sequence and cause variations in the level of translation 
among mitochondrial polypeptides. In order to resolve if patient mitoribosomes fail to 
melt secondary structures of incoming mt-mRNAs or stall during translation on 
emerging polypeptides motifs the technique of ribosome profiling could be applied. 
This novel technique allows characterisation of the pattern of binding sites on mRNAs 
by ribosomes at any particular moment (Weiss and Atkins, 2011) and has been already 
used to investigate mitochondrial translation (Rooijers et al., 2013). As it is based on 
deep sequencing of ribosome-protected mRNA fragments ribosome profiling generate 
large amount of data that allow in depth analysis of translation process. By using 
inhibitors of initiation and later the progression of translation it is possible to assess the 
speed of the translating ribosomes (Weiss and Atkins, 2011). In one of the study using 
ribosome profiling technique the translation rate in the mouse embryonic stem cell line 
was established at the processing of 6 amino acids per second (Ingolia et al., 2011). 
Moreover this technique enables to identify the source of ribosomes stalling, for 
example in the Ingolia et al. study; 1500 major pauses were detected caused by the 
specific 3 codon arrangement Pro-Pro-Glu. Unfortunately, mitochondrial ribosome 
profiling has not yet been fully established in our laboratory, although this is underway. 
Once optimized it could answer whether monosomes in patient fibroblasts have a lower 
rate of translation, possibly stalling on some specific mRNAs sequences or already 
translated peptides. 
Furthermore, the examination of the abundance of translation factors in the monosome 
immunoprecipitated with MRPL12 could clarify whether the interaction with mutated 
form is affected, which as already described can influence overall activity of ribosomes. 
Unfortunately, the limitation of material obtained from performed immunoprecipitation 
(Figure 4.12) did not allow further analysis. 
115 
 
Moreover, the CLIP results for MRPL12 performed with patient and control sample in 
order to investigate if this protein binds 16S rRNA directly and if so whether mutated 
MRPL12 interaction is altered causing decline in 16S level (Figure 4.9 B), would 
require further optimisation. The CLIP tags analysis for both MRPL12 control and 
mutated form present multiple sites of binding to 16S rRNA. Performing this assay with 
a higher concentration of SDS and introduction of additional washing steps of beads 
after incubation with cell lysate could possibly give a clearer more specific result. 
Although greater than 50 hits was suggested as showing specificity (by local experts), 
the number of CLIP sequences identified as 16S rRNA was considered as too low in 
order to unequivocally confirm a close and direct interaction with MRPL12, when 
compared with another ribosome interacting protein, RBFA, where over 3000 hits were 
mapped to one position on the 12S mt-rRNA. The MRPL12 data also included a high 
number of reads for 18S rRNA, which was used as one of controls, (data presented in 
Appendix 1.1; Table 1).  Interestingly, although patient and control exhibited the same 
pattern of possible binding to 16S rRNA, the interactions with tRNA
Glu
 (over 200 reads) 
and tRNA
Met
 (100 reads) was specific for mutated form of MRPL12. This potentially 
abnormal interaction could have negative effect on protein synthesis. Further, if the 
repeated CLIP data with patient fibroblasts would confirm binding to tRNA
Glu
 and 
tRNA
Met
, then the steady state level of these tRNAs could be checked as well as their 
location on sucrose gradient fractions. The high resolution northern blot potentially 
could answer which fraction of mutated MRPL12 binds to these species if any. 
Additionally, performing CLIP with different cell types for example HEK293 could 
give more reads as the mitochondrial mass in fibroblasts is significantly lower than 
other cell lines, which could be the reason for high background. This experiment could 
resolve the question of direct binding between MRPL12 and 16S mt-rRNA.    
 
 The data presented in this chapter provides a complicated image of one of the 
most conserved proteins in the ribosome, which shares many features not only with 
eubacterial homologues but also with eukaryotic analogues (Wahl and Möller, 2002). 
Although the experimental analyses undertaken to investigate the role of MRPL12 in 
human mitochondria clearly show that its presence is required for mitochondrial 
translation they do not draw a final molecular mechanism or stoichiometry of its 
activity.  
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To clarify the exact, potentially numerous, steps in mitochondrial gene expression in 
which MRPL12 takes part, including coupling the transcription and translation events in 
response to changing cell requirements for energy, more experimental work is required.  
 
This investigation of mutated MRPL12 presents new insights into the role of this 
conserved protein in human mitochondrial translation. Clearly the human homologue of 
bacterial L7/L12 has developed into a multifunctional protein potentially coupling 
transcription and translation process and surprisingly its dysfunction selectively affects 
different OXPHOS complexes. It is only one of few MRPs whose mutated forms have 
been reported as a source of mitochondrial translation deficiency triggering respiratory 
chain dysfunction. Two proteins of mt-SSU; MRPS16 (Miller et al., 2004) and MRPS22 
(Saada et al., 2007) as well as one mt-LSU protein MRPL3 (Galmiche et al., 2011) have 
so far been identified in patients as a cause of multiple OXPHOS deficiencies. 
Reported mutations were fatal in an early onset in case of MRPS16 (3 days of 
age) and MRPS22 protein (patients died at 2- 22 days of age) whereas in case of 
mutation in MRPL3 two out of four siblings were still alive at 3 years of age. Two 
siblings died at 17 months and 15 months of cardiac arrest. There is no doubt that it is 
important to pursue investigation into the basic biology of mitochondrial monosomes, 
which in the future may provide information that could lead to effective therapy, 
diminishing the devastating effects of mitochondrial dysfunction in young patients. 
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5.   Chapter 5: RBFA; Mitochondrial Ribosome Assembly Factor A. 
 
5.1 Introduction. 
Human mitochondrial ribosome binding factor A (RBFA; C18orf22) was identified by 
my host laboratory as one of proteins that interacted with mtRRF-FLAG (Rorbach et al., 
2008). Further investigation of this protein was then undertaken by Ricarda Richter as 
part of her PhD project. C18orf22 is the orthologue of bacterial RbfA that associates 
specifically with free 30S subunits, and that was first shown to inhibit a cold-sensitive 
mutation in 16S rRNA (C23U) of E. coli when overexpressed (Dammel and Noller, 
1995). Bacterial cells lacking RbfA exhibited a cold-sensitive phenotype (Dammel and 
Noller, 1995) identical to a reported mutant strain that contained a C to U transition 
located at the 5’ end pseudoknot helix of 16S rRNA (helix 1), predicted to cause 
weakening of the helix. C23U strain showed decreased polysome levels and 
accumulation of free 30S and 50S subunits (Dammel and Noller, 1993). Consistent with 
an involvement in 16S rRNA, RbfA was reported alongside another protein, RimM, as 
an essential factor for efficient processing of 16S rRNA. It was also observed that 
overexpression of RbfA in a strain deleted of RimM partially suppressed the slow 
growth and translational deficiency (Bylund et al., 1998). Thus, both proteins have been 
proposed to be associated with the 30S in the late stage of 16S rRNA maturation acting 
as accessory proteins assisting in the efficient assembly of the bacterial small ribosomal 
subunit. The biogenesis of eubacterial ribosome requires around 30 known assembly 
factors including those playing role in the rRNA modification and processing (Yang et 
al., 2014). In contrast, cytosolic ribosome assembly involves ~200 factors in S. 
cerevisiae (Strunk and Karbstein, 2009).  
The precursor of E. coli 16S rRNA, is the 17S that contains 115 additional 
residues at the 5’ end and 33nt at the 3’ terminus. It requires two endonucleases RNases 
E and G to process its 5’ end (Li et al., 1999) and four exonucleases at the 3’end (RNase 
II, RNase R, PNPase and RNase PH) (Sulthana and Deutscher, 2013). The correct 
folding of rRNA and assembly of 30S is facilitated by the Era and RsgA GTPases and 
chaperons such as already mentioned RbfA and RimM but also enzymes introducing 
modifications on selected bases (Clatterbuck Soper et al., 2013,Yang et al., 2014). 
Overall features of prokaryotic RbfA are that it is a small (15kDa; E. coli, 10.9 
kDa; T. thermophilus) cold shock protein, the expression level of which is rapidly 
increased in cells exposed to the low temperature (Jones and Inouye, 1996). Its deletion 
causes an inability of bacteria to adapt to the low temperatures. The level of mature 16S 
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rRNA and polysomes in mutant strains lacking RbfA is further reduced after exposing 
bacterial cells to 15ºC and as the 30S contains mostly immature pre-16S rRNA (Xia et 
al., 2003), whereas in the wild type cells the level of 30S- bound RbfA increases several 
fold. This is postulated to occur to promote rapid maturation of the bacterial small 
ribosomal subunit in order to overcome a translational block. NMR structure of E. coli 
RbfA lacking 25 residues at the C-terminal domain (CTD) revealed that it contains a 
type-II KH- domain fold topology, which is specific for RNA-binding proteins (Huang 
et al., 2003). It has been published that KH-domains mediate RNA-dependent protein-
protein interactions (Chen et al., 1997). Interestingly, in bacteria the overexpression of a 
GTP-binding protein Era, also containing a C-terminal KH domain, can partially rescue 
bacterial cells deleted of RbfA (Inoue et al., 2003). In a similar fashion to RbfA, Era is 
crucial for cell growth in E. coli and also associates with free 30S subunits. Its deletion 
causes accumulation of the same pre-16S rRNA, which has been observed in RbfA 
deleted strains, and there is also an increase of free ribosomal subunits 30S and 50S. 
Overexpression of the wild type Era in cells lacking RbfA suppressed the cold-sensitive 
phenotype, enhanced 16S rRNA processing and ribosome assembly. In contrast, the 
reciprocal was not true, RbfA overproduction could not substitute for Era (Huang et al., 
2003). However, another protein, KsgA, was able to rescue bacterial cells containing a 
cold sensitive mutation in Era (E200K; Lerner et al., 1995) that causes a growth defect 
below 30ºC (Lu and Inouye, 1998). KsgA is a methyltransferase that methylates two 
conserved neighbouring adenosine residues at the 3’end of SSU 16S rRNA (helix 45), 
which are situated in close proximity to the sequence complementary to the Shine-
Dalgarno sequence (Formenoy et al., 1994). Strikingly, E. coli mutants deprived of 
methylation at A1518-A1519 are resistant to the antibiotic kasugamycin (Helser et al., 
1971). These cells display only a slightly decreased rate of translation initiation 
(Poldermans et al., 1979) and decrease in accuracy of protein synthesis (Van Buul et al., 
1984). Interestingly, in S. cerevisiae disruption of the KsgA homologue Dim1p that is 
the cytosolic SSU 18S rRNA dimethyltransferase, was reported to be lethal (Lafontaine 
et al., 1994) but this was due to additional 18S rRNA-processing function (Lafontaine et 
al., 1995) as the lack of methylation of the two adenosines of helix 45 did not influence 
cell growth (Lafontaine et al., 1998). Lafontaine et al.,1998 showed that the lack of 
methylation at the 3’terminus of 18S rRNA is required in the in vitro translation system 
but only fine-tunes ribosomal function in vivo. The rate of growth of the E. coli strain 
deleted of KsgA is comparable with WT at 37 ºC but lowered temperatures (25ºC, 
20ºC) causes growth defects, accumulation of free SSUs and slowed pre-16S rRNA 
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processing (Connolly et al., 2008). Moreover, in the same publication it was presented 
that a catalytically inactive form of KsgA (E66A) with the capability to bind 16S rRNA 
strongly inhibited 70S ribosome formation and caused accumulation of SSUs associated 
with E66A. This result suggested that the methylation event is necessary for KsgA 
methylase to be released from the small subunit and that dissociation of KsgA is 
required for the SSU to be available for IF3 and/or large subunit. KsgA was described 
to methylate 30S subunits that were in a translationally inactive conformation (Desai 
and Rife, 2006), which then caused a change in the structure to optimize 70S function 
(Demirci et al., 2010). KsgA bound to SSUs, blocks the formation of the decoding site 
and ribosome assembly (Boehringer et al., 2012a). Interestingly, overexpression of 
RbfA in KsgA E. coli deletion mutants inhibited cell growth and caused the 
accumulation of aberrant 70S-like particles (Connolly and Culver, 2013). The authors 
suggest that these two proteins are linked in vivo. Indeed, structural analysis confirms 
that RbfA interacts with helices 44 and 45 positioned at the 3’end of 16S rRNA, 
perturbing their structure (Datta et al., 2007). KsgA also interacts directly with the 
conserved helix 45, methylates two adenosines and alters the structure of helix 44 
(Boehringer et al., 2012b). Era also binds at the 3’ end of 16S rRNA, to the 1531-
AUCACCUCCUUA-1542 sequence, which is directly preceded by helix 45 (residues 
1,507–1,528) (Tu et al., 2009). Authors propose that Era acts as a chaperone in the late 
stage of 16S rRNA maturation, possibly enabling correct cleavage at the 3’ end of pre-
16S rRNA and facilitating activity of KsgA. In the next publication the same group 
reports that Era also interacts directly with the helix 45 (Tu et al., 2011). 
Interestingly, RbfA and Era both interact with 3’ and 5’ regions of the SSU 
rRNA, in particular with helix h28, which is known to interact with helix h1. RbfA is 
known to bind and stabilise h1 and since Era may bind to this common structural 
element this may allow it to partially rescue bacterial cells depleted of RbfA by indirect 
stabilisation of h1 (Datta et al., 2007). This suppression is curious as in bacteria, the 
known function of RbfA is to promote processing of 5’ end of the 16S rRNA precursor, 
which involves direct binding with h1 whereas Era is involved at the other end of the 
molecule in the 3’end maturation (Sharma et al., 2005). Overall, the position of bacterial 
RbfA during the late stages of 30S maturation allows it broad interactions with 
numerous pre-16S rRNA structures, which is thought to implicate this protein in more 
than just the 5’ end maturation of 17S rRNA precursor to 16S. In summary, prokaryotic 
RbfA alongside KsgA, RimM, Era and a few others is classified as one of the factors 
taking part in the final steps of structural changes of 30S subunit before interaction with 
121 
 
50S (Shajani et al., 2011). Clatterbuck Soper et al., 2013 suggest that accessory proteins 
such as RbfA and RimM postpone particular RNA folding events to ensure the quality 
of 30S assembly.  
In human mitochondria homologues of Era and KsgA have already been 
described. ERAL1 (Era G-protein-like 1), the homologue of bacterial Era was 
investigated in my host laboratory and its direct interaction with ribosomal RNA was 
confirmed by crosslinking immunoprecipitation (CLIP) assays that I performed. The 
binding site mapped to the 3’end of SSU 12S mt-rRNA, which closely resembles the 
3’end of the bacterial SSU rRNA as it contains a stem-loop region (Dennerlein et al., 
2010) that encloses the two conserved adenine residues that are also dimethylated by a 
homologue of KsgA, human TFB1M (Cotney et al., 2009). 
Interestingly, ERAL1 depletion in HEK293 cells causes apoptosis and a 
significant decrease in a nascent 12S mt-rRNA level with no perturbation of mt-mRNA 
levels or mitochondrial protein synthesis (Dennerlein et al., 2010). Whereas silencing of 
TFB1M in HeLa cells was reported to cause cell growth arrest, with a decrease of 12S 
rRNA level but unaffected mitochondrial mRNAs levels and reduced mitochondrial 
translation rate (Cotney et al., 2009). 
The investigation of human RBFA carried by Ricarda Richter showed inhibition 
of cell growth in HEK293 cells depleted of this protein, which at 343 amino acids is 
approximately three times bigger than the bacterial counterpart. Sequence and structure 
alignment of bacterial RbfA and human mitochondrial RBFA showed marginal 
sequence similarity but a conserved structure of the type-II KH-domain in the 
mitochondrial orthologue. Analysis of mitoribosome assembly after three and six days 
depletion of RBFA in HEK293 cells, showed no significant changes (Appendix 1.3). 
Silencing of RBFA for six days did not cause significant reduction in the steady state 
levels of mitochondrial rRNA or any mt-mRNAs. Furthermore, 3 days RBFA depletion 
resulted in approximately 1.5 fold increase of the mitochondrial protein synthesis. In 
contrast, six days depletion caused subtle decrease in de novo synthesis of 15 - 20%. 
The depletion of RBFA did not significantly influence the steady state levels of 
mitochondrially encoded proteins or mtDNA. Moreover, mitochondrial ROS production 
was not affected nor was mitochondrial membrane potential. The mitochondrial mass 
was slightly increased after six days of RBFA silencing. Even after 6 days RBFA 
depletion only 6% more apoptotic cells were present in comparison to control. 
Interestingly, 3 days of ERAL1 depletion caused 35% cells to go into apoptosis. The 
initial CLIP assay performed by Ricarda Richter to identify binding RNA sequences of 
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RBFA-FLAG, failed to generate significant number of mitochondrial sequences 
nevertheless this preliminary data suggested an interaction of RBFA-FLAG with both 
the 3’end of 12S mt-rRNA and more surprisingly 5S rRNA. This intriguing result 
dictated that the first experiment that I performed in the further investigation of RBFA, 
aimed to assess the RNA binding ability of endogenous RBFA and precisely define the 
binding sequence or sequences using the CLIP technique. 
 
5.2 CLIP data, the answer to the mystery? 
I performed CLIP assay in order to identify specific binding sequences on mt-RNA by 
endogenous RBFA (as described in subsection 2.6.1) in HEK293T cells. The barcoded 
library generated from the obtained CLIP tags were IonTorrent sequenced by Dr. Helen 
Tuppen. All reads were collected and aligned to human mtDNA (revised Cambridge 
reference sequence) using the Torrent Suite software on the IonTorrent server. The 
alignment is presented in the form of a graph in Figure 5.1, where a linear 
representation of the human mtDNA acts as the x-axis and the number of reads located 
in each position occupies the y-axis. The locations of RBFA binding sites for which 
more than 50 CLIP reads were identified are indicated. The number of hits exceeding 
this threshold is primarily located in 12S mt-rRNA sequence. Figure 5.1 indicates that 
four significant binding positions on 12S mt-rRNA were identified; the first harbouring 
~160 reads at position 904-918nt (1), second ~ 1300 reads at position 1181-1211 nt (2), 
third ~ 1000 reads at position 1292-1312 nt (3) and fourth ~ 3400 reads at position 
1560-1582 nt (4). Other binding sites were identified in the sequence of tRNAMet (~450 
hits) and tRNAGlu (~120 hits).  
 
 
123 
 
 
Figure 5.1. Linear display of human Cambridge reference sequence of mtDNA with 
depicted number of RBFA CLIP tags. Human mtDNA is displayed in a linear format with 
locations of the IonTorrent identified CLIP tags mapped upon it. The number of CLIP hits was 
deemed as significant if it exceeded 50, hence the threshold on the y-axis. Y-axis starts from the 
nucleotide for which at least one hit was detected. The significant hits for endogenous human 
RBFA protein were identified in MTRNR1 (12S mt-rRNA) with four locations of CLIP hits. 
Other mapped positions were identified as tRNA
Met
 and tRNA
Glu
.  
 
The binding sequence harbouring the highest number of CLIP hits is situated at the 
3’end of 12S mt-rRNA (helix 45), covering the stem loop that contains two 
dimethylated adenines. This corresponded with the exact same binding sequence that 
was identified for ERAL1 protein investigated by me in my host laboratory. As already 
mentioned, both ERAL1 and RBFA are orthologues of bacterial Era and RbfA, which 
are maturation factors of the prokaryotic ribosome. Consistent with the bacterial 
function, human mitochondrial ERAL1 was described as a 12S chaperone, as its 
depletion in Hek293 cells causes a significant decline in nascent 12S rRNA. The CLIP 
assay result prompted further investigation, aiming to establish whether RBFA has the 
ability to compensate for the loss of ERAL1 and/or can ERAL1 make up for the loss of 
RBFA in human cells. 
 
5.3 Can RBFA and ERAL1 reciprocally compensate for    
                    each other’s function following siRNA depletion in human cells? 
In order to investigate any potential compensatory mechanism occurring between 
RBFA and ERAL1 in human mitochondria, two modified HEK293 cell lines were used. 
The first was engineered to be able to inducibly express RBFA-FLAG and the second 
ERAL1-FLAG. 
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5.3.1 Expression of RBFA-FLAG in the absence of ERAL1 does not 
compensate depletion in Hek293 cells. 
The first experiment was performed to identify if over-expression of RBFA could 
suppress the slowed growth phenotype that was seen in ERAL1 depleted cells. To 
establish if this were the case control HEK293 WT cells and a derived line that could 
express RBFA-FLAG were used. Both cell lines, grown in 6-well plates, were 
transfected with either non-targetting (NT) or ERAL1 specific siRNA (described in 
subsection 2.1.6). In the case of the RBFA-FLAG cell line, expression of the protein 
was induced with doxycycline 4 hr after siRNA transfection. To ensure the desired 
experimental conditions had been successfully achieved western blot analysis was 
performed to confirm the depletion of ERAL1 and expression of RBFA-FLAG (Figure 
5.2). 
 
 
 
 
 
 
 
 
 
Figure 5.2. Western blot analysis of ERAL1 depletion and RBFA-FLAG induction in 
HEK293 cell lines. Overexpression of RBFA-FLAG and depletion of ERAL1 protein were 
confirmed by western blot analysis of cell lysate (50 µg, 12% SDS-PAGE). RBFA-FLAG was 
detected with antibody against FLAG extension. Antibodies for proteins indicated were detected 
with ChemiDoc MP Imaging System (BioRad). 
 
To assess overall growth all cells were harvested and counted after 72 hr 
siRNA/induction treatment (see subsection 2.1.5) and the data presented as a histogram 
(Fig. 5.3).  The graph shows that expression of RBFA-FLAG does not rescue cells 
depleted of ERAL1 protein. Moreover, the number of cells is even lower in case of 
RBFA-FLAG cell line with silenced ERAL1 compering with control. 
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Figure 5.3. RBFA does not compensate ERAL1 loss in cells. Cell counts of HEK293 WT 
and HEK293 expressing RBFA-FLAG were taken after 72 hr siRNA treatment (NT control and 
siRNA targeted to the ERAL1 open reading frame were used at 33 mM final concentration). In 
case of RBFA-FLAG cells, the induction was triggered with doxycycline (1ng/ml final 
concentration) 4 hr after siRNA transfection. 15*10
4
 cells were seeded in six well plates in 
triplicates. Error bars are +/- SD. 
 
5.3.2 Expression of ERAL1-FLAG does not rescue the phenotype of RBFA 
depleted Hek293 cells. 
The second experiment aimed to assess whether ERAL1 can rescue cells depleted of 
RBFA. The same experimental approach was taken as described above. This time 
HEK293 expressing ERAL1-FLAG was used alongside control HEK293 WT. Both cell 
lines were transfected with RBFA or NT siRNA. Production of ERAL1-FLAG and 
depletion of RBFA was assessed by western blot analysis of cell lysates (CLs) (Figure 
5.4). 
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Figure 5.4. Western blot analysis of RBFA depletion and ERAL1-FLAG induction in 
HEK293 cell lines. Expression of ERAL1-FLAG and depletion of RBFA protein were 
confirmed by western blot analysis of CLs (50 µg, 12% SDS-PAGE). ERAL1-FLAG was 
detected with antibody against FLAG extension. Antibodies for proteins indicated were detected 
with ChemiDoc MP Imaging System (BioRad). 
 
The number of cells was counted 72 hr after transfection and the data presented as a 
graph in Figure 5.5. Again, no compensatory mechanism was observed when ERAL1-
FLAG was expressed in the absence of RBFA.  
 
 
Figure 5.5. ERAL1 does not compensate for RBFA loss. Cell counts of HEK293 WT and 
HEK293 expressing ERAL1-FLAG were taken after 72 hr siRNA treatment (NT control and 
siRNA targeted to the RBFA open reading frame, used at 50 mM final concentration).  
In ERAL1-FLAG cells the induction was triggered with tetracycline (1µg/ml final 
concentration) 4 hr after siRNA transfection. 15*10
4
 cells were seeded in six well plates in 
triplicates. Error bars are +/- SD. 
 
Comparison of graphs in Figure 5.3 and 5.5 shows that there was an even lower cell 
number for HEK293 expressing ERAL1-FLAG in the absence of RBFA (Figure 5.5) 
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than in case of HEK293 expressing RBFA-FLAG in the absence of ERAL1 (Figure 
5.3). 
 
5.4 Can overexpression of RBFA protect 12S mt-rRNA from degradation 
in the absence of ERAL1? 
In summary, no compensatory mechanism in cell growth rate was observed in the case 
of RBFA and ERAL1, although CLIP assay analyses showed that both proteins interact 
with precisely the same sequence of 12S rRNA and ERAL1 depletion causes significant 
decrease of 12S steady state level. In order to establish whether 12S mt-rRNA is 
protected by expressed RBFA-FLAG in the absence of ERAL1, two HEK293 cell lines; 
control and FLAG were grown under the same conditions as described in subsection 
5.3.2. Western blot analysis was performed to identify whether depletion of ERAL1 and 
expression of RBFA-FLAG was successful. As can be seen in Figure 5.6, depletion of 
ERAL1 was successful in both cell lines and RBFA overexpression was also confirmed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Western blot analysis of ERAL1 depletion and RBFA-FLAG induction in 
HEK293 cell lines. 15*10
4
 cells were seeded in six well plates in triplicates and grown for 72 hr 
in the presence of either si-NT or si-ERAL1 (33 mM final concentration). RBFA-FLAG was 
induced 4 hr after siRNA transfection. Cells from one of each triplicate were used to assess an 
efficiency of ERAL1 depletion and RBFA-FLAG expression. CLs (50 µg) were separated on 
12% SDS-PAGE. RBFA-FLAG was targeted with antibody against FLAG extension. 
Antibodies for proteins indicated were detected with ChemiDoc MP Imaging System (BioRad).  
 
RNA extracted from these cells was subjected to northern blotting. Analysis of 
MTRNR1 (12S) steady state levels in the absence of ERAL1 was reduced compared to 
NT controls in both wild type and RBFA expressing HEK293 cells (Figure 5.7). 
However, loss of ERAL1 in conjuction with induction of RBFA-FLAG showed no 
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change in comparison with control HEK293 WT. Since 12S rRNA levels were 
diminished to at least the same extent with ERAL1 depletion irrespective of RBFA 
expression, this result allowed me to conclude that the expression of RBFA-FLAG did 
not protect 12S from degradation in the absence of ERAL1. 
 
 
 
 
 
 
 
 
Figure 5.7. Northern blot analysis of 12S mt-rRNA (MTRNR1) steady state level in the 
absence of ERAL1 protein and expression of RBFA-FLAG. 18S rRNA was used as a 
loading control. Signals were detected via Storm PhosphoImager. HEK293 WT was used as a 
control. 
 
The experimental data described above clearly indicate that although RBFA interacts 
with the same sequence of 12S mt-rRNA (helix 45) as ERAL1, their interaction time 
and function differs since they do not reciprocally compensate for each other if either is 
absent. Moreover, the inability of RBFA to protect 12S mt-rRNA in the absence of 
ERAL1 strongly suggests that the latter interacts first with the 3’end of 12S rRNA 
during late maturation events of mt-SSU. In order to clarify the role of RBFA in 
ribosome maturation further investigation was undertaken.  
 
5.5 Assessment of mitoribosome assembly in RBFA depleted Hek293 cells. 
The data obtained by Ricarda Richter during her PhD studies concerning RBFA showed 
that there were no significant changes in the steady state levels of mitochondrial 
ribosomal proteins in HEK293 cell line depleted of RBFA. As already mentioned, her 
analysis of mitoribosome assembly after three and six days depletion of RBFA in 
HEK293 cells, showed no significant changes (Appendix 1.3). The same outcome was 
seen by western blot analysis of the mitoribosomes immunoprecipitated with MRPS27-
FLAG (interacting with mt-SSU). In a new experimental approach I performed 
immunoprecipitation of mitoribosomes with overexpressed ICT1-FLAG, which is 
integral to the mt-LSU. Thus, in order to investigate the influence of RBFA silencing on 
newly forming mitoribosomes, cells were depleted of RBFA after which ICT1-FLAG 
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overexpression was induced. This would allow immunoprecipitation to isolate only the 
mitoribosomes that were formed after depletion of RBFA had commenced. Hence, 
mitochondria were isolated from HEK293 cells grown in the presence of RBFA or NT 
siRNA for 4.5 days, where overexpression of ICT1-FLAG was induced after the first 48 
hr (Figure 5.8).  
 
  
 
 
 
 
 
 
 
Figure 5.8. Schematic representation of experimental approach taken in order to 
investigate mitoribosome assembly in the absence of RBFA protein. Detailed description in 
the text. 
 
Successful depletion of RBFA and overexpression of ICT1-FLAG were confirmed by 
western blot analysis of mitochondrial lysates (Figure 5.9A). One third of the 
immunoprecipitated mitoribosomes was analysed by western blot (Figure 5.9B). 
Proteins representing the mt-SSU (MRPS18B) and mt-LSU (MRPL3, MRPL12) of 
mitoribosomes were analysed and did not show any difference in their levels in the 
absence of RBFA compared with NT control. 
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Figure 5.9. Western blot analysis of mitoribosome immunoprecipitated with ICT1-FLAG 
in the absence of RBFA. A. Expression of ICT1-FLAG and depletion of RBFA protein in 
HEK293 cell lines were confirmed by western blot analysis of mitochondrial lysates (15 µg, 
12% SDS-PAGE). B. Western blot analysis of mitoribosome immunoprecipitated with 
overexpressed ICT1-FLAG in the absence of RBFA. ICT1-FLAG expression was induced for 2 
days with tetracycline (1µg/ml final concentration), and RBFA depleted for 4.5 days (siRNA 50 
nM final concentration). Antibodies for proteins indicated were detected with ChemiDoc MP 
Imaging System (BioRad). ICT1-FLAG was targeted with antibody against FLAG extension. 
 
Total RNA, including mt-rRNAs, was extracted from two thirds of the 
immunoprecipitate (subsection 2.4.1), which was reverse transcribed (subsection 2.4.3) 
and generated cDNA was used in Real Time PCR (subsection 2.4.4). Obtained results 
and calculations are presented in Table 5.1. The relative mitochondrial 12S rRNA and 
16S rRNA level was calculated as followed: first, the ΔCT of control (treated with NT-
siRNA) and RBFA depleted sample was calculated [ΔCT = CT (5S rRNA) - CT (mt-
rRNA)], then the differences between the ΔCT of si-NT and si-RBFA were taken [ΔΔCT 
= ΔCT (si-RBFA) - ΔCT (si-NT)]. The mean ΔΔCT for 12S mt-rRNA was -0.07 cycle, for 
16S mt-rRNA; -0.39. Due to the exponential amplification during real time PCR, one 
cycle represents a difference of 50% content. The RBFA depletion did not affect 12S 
mt-rRNA level and 16S mt-rRNA was only decreased by 19.5%, which can be easily 
considered as experimental error with such a sensitive method as Real Time PCR.  
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Table 5.1. SYBR green Real Time PCR analysis of 12S and 16S mt-rRNA levels. 
 IP of mitoribosome with ICT1-FLAG overexpressed in HEK293 cell 
line 
 Control 
(CT) 
Control 
ΔCT 
siRNA RBFA 
(CT) 
siRNA RBFA 
ΔCT 
ΔΔCT 
 
12S 13.09 +/- 0.22 4.37 13.43 +/- 0.07 4.3 -0.07 
16S 13.3 +/- 0.3 4.16 13.18 +/- 0.07 4.55 -0.39 
5S rRNA 17.46 +/- 0.03  17.73 +/- 0.05   
The measurement of relative level of 12S mt-rRNA and 16S mt-rRNA were performed four 
times (described in subsection 2.4.4). CT; cycle number, ΔCT; CT (5S rRNA) - CT (12 or 16S mt-
rRNA), ΔΔCT; ΔCT (si-RBFA) - ΔCT (si-NT). 
 
The described experiment clearly presents that the level of 12S mt-rRNA is not affected 
by silencing of RBFA in HEK293 WT cells, which is in contrast to the influence of 
ERAL1 depletion. The data obtained by CLIP assay for RBFA described in the next 
subsection determined the focus of the study on 12S.  
 
5.6 Further analysis of RBFA binding sites. 
As described earlier preliminary CLIP data suggested 5S binding. Further analysis of 
IonTorrent data indicated clear binding to 5S rRNA. Alignment of RBFA CLIP tags to 
5S rRNA sequence gave over 2000 reads. Whereas only 8 sequence reads were 
identified for SLIRP, 34 for MRPL12 WT and 47 for MRPL12 mutant (Table 5.2).  
 
Table 5.2. Summary of IonTorrent sequencing results for SLIRP, RBFA and MRPL12 (in 
control and patient fibroblasts) CLIP reads aligned to mtDNA map and 5S rRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity of the interaction between RBFA and 5S rRNA is strongly supported by 
very low number of reads identified for two other proteins. The data show that RBFA is 
capable of binding two different species of rRNA. Interestingly, 5S is still widely 
accepted to be absent from human mitoribosomes. Preliminary evidence obtained by 
Ricarda Richter during her PhD studies was confirmed by CLIP data described above  
       Investigated 
Protein 
Number of 
CLIP hits on 
    mtDNA 
Number of 
CLIP hits on 
5S rRNA 
sequence 
SLIRP 6,010 8 
RBFA 10,529 2,407 
MRPL12 
(Control) 
4,487 34 
MRPL12 
(Patient) 
4,371 47 
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indicating that RBFA associates transiently with the mt-SSU. The highest number of 
CLIP hits on 12S mt-rRNA was identified as binding at the 3’ terminal stem loop that 
contains two dimethylated adenines.  
The possibility of RBFA and 5S rRNA involvement in the process of dimethylation was 
therefore considered. The secondary structure of 5S rRNA shares similarity with known 
guide RNA particles taking part in introduction of post-transcriptional modifications of 
cytosolic rRNAs (Figure 5.10). According to the published data over 100 different 
analogues of the four standard ribonucleotides have been described involving 
modifications such as pseudouridinylation, alterations to the bases including 
methylation, deamination, reduction or thiolation (Chow et al., 2007). Human, cytosolic 
ribosomes contain over 200 modified nucleotides (Kiss, 2001) whereas E. coli 
ribosomes have only 36 identified modifications (Chow et al., 2007). Bacterial rRNA 
modifications are introduced by site-specific, single-protein enzymes recognising 
unique structures or RNA sequences. The high number of RNA modifications in 
eukaryotic cells is introduced by RNA-protein complexes. The noncoding RNA 
component of these complexes called snoRNAs is usually 60-300 nt long that guide the 
site specific modification of a target RNA.    
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10.  Secondary structure of 5S rRNA resembles this of snoRNA guiding 
isomerization of uridine to pseudouridine (Ψ). Secondary structure of A. 5S rRNA.  
B. H/ACA box snoRNA acting as a guide for pseudouridylation, taken from Kiss, 2001.  
 
Obtaining two distinct pools of CLIP tags did not indicate if RBFA binds both RNA 
species at the same time. In recent years CRAC technique originating from CLIP assay 
 
A 
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was used in studies concerning protein-snoRNA interactions in yeast. Briefly, following 
UV treatment, RNA-protein complexes are affinity purified under highly-denaturing 
conditions. Obtained RNA species are amplified after linker ligation and cDNA 
synthesis. PCR fragments are then sequenced on an illumina sequencing platform and 
identified bioinformatically. It was identified that the deep-sequencing reads can contain 
chimeric sequences (less than 0.5% of total) comprised of two RNA species (snoRNA 
and rRNA fragment, which undergoes modification) (Kudla et al., 2011). This can occur 
if two RNAs are aligned in very close proximity in vivo, which allows creation of a 
covalent bond between nucleotides caused by UV treatment or are ligated during the 3’ 
linker addition step on the beads (material and methods; subsection 2.6.1, Travis et al., 
2014). Therefore the CLIP data was interrogated using unix command-line text 
processing utilities by Dr. M. Bashton to identify if any of the 12S tags also contained 
5S sequences.  
Theoretical alignment of both rRNA species was postulated and this is presented 
in Figure 5.11. Interrogation of the 12S tags identified a chimeric 12S/5S rRNA 
sequence in the CLIP reads (Table 5.3), which strongly suggested simultaneous 
interaction of human RBFA with both ribosomal RNA species.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. Predicted alignment of 5S rRNA with 12S mt-rRNA 3’ terminal stem loop 
located in the helix 45 (blue). Theoretical alignment of 12S terminus with 5S was structured on 
the base of H/ACA box snoRNA acting as a guide for pseudouridylation (Figure 5.10 B). 
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The identification of any chimeric 12S/5S sequence strongly suggests that a fraction of 
5S rRNA is found in human mitochondria and that it interacts at some stage with 
mitoribosomes even if only transiently. In order to try to obtain a higher number of 
chimeric sequences CLIP assay was repeated and the results are in the process of being 
analysed.  
 
Table 5.3. Chimeric sequence of 5S rRNA and 12S mt-rRNA 3’end identified in Ion 
Torrent reads pool.  
 
 Sequence 
5S rRNA 
5’-GTCTACGGCCATACCACCCTGAACGCGCCCGATCTCGTCT 
GATCTCGGAAGCTAAGCAGGGTCGGGCCTGGTTAGTACTTGG
ATGGGAGACCGCCTGGGAATACCGGGTGCTGTAGGCTTT-3’ 
 
12S mt-rRNA 
stem loop 
sequence 3’ 
5’-GAGACAAGTCGTAACATGGTAAGTGTACTGGAAAGTGCACTT 
GGACGAACAAAG-3’ 
IonTorrent 
read 
 
5’-GGGGGGCCTGGTTAGTACTTGGATGGGAGACAAGTCGTAA 
CATGGTAAGTGTACTGGAAAGTGCACTTGGAC-3’ 
 
The table contains 5S rRNA, 3’end 12S mt-rRNA and IonTorrent read sequence, where 
nucleotides highlighted in green are part of 5S rRNA and underlined nucleotides originate from 
3’end 12S mt-rRNA. AA; dimethylated adenines. 
 
Because, the identified chimeric sequence contains 12S rRNA fragment 
enclosing two modified dimethylated adenines (Table 5.3), further investigation aimed 
to establish if RBFA influences this modification in human mitochondria. Again it is 
important to emphasize, that there is no experimental, published result showing activity 
of TFB1M in vitro. All of the available data describing the function of this enzyme 
originates from extrapolation in studies where the protein is depleted (Metodiev et al., 
2009; organ specific depletion in mice) or methyltransferase-deficient form of TFB1M 
was overexpressed in HeLa cells (Cotney et al., 2009). It is highly probable that in order 
to perform the methylation in vitro TFB1M requires other factors.  
 
5.7 The effect of RBFA depletion on 12S mt-rRNA post-transcriptional 
modifications.  
In pursuance of the possible involvement of RBFA in the dimethylation process of the 
two adjacent adenosines in helix 45, a primer extension assay was used (protocol in 
subsection 2.7). Briefly, as depicted in Figure 5.12, a radiolabelled primer 
corresponding to the terminal nucleotides of the 12S mt-rRNA sequence was annealed 
to the extracted RNA. The 3’ end of the primer sequence was at a distance of four 
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nucleotides to the first of the N6-dimethylated adenines. Elongation was allowed to 
proceed in a 5’ to 3’ direction. The first stop of the elongation process is at the point of 
modification, and is enforced by the use of low amounts of M-MLV reverse 
transcriptase and low concentration of dNTPs. The second stop (read-through) in this 
assay is caused by the lack of dGTP in the RT dNTPs mix, which prevents any 
extension past the first C in the 12S sequence (Figure 5.12; C in bold).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Schematic representation of primer extension assay to detect 
dimethylation of the AA in helix 45 of the 12S mt-rRNA 3’ stem loop. 
 
The primer extension assay used total RNA extracted from HEK293 cells, which 
allowed examination of the total pool of 12S mt-rRNA. Three independent RNA 
samples were obtained from cells grown for 7 days in specific conditions allowing 
investigation of nascent 12S methylation levels in the absence of RBFA. The schematic 
for cell treatment is presented in Figure 5.13B, where Sample 1 represents untreated 
control cells. Sample 2 and Sample 3 were grown in the presence of ERAL1 siRNA for 
the first 3 days in order to deplete the level of 12S by ~ 50%. Next, the medium 
containing ERAL1 siRNA was removed in order to allow cells to start to recover and  
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Figure 5.13. Primer extension analysis of dimethylation levels of total 12S mt-rRNA in 
the absence of RBFA in HEK293 cell line. A. Primer extension assays were performed with 
total RNA (4 µg) from each sample. Extension products were separated by electrophoresis in 
10% urea, sequencing gel, at 50W. Extension was also performed on in vitro synthesised 
unmethylated control. Signals were detected with Typhoon FLA9000 and analysed by Image-
Quant software (Molecular Dynamics, GE Healthcare). B. Schematic representation of the 7 day 
experimental approach undertaken to investigate methylation of helix 45 in the absence of 
RBFA. Cells were untreated (control, S1), grown for the first 3 days in the presence of ERAL1 
siRNA and for further 4 days with NT siRNA (S2), or treated with ERAL1 siRNA for 3 days, 
but then followed by 4 days silencing of RBFA (S3). The quantitation of the data from panel A 
is given above each treatment protocol. The percentage represents the unmethylated population 
of 12S rRNA and is calculated from the read-through (stop at C) as a fraction of the total signal 
(stop at modification + read-through). 
 
produce a new pool of 12S rRNA during the remaining 4 days in the presence of either 
NT siRNA (Sample 2: control), or RBFA targeting siRNA (Sample 3). If RBFA plays a 
role in the modification process then it would be expected that there would be a 
difference between the modification levels between NT and RBFA depleted cells. The 
untreated control (Sample 1) displayed 12 % unmethylated 12S rRNA, with a similar 
value of 15% in the control grown first in the presence of ERAL1 then NT siRNA 
(Sample 2), whilst the RBFA depleted sample (S3) had a 2-3 fold higher level of read-
through at 34%. The latter clearly presented a stronger relative signal for the read-
through, which illustrated a two to three fold increase in the unmodified pool of 12S 
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helix 45 in RBFA depleted cells. This interesting observation reinforced my CLIP data 
that showed a direct interaction of RBFA with the 3’ terminal stem-loop of 12S. These 
data taken together implicate this protein in the methylation process of the two highly 
conserved neighbouring adenines in helix 45. Further investigation aimed to establish 
the level of 12S rRNA methylation incorporated into A) mt-SSU, and B) fully 
assembled mitoribosome, in the absence of RBFA (Figure 5.14).  
 
 
Figure 5.14. Immunoprecipitation of the 12S rRNA via MRPS27-FLAG or ICT1-FLAG. 
Schematic representation of 12S mt-rRNA of the mt-SSU immunoprecipitated via A. MRPS27-
FLAG associated with mt-SSU, B. ICT1- FLAG incorporated into mt-LSU. B, beads; L, mt-
LSU; S, mt-SSU. 
 
The 12S mt-rRNA to be examined was extracted from the eluate of either mt-SSU 
immunoprecipitated by MRPS27-FLAG, or complete mitoribosomes 
immunoprecipitated by ICT1-FLAG from HEK293 cells. Both cell lines were grown for 
5.5 days in the presence of either NT or RBFA si-RNA. The successful overexpression 
of FLAG tagged proteins and depletion of RBFA was confirmed by western analysis 
and is presented in Figure 5.15. 
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Figure 5.15. Confirmation of the mt-SSU and LSU proteins over-expression and 
RBFA depletion by western blot analysis. HEK293 were grown in the presence of NT or 
RBFA siRNA for 5.5 days (transfection was repeated after 72 hr) followed by induction to 
express either MRPS27-FLAG or ICT1-FLAG (induction via tetracycline; 1µg/ml). Protein 
samples (50 µg) were separated by 12% SDS-PAGE and western analysis performed with 
antibodies as indicated; MRPS27-FLAG cells (A) and ICT1-FLAG cells (B). 
 
MRPS27-FLAG is a protein component of the mt-SSU, whilst ICT1-FLAG is an 
integral protein of mt-LSU. Any primer extension signal detected from the 
immunoprecipitation via ICT1 must represent mt-SSU associated with the mt-LSU in 
the form of an assembled mitoribosome. Thus the results of primer extension assay for 
12S mt-rRNA represent ‘free’ small subunit (if immunoprecipitation is via MRPS27) or 
incorporated into a fully assembled 55S particle (if immunoprecipitation is via ICT1) 
(Figure 5.16A). Quantification of the percentage un/dimethylated helix 45 (2x m
6 
2A) is 
presented graphically in panel B in the absence of RBFA versus control (each 
immunoprecipitation was performed at least twice). 
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Figure 5.16. Primer extension analysis of 12S mt-rRNA to detect methylation levels in 
28S and 55S particles in the absence of RBFA protein in HEK293 cell lines. A. HEK293 
cells overexpressing MRPS27-FLAG or ICT1-FLAG were grown for 5.5 days in a presence of 
NT or RBFA siRNA. Harvested cells were lysed and equal amounts of proteins were 
independently incubated with -FLAG–beads. After incubation 800 ng of Trizol extracted RNA 
from each sample was analysed by primer extension assays. Products were separated by 10% 
urea sequencing SDS PAGE, at 50W. In vitro synthesised unmethylated RNA was used as a 
control. Detection of signal was performed with Typhoon FLA9000 and analysed by Image-
Quant software (Molecular Dynamics, GE Healthcare). B. Densitometric data from A is 
presented graphically with percentage of the signals quantified for the read-through (stop at C) 
and for the stop at a dimethylation site (A936, A937) for NT control and RBFA depleted cells in 
each cell line.  
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Strikingly, there was a distinct difference between the percentage of the read-through in 
12S mt-rRNA immunoprecipitated from either the mt-SSU or the fully assembled 
mitoribosome. The read-through value obtained via MRPS27-FLAG 
immunoprecipitation is over three times higher in the absence of RBFA (38.4%) than in 
control sample (12%) obtained from cells transfected with NT si-RNA. This result 
suggests that silencing of RBFA decreases dimethylation level at the 3’end of 12S, 
where a lower percentage of adenines is modified, which allows M-MLV enzyme to 
proceed the extension reaction until the enforced stop caused by a lack of dGTP (read-
through signal). In contrast, the signal of the read-through for 12S mt-rRNA obtained 
from immunoprecipitation of the complete monosome via ICT1-FLAG in the absence 
of RBFA presents only 8.1% of the total signal (which is the sum of the methylation 
stop and read-through) compared with NT control (3.7%). In summary, the majority of 
the 12S mt-rRNA incorporated into 55S mitoribosomes contains modified A936, A937, 
even in the absence of RBFA. Whereas, 26.4% more of 12S immunoprecipitated via 
MRPS27-FLAG lack this modification in cells depleted of RBFA in comparison to 
control. The latter immunoprecipitation performed through small subunit of ribosome 
harbours free 28S and mitoribosomes. The immunoprecipitation via ICT1-FLAG 
gathers free large subunits (39S) and mitoribosomes, which means that all 12S obtained 
in this experiment, originates exclusively from fully assembled 55S.  
 
Primer extension assay clearly show that depletion of RBFA reduces the level of 
dimethylated adenines, but still 61.5% of analysed 12S rRNA is modified. This could 
partially be due to remaining maturated mt-SSUs produced prior to RBFA depletion. 
Moreover, since RBFA binds not only 12S but also 5S rRNA as chimeric sequences of 
12S/5S were identified by CLIP suggesting interaction of RBFA with both RNA 
species, one could assume that the methylation process requires all three factors for the 
highest efficiency. Since, 5S rRNA is only 120 nt it could play a function as a guide 
RNA in the dimethylation reaction of adjacent adenosines at 3’end of 12S mt-rRNA, 
with RBFA playing a role of a factor enabling optimal alignment of both RNAs for the 
methyltransferase. This exciting possibility will be further investigated in in vitro 
reactions containing unmethylated12S rRNA 3’end of 53 nt length, RBFA, 5S rRNA, 
and TFB1M.     
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5.8. The level of methylation at the 3’ terminus of 12S mt-rRNA when     
bound with RBFA-FLAG or ERAL1-FLAG. 
As previous experiment strongly suggest involvement of RBFA in the methylation 
process of 12S helix 45 and as ERAL1 also interacts with this sequence further 
experiments were performed to establish the level of methylation when 12S is 
immunoprecipitated with either RBFA or ERAL1. Summarizing, the two cell lines were 
grown with tetracycline for 72 hr to overexpress RBFA-FLAG or ERAL1-FLAG. The 
12S mt-rRNA to be examined was Trizol extracted from the pool of either mt-SSU 
immunoprecipitated by RBFA-FLAG, or ERAL1-FLAG and the primer extension assay 
performed (Figure 5.17).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 5.17. Primer extension analysis of 12S mt-rRNA to detect methylation levels in 
28S immunoprecipitated with overexpressed ERAL1-FLAG or RBFA-FLAG. RBFA-
FLAG or ERAL1-FLAG cell lysates were independently incubated with FLAG–beads. After 
incubation, 500 ng of Trizol extracted RNA from each sample was analysed by primer 
extension assay. Products were separated by 10% urea sequencing SDS PAGE, at 50W. 
Detection of signal was performed with Typhoon FLA9000 and analysed by Image-Quant 
software (Molecular Dynamics, GE Healthcare). The percentage of methylated 12S pool 
interacting with RBFA-FLAG or ERAL1-FLAG is presented above the bands.  
 
The level of methylation immunoprecipitated with RBFA-FLAG was 96% in contrast to 
just 26% of modified species in the ERAL1-FLAG total pool.  
 
26% 96%
stop:
2x m62A
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no dGTP 
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This striking difference enabled to establish the order of RBFA and ERAL1 interaction 
with helix 45 of 12S mt-rRNA. As ERAL1-FLAG immunoprecipitated mostly 
unmodified 12S (74%) and previous experiment clearly demonstrated that in HEK293 
cells most of the 12S is methylated at the 3’ terminus (~88%) then this protein clearly 
interacts with helix 45 before RBFA takes over this location to facilitate methylation by 
direct interaction. It has to be emphasised that 26% of 12S bound by ERAL1-FLAG is 
modified at the 3’ terminus. This result suggests that ERAL1 is also able to assist 
TFB1M during methylation process. As 4 days depletion of RBFA causes 2-3 fold 
decrease in methylated 12S, but still more than 60% remains methylated (Figure 5.13) 
with no decrease in the steady state level (Ricarda Richter thesis) it cannot be excluded 
that ERAL1 is able to present helix 45 to TFB1M although with lower efficacy so the 
methylation still occurs but with lower rate.  
 
5.8 Discussion. 
The inhibitory effect of RBFA depletion on the HEK293 rate growth was the only 
indication of an important function in human mitochondria played by this protein in the 
doctoral studies of Ricarda Richter. Interestingly, none of the thorough analysis 
performed by Ricarda Richter, aiming to establish the function of RBFA showed 
significant changes in the assembly of the mitoribosomes in RBFA depleted cells. 
Furthermore, no decline was observed in mitochondrial RNA species or mtDNA, with 
only marginal decrease of mitochondrial translation rate in cells grown in the presence 
of RBFA si-RNA for 6 days.  
The experimental investigation that I have undertaken in this study was driven 
by the data obtained from the CLIP assay (Figure 5.1). This clearly showed that RBFA 
interacts directly with 12S mt-rRNA. The highest number of hits was identified for the 
stem loop at the 3’ terminus of 12S (helix 45). The same region had been already found 
by my CLIP analysis to be binding site of another mt-SSU protein ERAL1, (Dennerlein 
et al., 2010). Although sharing the site of interaction, these two proteins do not 
compensate for each other when one is depleted in human cells (subsection 5.3). This 
was evident as overexpressed RBFA-FLAG did not protect nascent 12S mt-rRNA from 
degradation in the absence of ERAL1. This demonstrated separate functions for RBFA 
and ERAL1 and steps of the mt-SSU maturation process in which these two factors 
interact with 12S mt-rRNA. Clearly, human RBFA with its expanded mass in 
comparison to bacterial RbfA, did not lose the ability to bind directly mt-rRNA. Also its 
function can not be compensated by ERAL1. Although it has to be remembered that 
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even eubacterial EraL1 can only rescue E. coli cells lacking RbfA in higher 
temperatures (Inoue et al., 2006).The primer extension assay performed on total RNA 
extracted from RBFA depleted HEK293 cells indicates a 2-3 fold decrease of modified 
12S at the 3’ terminus (Figure 5.13). The outcome of this experiment demonstrates 
direct evidence of RBFA being an accessory protein in the maturation of 28S. Further 
investigation where 12S mt-rRNA was obtained from cells depleted of RBFA for 5.5 
days and immunoprecipitated with the small subunit protein (MRPS27-FLAG) or large 
subunit (ICT1-FLAG) gave further insight into the biogenesis of mt-ribosome (Figure 
5.14). First, analysis of 12S incorporated into mt-SSU presented as a 3-fold decrease in 
the level of methylation of helix45, reinforcing previous results. Interestingly, the 
majority of 12S incorporated into monosomes and immunoprecipitated with ICT1-
FLAG despite 5.5 days depletion of RBFA, contained just 8.1% unmethylated A936, 
A937 versus 3.7% in control samples. This result demonstrates that monosomes contain 
almost exclusively methylated 12S mt-rRNA, possibly recycling already fully matured 
28S particles when cells are depleted of RBFA.  
The analysis of CLIP reads for RBFA revealed an astonishing and unexpected 
interaction of this protein with 5S rRNA. Over 2000 hits were identified as 5S 
sequences, with chimeric 5S/12S sequence generating direct evidence of simultaneous 
interaction of RBFA with these two RNA particles, which could only occur in the 
mitochondrial matrix. It has to be highlighted that chimeric sequences are very rare and 
even in the large scale sequencing techniques generating millions of reads compared to 
the hundreds of thousands by IonTorrent detected only ~0.5%. Therefore, identifying 
the presence of only a few 5S/12S chimerae suggests that the interaction between 5S 
and 12S rRNA species is real. Moreover, it strongly suggests direct interaction of 5S 
with mt-SSU. The character of this interaction still needs to be elucidated. Since, 
involvement of RBFA in the process of dimethylation of two A936, A937 in the stem loop 
of 12S helix 45 has been shown, it is tempting to propose that the 5S rRNA interaction 
with the ribosomal RNA of the mt-SSU represents a novel phenomenon in mammalian 
mitoribosome biogenesis, whereby the 5S molecule plays the role of a guide RNA 
templating helix 45 for methyltransferase activity, presumably by TFB1M. 
Simultaneous interaction of RBFA with both RNA species could potentially facilitate 
their optimal conformation for the methyltransferase to act upon. The two modified 
adenines in helix 45 at the 3’end of the 12S rRNA have been postulated to present a 
check-point in human mitoribosome biogenesis that can influence the cell homeostasis. 
Overexpression in HeLa cells of TFB1M, the methyltransferase that is reported as 
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responsible for this modification causes hypermethylation of A936, A937, causing faulty 
mitochondrial biogenesis without any effect on mtDNA level, transcription or 
translation. It does however, predispose cells to stress-related cell death (Cotney et al., 
2009). Interestingly, hypermethylation is also characteristic for the cells with the 
deafness-associated A1555G mtDNA mutation, despite unaffected TFB1M level 
(Cotney et al., 2009). The increase in methylation was postulated to be caused by 
structural changes in the 12S mt-rRNA triggered by the mutation located in close 
proximity to A936, A937, which might allow enhanced accessibility for TFB1M. 
Therefore, it is tempting to speculate that this conserved modification requires a very 
specific team of factors and most of all has to be very tightly regulated since over-
expression of methyltransferase-deficient form of TFB1M was reported to cause 
decreased steady state levels of 12S rRNA, decreased mitochondrial translation and cell 
growth inhibition in HeLa cells (Cotney et al., 2009) and its knock-out in mice was 
reported to be embryonic lethal (Metodiev et al., 2009). This modification may present 
the “all-clear” signal for the small ribosomal subunit to assemble into a mitoribosome 
and potentially represents a signal for the cell, which influences its overall activity. 
Therefore, the involvement of the 5S rRNA in methylation process linking cytosolic and 
mitochondrial ribosomes biogenesis is more than understandable. The 5S rRNA seems 
to be the perfect candidate for the job. It is enough small to undertake the role of a guide 
RNA and it is already postulated to influence p53 protein, which is the regulator of cell 
proliferation and guardian of cellular homeostasis (Madan et al., 2011).  
In has been recently published that in cases of impaired cytosolic ribosomal 
biogenesis, 5S RNP (ribonucleoprotein) complex consisting of 5S rRNA, RPL5 and 
RPL11 interacts and inhibits MDM2 (mouse double minute 2 homologue; inhibits p53 
activity through proteasome-mediated degradation) thereby activating p53 protein 
(Sloan et al., 2013). Moreover, p53 has been reported to positively regulate OXPHOS in 
mice and human cancer cell lines via transcriptional upregulation of cytochrome c 
oxidase 2 (Matoba et al., 2006). Alternatively it inhibits, glycolysis (Bensaad et al., 
2006). These reported findings are of enormous importance for mitochondrial research 
as they show emerging pathways of bidirectional communication between mitochondria 
and the rest of the cell. The preliminary data obtained during this study, which suggests 
involvement of 5S rRNA in mitoribosomes biogenesis via conserved modification of 
helix 45, may be a part of a novel signalling pathway connecting mitochondrial 
ribosomal biogenesis with energetic requirements of the cell. Since RBFA protein has 
been shown to affect the level of this modification it can be easily postulated as one of 
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the ribosomal maturation factors with a role far beyond the double boundaries of 
mitochondrial membranes, possibly influencing metabolic status of the cell. Moreover, 
data presented in this chapter very strongly indicate that this astonishing protein has a 
very specific partner 5S rRNA, the presence of which in human mitochondria was 
controversial and its possible mitochondrial function is unknown.  
The final experiment described in this chapter unveils the order of RBFA and 
ERAL1 interaction with 12S mt-rRNA (helix 45). A striking difference in the level of 
dimethylation of A936, A937 in helix 45 was observed, when 12S was immunoprecipitated 
with RBFA-FLAG compared to ERAL1-FLAG (Figure 5.17). The RBFA protein binds 
almost exclusively modified 12S (96%) whereas ERAL1 interact with mostly 
unmodified helix 45 (74%). This final result is strongly supported with the outcome of 
the northern blot presented in the subsection 5.7 indicating that expressed RBFA-FLAG 
can not protect 12S mt-rRNA against degradation in the absence of ERAL1 in HEK293 
cells. Taken together these data suggest that ERAL1 interacts first with the 3’end of 12S 
rRNA followed by RBFA binding and methylatrasnferase activity during late 
maturation events of mt-SSU.  
In summary, the data specify that although RBFA interacts with the same 
sequence of 12S mt-rRNA (helix 45) as ERAL1, their interaction time and function 
differs since they do not compensate for each others absence. Furthermore, RBFA is 
unable to protect 12S mt-rRNA in the absence of ERAL1 and is bound only to 
methylated 12S whereas ERAL1 mostly interacts with unmodified species. 
Using the data it is possible to design a model of late stage maturation of 12S 
mt-rRNA involving helix 45, where the methyl groups are introduced by TFB1M but 
the optimal conditions for this enzymatic process are delivered by the presence of 
RBFA protein potentially interacting with 5S rRNA and helix 45. Whereas ERAL1 
guards unmethylated 12S from transcription until the process of maturation when the 
three factors mentioned above take over and act upon the 3’ terminal stem loop, 
followed by assembly of mt-SSU and mt-LSU into the mitoribosome (Figure 5.18). At 
this point it has to be emphasised that ERAL1 does not bind exclusively to unmodified 
helix 45 as primer extension assay result present that ¼ of the total pool of 12S 
interacting with ERAL1 is modified (Figure 5.17). The MRPS27-FLAG 
immunoprecipitation following RBFA depletion showed a substantial pool of modified 
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Figure 5.18. Theoretical final steps of 28S maturation involving ERAL1, RBFA, 5S rRNA 
and TFB1M.  
 
12S mt-rRNA (61%) suggesting that either ERAL1 also has the ability to present helix 
45 to the methyl transferase or that the enzyme can work but less efficiently before 
ERAL1 dissociates or on unchaperoned helix 45. Although this pathway is not optimal 
in 28S biogenesis, since just 26% of ERAL1-bound 12S mt-rRNA was modified, it 
could potentially sustain the source of newly formed and methylated at helix 45 12S. It 
is highly possible that the dimethylation of A936, A937 is crucial in the biogenesis of 
human mt-ribosome as evolutionary changes did not erase it and there appears to be 
more than one pathway to introduce it. As ERAL1 cannot rescue HEK293 cells 
depleted of RBFA (Figure 5.5) it can be postulated that the latter, potentially with 5S 
rRNA, provides optimal conditions for TFB1M to dimethylate A936, A937 in the helix 45 
and/ or RBFA has other functions in the 28S assembly process. Three other binding 
sites mapped to 12S mt-RNA suggest this possibility (Figure 5.1). The first interaction 
site harbouring ~160 reads at position 904-918nt (1) corresponds to helix 18 of 12S mt-
rRNA, second ~ 1300 reads at position 1181-1211 nt (2) is located in helices 28, 29 and 
30, third ~ 1000 reads at position 1292-1312 nt (3) maps to helices 35 and 38 (Figure 
5.1) according to the current secondary structure of 12S (Kaushal et al., 2014). The 
position (1) is located in the 5’ domain of the mt-SSU that forms the body, position (2) 
and (3) are located in the 3’major domain (the head of mt-SSU). Fourth position 
mapped to helix 45 with the highest number of reads identified is mapped to 3’ minor 
domain. Datta et al., 2007, presents number of interacting sites of eubacterial RbfA on 
16S rRNA including the head, the body and 3’ minor domain with contacts span helices 
h1, h18, h28, h29, helix 44 and 45 and to a lesser extent h30.  
The binding of RbfA to 30S subunit causes displacement of helix 44 which is directly 
involved in mRNA decoding and tRNA binding whereas helix 45 is rotated out of the 
30S platform. The X-ray crystal structure of the Thermus thermophilus 30S ribosomal 
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subunit deprived of dimethylation of two adenosines in helix 45 indicates that this 
modification is required for the formation of the packing interaction between helix 45 
and 44 (Demirci et al., 2010). Connolly and Culver, 2013 propose that eubacterial RbfA 
and KsgA methylase function together in the SSU maturation process. Moreover, 
another recent study of pre-30S complexes in E. coli strains lacking RbfA or RimM 
proteins give new insight into the late stages of assembly intermediates. The authors 
propose that RbfA can act upon different parts of 16S rRNA in early and late stages of 
30S assembly, coordinating optimal folding of rRNA (Clatterbuck Soper et al., 2013).   
Summarizing, the data described in this chapter present a new human 
mitochondrial protein RBFA, which interacts with 12S mt-rRNA in a very specific 
location containing two modified residues almost completely conserved in phylogeny. 
Although this broad conservation strongly suggests an important function, over two 
decades of studies have not fully answered what is the exact mechanism in which the m2 
6
A residues take part. As already mentioned, depletion of the methyltransferase KsgA in 
bacteria is dispensable at 37 C, but in mice loss of TFB1M is lethal. In general the cause 
for the existence of modified nucleotides is still unclear but they are mapped to 
functionally important regions of ribosomal RNAs and their number rises with the 
increased complexity of the organism (Chow et al., 2007). The methylation of two 
adenines at the 3’end of 12S mt-rRNA was the first confirmed modification in this 
molecule (Rorbach and Minczuk, 2012). Very recently another methylation site was 
identified (cytosine 911), introduced by methyltransferase NSUN4 (Metodiev et al., 
2014). 
The astonishing result of the CLIP assay indicating two rRNA species as 
interacting partners of RBFA, followed by identification of chimeric read containing 
fragments of both 12S and 5S rRNA could be the first step in deciphering the role of 
this modification in human mitoribosome. 
 
The data described here represent only a prelude in the description of human 
RBFA function, which requires further investigation. Ongoing experiments aim to 
establish whether addition of 5S rRNA and RBFA enable TFB1M to dimethylate A936, 
A937 in the 3’ stem loop of 12S rRNA in an in vitro reaction. Further, the CLIP assay for 
RBFA has been repeated and the IonTorrent reads are being analysed in order to 
identify more chimeric sequences. The gel shift technique will be also used to identify 
whether in the absence of other factors RBFA can interact simultaneously with both 5S 
and 12S rRNA.   
148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Final Discussion 
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6. Chapter 6: Final Conclusions. 
 
My PhD project was focused mainly on two mitochondrial proteins MRPL12 and 
RBFA.  
Preliminary investigation undertaken for SLIRP protein was not followed up due to 
publications from competing groups that arose during the course of my studies. I 
present below a summary of the main achievements and advances that my work has 
made in each of the designated projects. 
 
6.1 SLIRP  
The CLIP assay was performed in order to assess whether or not SLIRP (SRA stem-
loop interacting RNA binding protein) was able to bind mtRNA directly (Figure 3.2). 
The CLIP data revealed that the predicted RRM domain in SLIRP is functional and acts 
to bind RNA in human mitochondria. The CLIP reads were located in 12 of the 13 mt-
ORFs with the exception of MTND6. This result remains in agreement with now 
published data showing dependence of mt-mRNAs stability on SLIRP presence in 
human and mouse cells (Sasarman et al., 2010, Ruzzenente et al., 2011, Chujo et al., 
2012). SLIRP was reported to be in high-molecular weight complexes with LRPPRC. 
The latter also contains RNA binding domains, 22 of which are PPR motifs. The CLIP 
result for SLIRP shows unequivocally that this protein interacts directly, not just via 
interaction with LRPPRC, with messenger RNA in vivo in human mitochondria. 
 
6.2 MRPL12 
MRPL12 belongs to the group of conserved mitochondrial proteins having the bacterial 
orthologue called L7/L12. Moreover it is assigned to a unique pool of acidic ribosomal 
proteins, the analogues of which are present throughout phylogeny. The unique features 
of these proteins are due to their dynamic character and exchange of location between 
ribosomal LSU and the free pool, postulated to be a regulatory mechanism of translation 
process in response to fluctuations in cell metabolism.  
Obtaining immortalised fibroblasts from the patient with mutated form of MRPL12 
allowed me to study function of this protein in human mitochondria. The point mutation 
causing substitution of Alanine 181 by Valine in C terminal domain of MRPL12 (Figure 
4.1) caused a reduction in the steady state level to only 30% of control value (Figure 
4.3) with the free pool determined as absent via the sucrose gradient fractionation of 
mitochondrial lysate (Figure 4.6). Furthermore, a reduced number of MRPL12 
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molecules per mt-LSU was observed (Figure 4.12). However, the reduction in the level 
of MRPL12 did not affect overall mitoribosome assembly, but a visible decline in 
mitochondrial translation was detected in the in vivo 
35
S-metabolic labelling assay 
(Figure 5.7). Interestingly, the decrease in the rate of translation differentiated between 
polypeptides with highest decrease observed in products for COX and ATP6 subunits 
whilst cyt b was unaffected. As the steady state levels of MTCOX1, MTND1 and cyt b 
transcripts were not decreased (Figure 4.9) the reduced level of MRPL12/LSU can be 
postulated as the main reason for mitoribosome dysfunction, although the reduction in 
translational efficiency for different mitochondrially encoded subunits varied. Overall, 
my investigation revealed that although the stoichiometry of MRPL12 mutant/LSU is 
affected in the patient cell line, the mitoribosomes are assembled but their efficacy is 
lowered. The main technique, which could be applied to further investigate MRPL12 
function, is ribosome profiling. It would allow to establish whether mitoribosomes with 
reduced numbers of MRPL12 molecules stall on specific sequences of mt-mRNAs, 
which slows down the translation.   
 
6.3. RBFA. 
This protein has not yet been characterised in the literature. The studies by Ricarda 
Richter, during her doctoral studies in my host laboratory, demonstrated an inhibitory 
effect of RBFA depletion on the HEK293 rate growth and clear localisation to the mt-
SSU. None of the other analyses performed clarified is the function of this protein in 
mitoribosome assembly. The profile of mt-SSU and mt-LSU location was not changed 
in sucrose gradient fractions after RBFA silencing (for 3 and 6 days in HEK293 cells; 
Appendix 1.3). Furthermore, no decline was observed in mitochondrial RNA species or 
mtDNA, with only marginal decrease of mitochondrial translation rate in cells grown in 
the presence of RBFA si-RNA for 6 days. My project continued with characterisation 
and the results presented in my thesis indicate that RBFA: 
 Interacts directly with 3’ terminal stem loop of 12S mt-rRNA (Figure 5.1). The 
same sequence as already described for ERAL1 protein, by me in my host 
laboratory (Dennerlein et al., 2010). 
 Participates in the methylation process of two neighbouring adenines located in 
the 3’ terminal stem loop of 12S mt-rRNA (Figure 5.13). 
The primer extension assay performed for 12S mt-rRNA immunoprecipitated with 
MRPS27-FLAG or ICT1-FLAG (Figure 5.14) from HEK293 cell lysates where RBFA 
was silenced for 5.5 days indicate that: 
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 The level of methylation at the 3’ terminus of 12S incorporated into small 
subunit of mitoribosome (28S) was decreased by 26%. 
 The mitoribosomes (55S) contained almost exclusively 28S with methylated 12S 
at the 3’ end, even after 5.5 days of RBFA depletion. This observation clearly 
indicates that fully assembled mitoribosomes favour modified 12S and are able 
to recycle those mt-SSU, which were assembled before RBFA depletion. 
The primer extension assay applied for 12S mt-rRNA immunoprecipitated with 
ERAL1-FLAG or RBFA-FLAG (Figure 5.17) to investigate the order in which ERAL1 
and RBFA binds to the 3’ terminus of the 12S presents clearly that: 
 ERAL1 binds mostly unmethylated 12S (74%) 
 whereas RBFA interacts almost exclusively with 12S methylated at the 3’ 
terminus (96%). 
This experiment strongly suggests that RBFA succeeds ERAL1 binding at the 3’ 
terminus of 12S mt-rRNA (helix 45). 
Overall, the results described above assign RBFA as a new member of maturation 
factors of the mammalian mt-SSU. 
Finally, the CLIP assay revealed that RBFA binds second rRNA species 5S rRNA 
(Table 5.2). Identification of chimeric CLIP reads containing both 5S and 12S rRNA 
fragments suggest that RBFA interacts with both RNA species simultaneously in the 
mitochondrial matrix. Resemblance of the 5S rRNA secondary structure to the snoRNA, 
which guides modifications on cytosolic rRNA led to the hypothesis of a novel function 
for 5S rRNA to guide methylation at the 3’ terminus of mt-12S rRNA. 
Further investigation aims to test this hypothesis: 
 Gel shift experiments will be performed to potentially show simultaneous 
interaction of RBFA with 5S and 12S rRNA in vitro.   
 In order to assess influence of 5S rRNA on the level of methylation at the 
terminal stem loop of 12S rRNA, siRNA silencing of 5S rRNA in HEK293 
cells will be attempted followed by primer extension assays. 
 
In conclusion, obtained data strongly assign RBFA to the group of factors responsible 
for maturation of the mt-SSU and mitoribosome assembly. 
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Appendix 1.1 
 
Table A1. Table of CLIP hits mapped to genes used as controls in the assay performed 
for SLIRP, MRPL12 protein in patient and control sample and RBFA.  
Gene 
SLIRP RBFA MRPL12 Control 
 
 
 
 
 
 
 
 
 
 
 
 
 
18S 
Position in 
the gene 
Number of 
hits 
Position in the 
gene 
Number of 
hits 
Position in 
the gene 
Number of hits 
1760-1805 50-66 13-81 51-52 3-114 73-141-62 
  268-374 54-90-64 224-257 55-114 
  393-452 50-62-50 257-378 114-1126-177 
  492-591 53-240-53 394-491 ~150 
  592-691 59-345-55 493-580 
901-2145-273 
(~700 hits for 
patient sample) 
  932-1003 52-50-52 581-590 237-119 
  1084-1226 
114-1125-
63 
592-683 120-300-124 
  1314-1487 51-100-49 683-804 124-65 
  1497-1600 49-152-52 805-997 120-761-77 
  1754-1859 54-545-47 997-1239 77-600-132 
    
1245-1302-
1356 
158-3005-497 
    1356-1638 300-497-400 
    
1755-1802-
1848 
77-792-92 
 
 
 
 
  28S 
 
 
3034-3060 52-120-60 132-241 
63-140-
169-56 
1-68 57-79-52 
3079-3086 353-326 1258-1263 99-132 59-371-55 102-257 
  1281-1374 65-80-50 1257-1265 116-127 
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1529-1625 
 
52-80-50 
 
1283-1418 
 
52-80-50 
 
  1692-1782 51-205-66 1482-1648 50-200-61 
  1827-1949 50-150-83 1699-1752 55-50 
  2399-2523 56-70-50 1796-1945 58-200-62 
  2696-2826 55-100-50 2261-2379 54-180-94 
  3642-3733 56-174-77   
  4020-4126 87-153-53 2396-2537 61~200~96 
  4180-4278 52-155-50 2538-2830 98~300-82 
  4314-4486 51-150-50 2880-2889 50-50 
  4899-5064 62-130-68 3078-3087 332-150 
    3565-3643 54-100-88 
    3644-3809 91-274-51 
    3872-3964 58-166-57 
    4031-4099 54-60-53 
    4149-4242 52-150-91 
    4246-4267 140-60 
    4300-4381 90-178-56 
    4384-4456 121-53 
    4528-4560 54-58 
    4564-4717 70-503-54 
176 
 
 
Four nuclear genes were checked for content of CLIP reads: tubulin (no significant number of 
reads identified), EIF4E (no significant number of CLIP sequences mapped), 18S rRNA and 
28S rRNA (more than 50 sequences located in one position with approximate number of hits are 
presented in the table below). Considering very high abundance of all checked RNA species, 
can be concluded that for SLIRP and RbfA protein all controls confirm specificity of binding to 
mt-RNAs. In case of MRPL12 protein (mapped reads presented for control sample were 
comparable with patient sample unless otherwise specified in the table). The high number of 
hits mapped in few positions of 18S rRNA (highlighted in red) were identified for MRPL12 
protein in both control and patient samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    4728-4793 53-69-53 
    4854-4887 53-61-56 
             4892-5068 82-191-63 
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Figure A1. Alignment of MRPL12 CLIP tags from control and patient fibroblasts on 
mtDNA map. RNA species bound by MRPL12 in vivo were identified following CLIP method 
as described in the subsection 2.6.1 in control and patient fibroblasts. WT MRPL12 and mutated 
form with substitution of alanine 181 to valine had the same positions of CLIP sequences 
identified on 16S rRNA with the highest number of reads mapped at the 5’end (~450 reads for 
control and above 500 for subject sample). Three more locations on 16S were identified in the 
range of reads between 280-180.  Two binding positions were localised in the sequences of 
tRNA
Met 
and tRNA
Glu 
in patient fibroblasts in contrast to control with no reads mapped in these 
two locations. In both samples ~70 reads were mapped to 3’end of 12S rRNA. 
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Appendix 1.3 
 
 
 
Figure A2. Western blot analysis of sucrose gradient fractions for HEK 293 cell lysates. 
Cells were grown for 3 and 6 days in the presence of NT or RBFA (mtRbfA) siRNA. In order to 
assess ribosome assembly pattern in RBFA depleted HEK 293T cells antibodies for mt-SSU 
protein (MRPS18B) and mt-LSU protein (MRPL3) were used. RBFA antibody was applied to 
check depletion efficiency in cells incubated with targeting siRNA. Analysis of ribosome 
assembly was performed by Ricarda Richter. 
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Appendix 1.4 
 
Table A2. Table of CLIP hits mapped on mtDNA obtained for SLIRP protein.  
 
 
The genes, specific positions and sequences of CLIP tags are presented. Short dNTPs sequences 
found in at least ten different tags are highlighted (12 fragments contain CGC sequence (green); 
12 fragments contain CTG (yellow); 10 fragments contain GAG (purple), 7 fragments contain 
both CGC and CTG fragments). 
 
 
 
 
 
 
 
 
 
 Gene 
Position in  
mtDNA 
No. of 
reads 
3’ to 5’ CLIP read sequence 
1 
mtTF1 
binding site 
269-294 ˃ 600 ACACAGACATCATAACAAAAAATTT 
2(!) 
MTRNR1 
3’termini 
1561-1594 20 CGTAACATGGTAAGTGTACTGGAAAGTGCACTTG 
3 MTND1 4020-4048 12 CACTACAATCTTCCTAGGAACAACATATG 
4 MTND2 5222-5262 ~ 87 AGGAGGCCTGCCCCCGCTAACCGGCTTTTTGCCCAAATGG 
5 MTCOI 5959-5988 ~30 ACCTATTATTCGGCGCATGAGCTGGAGTCC 
6 MTCOI 6122-6152 40 CATAATCGGAGGCTTTGGCAACTGACTAGTT 
7 MTCOI 6551-6582 ~ 160 CACCACCTTCTTCGACCCCGCCGGAGGAGGAG 
8 MTCOI 6848-6871 20 CACCGGCGTCAAAGTATTTAGCTG 
9 MTCOI 7026-7065 ˃ 20 GCCCACTTCCACTATGTCCTATCAATAGGAGCTGTATTTG 
10 MTCOII 7873-7900 ˃ 40 CATCAAATCAATTGGCCACCAATGGTAC 
11 MTCOII 8135-8177 ˃30 TTCACCGCTACACGACCGGGGGTATACTACGGTCAA TGCTCTG 
12 ATPase8 8372-8394 29 CAACTAAATACTACCGTATGGCC 
13 
ATP8ase8- 
ATPase6 
8562-8592 152 CACAATCCTAGGCCTACCCGCCGCAGTACTG 
14 ATPase6 8657-8685 ~680 CCACCCAACAATGACTAATCAAACTAACC 
15 ATPase6 8974-9002 ˃600 CTCATTCAACCAATAGCCCTGGCCGTACGC 
16 MTCOXIII 9279-9322 ~30 CTCCTAATGACCTCCGGCCTAGCCATGTGATTTCACTTCCAC TC 
17 MTCOXIII 9563-9597 ~26 AGGCATCACCCCGCTAAATCCCCTAGAAGTCCCAC 
18 MTCOXIII 9917-9948 ~20 CGCCGCCTGATACTGGCATTTTGTAGATGTGG 
19 MTND3 10161-10186 ˃60 ACCCCTTACGAGTGCGGCTTCGACCC 
20 MTND4L 10644-10675 16 GTGCCTATTGCCATACTAGTCTTTGCCGCCTG 
21 MTND4 10993-11029 ~35 GGCAAGCCAACGCCACTTATCCAGTGAACCACTATCA 
22 MTND4 11872-11896 ˃200 CACTATTAACCTACTGGGAGAACTC 
23 MTND5 13682-13712 ~26 CCCTACTAAACCCCATTAAACGCCTGGCAGC 
24 MTCYTB 14814-14842 37 CCCCATCCAACATCTCCGCATGATGAAAC 
25 MTCYTB 14956-14985 28 TCGAGACGTAAATTATGGCTGAATCATCCG 
26 tRNA
Pro
 15957-15991 22 CAGAGAAAAAGTCTTTAACTCCACCATTAGCACCC 
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Multiple respiratory chain deficiencies represent a common cause of mitochondrial diseases and are associated
with a wide range of clinical symptoms. We report a subject, born to consanguineous parents, with growth
retardation and neurological deterioration. Multiple respiratory chain deficiency was found inmuscle and fibro-
blasts of the subject aswell as abnormal assembly of complexes I and IV. Amicrosatellite genotyping of the family
members detected only one region of homozygosity on chromosome 17q24.2–q25.3 in which we focused our
attention to genes involved in mitochondrial translation. We sequenced MRPL12, encoding the mitochondrial
ribosomal protein L12 and identified a c.542C>T transition in exon 5 changing a highly conserved alanine into
a valine (p.Ala181Val). This mutation resulted in a decreased steady-state level of MRPL12 protein, with altered
integration into the large ribosomal subunit.Moreover, an overall mitochondrial translation defectwas observed
in the subject's fibroblasts with a significant reduction of synthesis of COXI, COXII and COXIII subunits. Modeling
ofMRPL12 showsAla181 positioned in a helix potentially involved in an interface of interaction suggesting that the
p.Ala181Val changemight be predicted to alter interactionswith the elongation factors. These results contrastwith
the eubacterial orthologues of human MRPL12, where L7/L12 proteins do not appear to have a selective effect on
translation. Therefore, analysis of themutated version found in the subject presented here suggests that themam-
malian protein does not function in an entirely analogous manner to the eubacterial L7/L12 equivalent.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.
1. Introduction
The mitochondrial machinery responsible for oxidative phosphoryla-
tion (OXPHOS) comprises five enzyme complexes containing approxi-
mately 80 proteins of which only 13 are encoded by the mitochondrial
genome (mtDNA) [1]. OXPHOS deficiencies affecting a single or multiple
complexes can result from mutations in either mitochondrial or nuclear
genes and are associated with a variety of disease mechanisms [2,3].
With the advent of Next Generation Sequencing there is an increasing
number of pathogenic mutations being identified that are not solely re-
stricted to the 80 genes encodingOXPHOS components, thus highlighting
the importance of mechanisms impacting onmitochondrial gene expres-
sion [4,5]. Combined OXPHOS deficiencies can arise from alterations in
mtDNA, its maintenance [6], cardiolipin levels [7,8], or where none of
these are affected, from direct defects in synthesis of mitochondrially
encoded proteins [9]. This last group constitutes a heterogeneous mix of
patients suffering from awide range of clinical symptomsmaking clinical
diagnosis difficult [10]. Genetic diagnosis is yet more elusive in children
with mitochondrial disease where unidentified nuclear mutations
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account for the majority of cases [11]. This diagnostic problem is
compounded by our relatively poor understanding of the complex mo-
lecularmachinery that drives translation inmitochondria. This machin-
ery comprises over a hundred proteins [12], all of which are putative
candidate genes for translation deficiencies in human. Indeed, transla-
tion deficiencies represent a growing cause of multiple OXPHOS defi-
ciencies with several published pathogenic mutations in genes related
to the intra-organellar protein synthesis. Although many mutations as-
sociated with impaired mitochondrial translation currently map to
tRNA genes [13] and a few ribosomal RNA (rRNA) [14], the list of nucle-
ar gene mutations is steadily growing as mutations in genes encoding
mitochondrial translation factors such as GFM1 (OMIM: 606639)
[15,16], TSFM (OMIM: 604723) [17] and TUFM (OMIM: 602389) [18];
mitochondrial aminoacyl-tRNA synthetases (RARS2 (OMIM: 611524)
[19], DARS2 (OMIM: 610956) [20], YARS2 (OMIM: 610957) [21],
SARS2 (OMIM: 612804) [22], HARS2 (OMIM: 600783) [23], AARS2
(OMIM: 612035) [24], MARS2 (OMIM: 609728) [25], EARS2 (OMIM:
612799) [26]), FARS2 (OMIM: 611592) [27]; tRNA-modifying enzymes
(PUS1 (OMIM: 608109) [28], TRMU (OMIM: 610230) [29], MTO1
(OMIM: 614667) [30]); other factors (C12orf65 (OMIM: 613541) [31],
TACO1 (OMIM: 612958) [32], LRPPRC (OMIM: 607544) [33], C12orf62
(OMIM: 614478) [34]) and mitochondrial ribosomal proteins
(MRPS16 (OMIM: 609204) [35], MRPS22 (OMIM: 605810) [36],
MRPL3 (OMIM: 607118) [5]) have been successively reported
(reviewed in Ref. [14]). Relatively few cases of OXPHOS deficiencies as-
sociated with mutations in mitochondrial ribosomal proteins (MRPs)
have been described so far. MRPS16 mutations have been described in
only one family with agenesis of corpus callosum and dysmorphism.
MRPS22mutations lead to cardiomyopathy, hypotonia and tubulopathy
in a first family and Cornelia de Lange-like dysmorphic features, brain
abnormalities and hypertrophic cardiomyopathy in another family. Fi-
nally, we recently identified MRPL3 mutations in four siblings of the
same family presenting cardiomyopathy and psychomotor retardation.
Since the mammalian mitoribosome (55S) is ~2 megadalton machine
consisting of approximately 80 components that make up the 28S
small (SSU) and 39S large subunit (LSU), it is likely thatmore pathogen-
ic mutations in the constituent polypeptides will be uncovered. One of
the substantial differences between the mammalian mitoribosome
and those of eubacteria (70S) or the eukaryotic cytosol (80S) is the re-
versal in the protein to rRNA ratio. The 70S and 80S particles contain
~70% rRNA, whilst human mitoribosomes contain ~70% protein. This
change in the ratio represents both an acquisition of new MRPs as
well as loss of bacterial orthologues [37,38]. MRPL12 does have a bacte-
rial orthologue, which through its interactions with translation factors
is important in protein synthesis regulating both speed and accuracy
[39–41].
Here we investigate the genetic basis of disease in a subject born to
consanguineous parents, who initially presented with growth retarda-
tion and then neurological distress, with evidence of compromised
mitochondrial protein synthesis. We have identified the causative
mutation to be in MRPL12, encoding a protein of the large subunit of
mitochondrial ribosome. This is an important finding indicating that
the function and consequence of dysfunction cannot automatically be
extrapolated from an apparent orthologue. We show that proteins
involved in mitochondrial translation, even close orthologues as sub-
mitted here, can defy predictions. Moreover, mutations in such genes
that should affect all mitochondrially encoded gene products can exert
respiratory chain complex specific defects.
2. Materials and methods
2.1. Analysis of oxidative phosphorylation activities
Spectrophotometric assays of respiratory chain and complex V
enzymes were carried out as previously described [42]. Mitochondrial
suspension from cultured skin fibroblasts was obtained after suspending
50 μl of frozen cells in 1 ml of mitochondria extractionmedium (20 mM
Tris–HCl (pH 7.2), 250 mM sucrose, 2 mM EGTA, 40 mM KCl, 1 mg/ml
BSA) supplemented with 0.01% (w/v) digitonin and 10% Percoll (v/v).
After 10 min at 4 °C, the sample was pelleted, washed in extraction
medium and pelleted before resuspension in 30 μl of extractionmedium
for respiratory chain enzyme measurements.
2.2. Microsatellite genotyping and mutation screening
A genome-wide search for homozygosity was undertaken with 382
pairs of fluorescent oligonucleotides from the Genescan Linkage
Mapping Set, version II (Perkin-Elmer) under conditions recommended
by the manufacturer. Amplified fragments were electrophoresed and
analyzed with an automatic sequencer (ABI 377). The polymorphic
markers had an average spacing of 10 cM throughout the genome.
Genes encoding mitochondrial proteins were selected in Mitocarta
[43]. The exons and exon–intron boundaries of theMRPL12 gene were
amplified using specific primers (sequences available on request)
with initial denaturation at 96 °C — 5 min, followed by 30 cycles of
96 °C — 30 s, 55 °C — 30 s, 72 °C — 30 s, and a last extension at 72 °C
for 10 min. Amplification products were purified by ExoSapIT
(Amersham, Buckinghamshire, UK) and directly sequenced using the
PRISM Ready Reaction Sequencing Kit (Perkin-Elmer, Oak Brook, IL)
on an automatic sequencer (ABI 3130xl; PE Applied Biosystems, Foster
City, CA).
2.3. Cell culture
Human skin fibroblastswere cultured in DMEMmedium (Dulbecco's
modified Eagle'smedium, Gibco) supplementedwith 10% (v/v) fetal calf
serum (FCS), 2 mM L-glutamine, 50 μg/ml uridine, 110 μg/ml pyruvate,
10,000 U/ml penicillin G and 10,000 μg/ml streptomycin.
2.4. Protein analysis
For blue native-polyacrylamide gel electrophoresis (BN-PAGE),
mitochondria and OXPHOS complexes were isolated as described
[44]. Solubilized OXPHOS proteins (20 μg) were loaded on a 4–16%
(w/v) polyacrylamide non-denaturing gradient gel (Invitrogen).
SDS–PAGE analysis was performed on either solubilized mitochondrial
proteins (40 μg) or cell lysate (50 μg) extracted from cultured skin
fibroblasts. After electrophoresis, gels were transferred to a PVDFmem-
brane (GE-Healthcare) and processed for immunoblotting.
2.5. Metabolic labelling of mitochondrial translation products
In vitro labeling of mitochondrial translation products was a
modification fromChomynet al. [45]. Essentially, cultured skinfibroblasts
were preincubated in methionine/cysteine-free DMEM (2 × 10 min)
followed by a 10 min in the presence of emetine (100 μg/ml).
Radiolabel (125 μCi/ml EasyTag™ express35S protein labelling
mix — NEG772002MC, PerkinElmer) was then added for 1 h at
37 °C and chased for 1 h. Cells were harvested in cold 1 mM EDTA/PBS,
washed 3 times in cold PBS and the pellet resuspended in 30 μl PBS
containing 1× EDTA free protease inhibitors (Roche) and 1 mM PMSF.
Samples were treated with 2× dissociation buffer (20% (v/v) glycerol,
4% (w/v) SDS, 250 mM Tris–HCl pH 6.8, 100 mM DTT) and 12 U
Benzonase nuclease (Novagen) for 1 h and separated on a 15% (w/v)
SDS–PAGE. The gel was fixed overnight (3% (v/v) glycerol, 10% (v/v)
acetic acid, 30% (v/v) methanol) and vacuum dried (60 °C, 2 h).
Radiolabelled proteins were visualized by PhosphorImage and analyzed
with Image-Quant software (Molecular Dynamics, GE Healthcare).
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2.6. Homology modeling of the human MRPL12 protein
The three dimensional structure of the humanMRPL12 (residues 64 to
198) wasmodeled by comparative proteinmodeling and energyminimi-
zation, using the Swiss-Model program (http://swissmodel.expasy.org/)
in the automated mode. The 2 Å coordinate set for the ribosomal protein
L12 from Thermotoga maritima (PDB code: 1dd3) was used as a template
for modeling the human MRPL12 protein. Swiss-Pdb Viewer 3.7 (http://
www.expasy.org/spdbv) was used to analyze the structural insight into
MRPL12 mutation and visualize the structures.
2.7. Cell lysates, Westerns and isokinetic sucrose gradients
Cell lysates were prepared from fibroblasts by addition of cold lysis
buffer (50 mM Tris–HCl pH 7.5, 130 mM NaCl, 2 mM MgCl2, 1 mM
PMSF, 1% (v/v) NP-40) to cell pellets, which were vortexed for 30 s,
centrifuged at 600 g for 2 min (4 °C) to remove nuclei and the superna-
tant retained. These were used for standard westerns as described [46].
Mitochondria were prepared as above and lyzed in 50 mMTris–HCl pH
7.4, 150 mMNaCl, 1 mM EDTA, 1% Triton X-100, protease inhibitor mix
(EDTA free, Roche), 1 mM PMSF, 10 mM MgCl2. Mitochondrial lysates
(0.3 mg) were loaded on a isokinetic sucrose gradient (1 ml 10–30%
(v/v)) in 50 mM Tris–HCl (pH 7.2), 10 mM Mg(OAc)2, 40 mM NH4Cl,
0.1 M KCl, 1 mM PMSF, 50 μg/ml chloramphenicol), and centrifuged
for 2 h 15 min at 100,000 g at 4 °C. Fractions (100 μl) were collected
and 10 μl aliquots were analyzed directly by western blotting [47].
Immunodetection was performed using the following primary
antibodies: anti-CI-Grim19, CII-SDHA 70 kDa, CIII-core2, CIV-COXI,
CIV-COXII, CV-subunit β, cyt c, NDUFB8 (mouse monoclonal antibod-
ies, MitoSciences); anti-MRPL3 goat polyclonal, MRPS18B rabbit
polyclonal, MRPS25 rabbit polyclonal and ICT1 rabbit polyclonal anti-
bodies (Protein Tech Group, Inc., Chicago); anti-DAP3 mouse mono-
clonal, POLRMT rabbit polyclonal (Abcam); and anti-Porin, mouse
monoclonal antibodies (Invitrogen). Anti-MRPL12 rabbit polyclonal
antibody was custom made (Eurogentec). Secondary antibody detec-
tion was performed using peroxidase-conjugated anti-rabbit, anti-
goat or anti-mouse IgG (Abcam or Dako). The signal was generated
using ECL+ (Pierce, Rockford, USA) and visualised by phosphorimaging
and analyzed by ImageQuant software.
2.8. RNA and Northern blotting
RNA was isolated from fibroblasts using Trizol following manufac-
turer's protocol (Invitrogen). Northern blots were performed as
described [48]. Briefly, aliquots of RNA (5 μg) were electrophoresed
through 1.2% (w/v) agarose under denaturing conditions and trans-
ferred to GenescreenPlus membrane (NEN duPont) following the
manufacturer's protocol. Radiolabelled probes were generated using
random hexamers on PCR-generated templates corresponding to
internal regions of the relevant genes.
3. Results and discussion
3.1. Clinical report
The subject, a boy, was born to first cousin Roma/Gypsy parents by
cesarean section, at 41 weeks of pregnancy with severe general
hypotrophy (birth weight 2250 g, height 48 cm, Occipitofrontal
Circumference 34 cm). His clinical examination at birth was normal
and initial investigations failed to identify the cause of his severe
hypotrophy (normal blood caryotype, heart ultrasound, bone age,
CT scan and metabolic workup). He failed to thrive thereafter and
was repeatedly admitted in the first 12 months for gradual worsening
of his condition (weight and height: −4SD, OFC: −2SD). Clinical
examination at 10 months showed severe denutrition, muscle weak-
ness but detectable deep tendon reflexes and no major trunk
hypotonia. He started walking with aid at 12 months. Basal growth
hormone (GH) levels in plasma were normal (0.5 ng/ml) but plasma
IGF1 was very low (0.07 U/ml, normal 0.2). Stimulation by ornithine
triggered an adequate elevation of plasma GH with correction of plas-
ma IGF1 (GH: 46.9 ng/ml, IGF1: 0.2 U/ml, and 0.45 U/ml following
GH administration). These results ruled out a dwarfism of endocrine
origin. Yet, high plasma lactate (3.5 to 4.4 mmol/l, normal below
2.2) prompted skeletal muscle, liver and skin biopsies that revealed
a multiple respiratory chain enzyme deficiency in muscle and liver
homogenate and cultured skin fibroblasts (Table 1) [42].
He had a first episode of generalized tonic seizure aged 2 years and
his neurological condition rapidly worsened following an episode of
acute fever (40 °C) caused by a respiratory infection. At that age, he
had severe denutrition, flat weight curve, no weight and height gain
(−5 SD) and amildly enlarged liver. Neurological examination revealed
overt psychomotor retardation, severe trunk hypotonia, inability to sit
and stand unaided and no speech. Intermittent horizontal nystagmus,
with cerebellar ataxia and tremor were noted. He had a mild facial
dysmorphism, with round face, epicanthic folds, arched palate, short
neck, low-set ears and a unique bilateral median palmar crease. Brain
MRI showed T1 hyposignal and T2 hypersignal of white matter and
basal ganglia. Rapid aggravation of respiratory conditions required
endotracheal intubation and assisted ventilation. Plasma lactates rose
to 3.3–4.2 mmol/l, he gradually developed abnormal limb movements
then fell into a deep coma, and died following a cardiac arrest.
During the next pregnancy, the mother expected dizygotic twin
fetuses. A prenatal diagnosis based on assessment of respiratory chain
enzyme activities in cultured skin fibroblasts on amniotic fluid was
offered. Hemoglobin contamination of the samples rendered the very
low respiratory chain activities; despite this the activity ratios clearly
showed a severe complex IV deficiency in cells from the fetus twins
leading to termination of the second pregnancy. The same test was
normal in the third pregnancy and a normal baby girl was born, now
14 years old (Table 1).
3.2. Blue native-PAGE analysis
Whilst skin fibroblasts were propagated for enzyme analysis it was
clear that those from the subject harboring themutation had a reduced
doubling time on glucose medium compared to control lines (data
available on request). Cell extracts were subsequently prepared and
SDS–PAGE/western blot analysis revealed reduced steady-state level
of COXII subunit, consistent with the decreased CIV activity (Fig. 1A).
Moreover, we also observed a decreased amount of nuclear encoded
protein NDUFB8 (Fig. 1A), which joins late in complex I assembly [44]
and is consistent with the low CI activity in the biopsies. These
decreases were consistent with the BN-PAGE data from fibroblast
mitoplasts (Fig. 1B, method as described [49]). Both complexes I and
IV, detected by anti-GRIM19 antibody or mitochondrially-encoded
COXI,were severely decreased in the subject, which in contrast exhibited
control levels of complex II (70 kDa SDHA subunit) and complex III (Core
2 subunit) (Fig. 1B). No partial complexes were observed.
3.3. Identifying the causative mutation by Microsatellite genotyping and
mutation screening
In order to identify the causative mutation a genome-wide search
for homozygosity was undertaken using 382 polymorphic microsatel-
lite markers (Genescan Linkage Mapping Set, version II (Perkin-Elmer).
We obtained evidence for homozygosity in all affected individuals at
loci D17S785, D17S784, and D17S928 on chromosome 17q24.2–q25.3
(Fig. 2A). No other homozygous region was found with other markers.
This 32.7 cM region was then refined by additional microsatellite
markers reducing the critical region to the 25 cM interval, defined by
loci D17S1352 and D17S928. This corresponds to a 8.4 Mb physical
region containing more than 170 genes, 10 of which encode
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mitochondrial proteins or proteins predicted to be mitochondrially
targeted (FDXR (MIM 103270), ICT1 (MIM 603000), ATP5H (MIM
607196), MRPS7 (MIM 611974), SLC25A19 (MIM 606521), MRPL38
(MIM 611844), PGS1 (NM_024419),MRPL12 (MIM 602375), SLC25A10
(MIM 606794), FASN (MIM600212)). Considering themultiple RC defi-
ciency observed in patient muscle, liver and fibroblasts and the abnor-
mal BN-PAGE pattern reminiscent of translation deficiencies, we
focused on genes involved in mitochondrial translation, excluding mu-
tations inMRPS7,MRPL38 and ICT1 by direct sequencing.
Sequencing of MRPL12 exons and exon–intron boundaries on
genomic DNA (primer sequences available on request) from the
affected child identified a homozygous c.542C>T transition in exon
5 (RefSeq accession number NM_002949.3, Fig. 2B). This mutation
changed a highly conserved alanine into a valine (p.Ala181Val, Fig. 2C)
and was predicted by Polyphen2 (http://genetics.bwh.harvard.edu/
pph2/) and SIFT (http://sift.jcvi.org/) software to be “probably damag-
ing” and “deleterious” respectively. The parents were heterozygous
for the mutation, both twin fetuses were homozygous and the healthy
girl was wild-type homozygous. This mutation was absent from 100
controls of the same ethnic origin and from all SNP databases. Further,
no additional MRPL12 mutation could be identified in two other
unrelated subjects with similar clinical presentation and biochemical
defect.
To demonstrate the deleterious nature of the p.Ala181Val MRPL12
substitution we used, overexpression of wild-type or mutant human
MRPL12 cDNA in the SV40-immortalized fibroblasts but rather reca-
pitulating the respiratory phenotype of the patient fibroblasts, this
was found to be lethal. Cells stopped growing, became polynucleated
and progressively died.
3.4. In silico analysis of the putative impact of A181V substitution
HumanMRPL12 is 27.5% identical in amino acid sequence to the pre-
viously crystallized T. maritima L12 ribosomal protein. The C-terminal
domain (CTD) (107 to end in Escherichia coli) is conserved in evolution
[50] and is required for initial binding and GTPase activation for both
EF-Tu and EF-G. Indeed, both EF-Tu and EF-G have greatly diminished
GTPase activity on ribosomes lacking the CTD of L12 [51,52]. Superim-
position of MRPL12 with the Thermus thermophilus 70S ribosome (PDB
code: 2WRL) lacking L7/L12 stalk proteins shows that MRPL12 Ala181
is located within this highly conserved region (Fig. 3A). Moreover,
modeling of MRPL12 shows Ala181 positioned in a helix potentially in-
volved in translation factor interactions (Fig. 3A/B). Bacterial L7/L12
CTDs also contain a number of strictly conserved residues that are in-
volved in the initial contact with elongation factors [52,53] and crucial
for translation [54]. Alanine is one of the best helix forming residues
PC
CI - Grim19
CV – F1β 
CII - SDHA 
CIII - Core 2
CIV - COXI 
NDUFB8
COXII
Cyt c
Porin
C PA
B
Fig. 1. Steady state levels of the oxidative phosphorylation components and complexes.
A. Western blot analysis was performed on cytoplasmic extracts (40 μg) of cultured
patient (P) and control (C) fibroblasts to determine steady state levels of COXII
(MitoSciences). In the absence of other antibodies to mitochondrially encoded pro-
teins, NDUFB8 (MitoSciences) was monitored as a marker for Complex I. Levels of
cytochrome c (MitoSciences) and porin (Invitrogen) were determined as controls for
the respiratory chain and mitochondrial mass respectively. B. BN-PAGE of mitochon-
dria prepared from cultured skin fibroblasts of patient (P) and control (C) was ana-
lyzed by western using antibodies (all MitoSciences) directed against GRIM19, SDHA
70 kDa, Core 2, COXI and F1β subunit to identify steady state levels of complexes I, II,
III, IV and V respectively.
Table 1
Respiratory chain activities in muscle mitochondria, liver homogenate and fibroblasts.
Muscle
mitochondria
Liver
homogenate
Liver homogenate Fibroblasts Amniotic cells
P C P C Twin 1 fetus Twin 2 fetus C P C Twin 1 fetus Twin 2 fetus 3rd pregnancy C
Absolute activities (nmol/min/mg prot)
CI – – – – – – – 17 27–44 – – – –
CII 170 75–157 – – 63 57 74–196 59 33–71 – – – –
CIII 697 494–1004 493 128–217 106 73 70–236 505 318–820 1.44 2.1 16.5 19–21
CIV 374 540–1073 7 131–241 57 32 68–284 90 189–429 0.88 0.77 32 26–36
CV 538 209–454 – – – – – 100 53–133 – – – –
CI + III 89 113–311 27 35–67 – – – – – – – – –
CII + III 443 164–357 365 50–98 37 23 38–104 167 69–146 2.22 1.38 8.7 6.5–8.4
CS – – – – 65 45 40–104 293 112–264 – – – –
Activity ratios
CIV/CI + III 4.2 3.4 ± 0.8 – – – – – – – – – – –
CIV/CII + III 0.8 3.1 ± 0.5 0.01 3.0 ± 0.4 1.5 1.39 2.7 ± 0.3 0.5 3.0 ± 0.2 0.61 0.55 3.6 2.1–3.3
CIV/CI – – – – – – – 5.4 10.1 ± 1.0 – – – –
CIV/CII – – – – – – – 1.5 6.1 ± 0.7 – – – –
CIV/CIII 0.5 1.5 ± 0.2 0.01 2.0 ± 0.6 0.54 0.4 1.2 ± 0.1 0.2 0.6 ± 0.04 0.39 0.37 1.9 0.7–1.2
CIV/CV 0.7 2.5 ± 0.8 – – – – – 0.9 3.5 ± 0.4 – – – –
CI–CV, complexes I–V; CS, citrate synthase; P, subject; C, control. Abnormal activity values and ratios are shown in bold.
Spectrophotometric assays of respiratory chain and complex V enzymes were carried out as previously described [42]. Haemoglobin contamination of amniotic cells reduced
accuracy of the absolute values of RC complex activities but not the ratios.
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and substitutions can therefore have profound energetic effects by
perturbing packing interactions or tertiary contacts [55]. Thus, the
p.Ala181Val change might be predicted to alter interactions with
the elongation factors, and since MRPL7/12 bound to elongation fac-
tors is predicted to have a higher affinity for the ribosome [54], the
mutation may in turn affect both rate and accuracy of mitochondrial
translation.
3.5. Ribosome assembly
The steady state level of MRPL12 in the subject's fibroblasts was re-
duced to 30% of control value (Fig. 4A and B). The mt-LSU protein ICT1
was also decreased (~30% of control values) as was MRPL3 (by 37%)
suggesting that a consequence of the MRPL12 mutation is a global
defect in assembly of the large ribosomal subunit (mt-LSU). In order
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D17S1839
D17S785
D17S784
D17S928
A
C
B
A181V
Homo sapiens    PVDKVKLIKEIKNYIQGINLVQAKKLVESLP---QEIKANVAKAEAEKIK
Bos taurus    PVDKVKLIKEIKNYVQGINLVQAKKLVESLP---QEIKANVAKAEAEKIK
Mus musculus    PVDKVKLIKEIKNYVQGINLVQAKKLVESLP---QEIKANVAKAEAEKIK
Xenopus laevis   ATDKVKLIKEVKNCIQGLNLVQAKKLVEALP---QEIKANVSKDEAEKIK
Gallus gallus   ATDKVKLIKEVKNFVPGINLVQAKKLVESLP---QEIKANVSKEEAEKIK
Drosophila melanogaster  EKQKVALIKEVKNLLEGMNLVQAKKFVESAP---TIVKEDIPKEEAEKLK
Caenorhabditis elegans  DTKKIAIIKEIRNAIPGLNLVQAKKFVETAP---VNVKEDLGKAEADELK
Arabidopsis thaliana  ASDKIKVIKEVR-TFTSLGLKEAKELVEKVP---AILKQGVTKEEANEII
Saccharomyces cerevisiae  TKTKAKVIKEVK-GLLGLSLVEAKKFVEAAP---KVLKENVAKDDAEKIK
Escherichia coli   A-NKVAVIKAVR-GATGLGLKEAKDLVESAP---AALKEGVSKDDAEALK
Thermotoga maritima  Q-NKIQVIKVVR-EITGLGLKEAKDLVEKAGSPDAVIKSGVSKEEAEEIK
Thermus thermophilus  A-KKLEVIKDVR-AITGLGLKEAKDLAEKGGP----VKEGVSKQEAEEIK
Yersinia pestis   E-NKVAVIKAVR-GATGLGLKEAKDLVESAP---AVLKEGVNKDEAETLK
Pseudomonas aeruginosa  D-KKVNVIKVVR-ELTGLGLKEAKAVVDGAP---GVVKEGASKEEAEAAK
Staphilococcus saprophyticus S-SKIKVVKAVK-EATGLGLKDAKELVDGAP---KVIKEALPKEEAEKLK
        *  ::* ::    .:.* :** ..:        :*    * :*:
nt 542 nt 542nt 542
G G G G G G G GC T AA AT
mother
GA G G G G G G G GCC T AA AA
control
G G G G G G GTC T AA AA
C
patient
Fig. 2. Microsatellite genotyping and mutation screening. A. Pedigree and haplotypes of the family are given (top to bottom) for loci D17S949, D17S1350, D17S1352, D17S1839,
D17S785, D17S784 and D17S928. B. Sequence analysis ofMRPL12 in patient subject (left panel), mother (centre panel) and a control (right panel). The arrow indicates the position
of the mutation. Amplification products were sequenced using the PRISM Ready Reaction Sequencing Kit (Perkin-Elmer, Oak Brook, IL) on an automatic sequencer (ABI 3130xl; PE
Applied Biosystems, Foster City, CA). C. Amino acid alignment of MRPL12 (H. sapiens to S. cerevisiae) and L7/L12 (E. coli to S. saprophyticus) proteins. The arrow indicates the
conserved amino acid that the MRPL12 mutation changes from an alanine to a valine. Below * designates identity, whilst and: indicate increasing levels of similarity.
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to estimate the effect of theMRPL12mutation on assembly of thewhole
ribosome, we also tested three proteins of the small ribosomal subunit
(SSU), MRPS18B, MRPS25 and DAP3. These were modestly decreased
with levels of ~60–80% of control (Fig. 4A and B). Correspondingly, 16S
and 12S rRNA levels were decreased by 35% and 22% respectively
(Fig. 7A). Since porin indicated that there was no compensatory mito-
chondrial biogenesis and staining of the mitochondrial network with
tetramethylrhodamine methyl ester showed no significant
alteration in amount or distribution of mitochondria (AR and ZCL
unpublished observation) we conclude that the MRPL12 mutation
destabilizes the protein resulting in less mt-LSU and to a lesser
extent of the small subunit.
In order to determine whether the MRPL12 mutation also induced
changes in composition and assembly of the mitochondrial ribosomal
large and small subunits, mitochondrial lysates from cultured fibro-
blasts (subject and control) were fractionated on isokinetic sucrose
gradients (10–30%, as in Ref. [47]). If assembly of either the large
subunit or the entire ribosome was affected then the distribution of
individual ribosomal proteins would change within the gradient pro-
file. On analysis MRPL12 from the patient was substantially decreased
in all fractions but detectable in the fractions consistent with mt-LSU;
however it was noticeably absent from the free pool (fractions 1 and
2, Fig. 5). This was in contrast to the control that exhibited a pool of
free MRPL12, which has been reported to interact with POLRMT
[56]. MRPL3 was also slightly reduced in subject cells but remained
in fractions consistent with the large subunit. The MRPL12 mutation
impacted more modestly on the small ribosomal subunit, with DAP3
apparently unaffected and MRPS18B found in lower amounts only in
fractions 4 and 5 but otherwise with similar steady state levels and dis-
tribution profile compared to control. Since POLRMT and MRPL12 have
been published as interactors, we analyzed both the steady state level
and gradient distribution of POLRMT to see if these were affected by
the MRPL12 mutation. Overall levels in the subject sample were de-
creased to 63% of control value (Fig. 5B) but distribution in the gradient
appeared largely unaffected with the exception of fraction 11, where
levels were lower than control (Fig. 5A bottom panels).
MRPL12
CTD
NTD
Ala181
L10
L11 Ala181
Ala181
A B
CTD
NTD
Fig. 3.MRPL12 and its position in the ribosome. A. The three dimensional structure of the human MRPL12 (residues 64 to 198) was modeled by comparative protein modeling and
energy minimization, using the Swiss-Model program in the automated mode. The 2 Å coordinate set for the ribosomal protein L12 from Thermotoga maritima (PDB code: 1dd3)
was used as a template for modeling the human MRPL12 protein. Swiss-Pdb Viewer 3.7 (http://www.expasy.org/spdbv) was used to analyze the structural insight into MRPL12
mutation and visualize the structures. The A181 residue shown (in red) is localized in a helix that is likely to be at the interface of an interaction with translation factors. B. Potential
MRPL12 interactions within the ribosomal L7/L12 stalk. Swiss-Pdb Viewer 3.7 (http://www.expasy.org/spdbv) was used to superimpose MRPL12 on the Thermus thermophilus 70S
ribosome (PDB code: 2WRL) without L7/L12 stalk proteins. MRPL12, L10 and L11 are shown in green, blue and yellow respectively. The Ala181 residue (in red) is located in the
MRPL12 CTD. The p.Ala181Val change has a high probability of altering interactions of MRPL12 with elongation factors and might be predicted to affect initial binding, decreasing
both rate and accuracy of mitochondrial translation. NTD: N-terminal domain; CTD: C-terminal domain.
MRPL12
MRPL3
ICT1
DAP3
MRPS18B
MRPS25
Porin
LSU
SSU
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0%
20%
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100%
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A B
Fig. 4. Analysis of mitoribosomal components. A. Cell lysates (50 μg) from patient (P) and control (C) fibroblasts were separated by SDS–PAGE followed by western to decorate
various components. Polypeptides of the large ribosomal subunit (LSU) included MRPL12 (Eurogentec), MRPL3 (PTG labs), ICT1 (PTG labs) and small ribosomal subunit (SSU)
included DAP3 (Abcam), MRPS18B (PTG labs) and MRPS25 (PTG labs). Porin (Invitrogen) was used as a loading control. B. Densitometric values from 3 independent experiments
as described in panel A represent the levels of MRPL12, MRPL3, ICT1, DAP3, MRPS18B and MRPS25 in subject compared to control fibroblasts.
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3.6. In vitro translation
To identify any effect on global mitochondrial protein synthesis, we
studied de novo mitochondrial translation in cultured skin fibroblasts,
as described in Ref. [45]. Although there was an overall decrease inmito-
chondrial translation compared to control, densitometric profiles showed
that certain polypeptides weremore affected than others (Fig. 6). In par-
ticular, there was a significant reduction of synthesis of COXI, COXII and
COXIII subunits. Consistent with the respiratory chain activities, complex
I polypeptides were affected to a lesser extent and cytochrome b from
complex III appears to be spared. Despite the potential role of MRPL12
in translational accuracy, no aberrant translation product could be
detected.
3.7. Steady-state level of mitochondrial transcripts
MRPL12 has been shown to interact with the mitochondrial RNA
polymerase (POLRMT) and to stimulate mitochondrial transcription
[56,57]. Since the steady-state level of POLRMT in subject fibroblasts
was modestly decreased, we analyzed the steady-state level of mito-
chondrial transcripts to see if these were similarly affected. Northern
blots on control and subject fibroblast RNA did not show a decrease
that paralleled the reduced levels of POLRMT. In fact there was a
slight increase of MTND1 in subject cells compared to control, whilst
MTCOI and MTCYB transcripts appeared unaffected (Fig. 7A). Con-
versely, as mentioned earlier, the levels of 16S and 12S rRNA were
modestly decreased (Fig. 7A) in a proportion that was consistent
with the loss of MRPs with which they would associate. Analysis of
the distribution on 10–30% (w/v) sucrose gradients (as in Ref. [58])
of two mt-mRNAs, MTCOI and MTND1, showed a relatively similar
pattern for subject and control but in each case a smaller proportion
of the subject transcript sedimented to the final fraction (data avail-
able on request). This was also true for the 16S and 12S rRNA. As no
major redistribution in the sucrose gradient was observed, it is un-
likely that the MRPL12 mutation causes a global defect in assembly
of the mitoribosome.
Since the levels of POLRMT were slightly decreased with normal
or slightly elevated levels of mt-mRNA, we assessed the stability of
transcripts to see if the half-lives were extended to compensate for
reduced synthesis in order to maintain normal steady state levels.
Mitochondrial transcription was poisoned by addition of low levels
of ethidium bromide and RNA prepared at numerous time points
thereafter (0–16 h). Densitometry of the subsequent Northern dem-
onstrated that half-lives ofMTCOI andMTND1were extended, the lat-
ter more so, consistent with the modest increase in steady state levels
(data available on request).
3.8. MRPL12 dimerization and interaction with the mitoribosome
MRPL12 is the orthologue of eubacterial L7/L12, where L7 is identical
to L12 except that it is N-terminal acetylated. L7/L12 is also phosphory-
lated, which can affect both conformation and binding to partner
fractions1 2 3 4 5 6 7 8 9 10 11
28S
39S 55S
10 – 30 % sucrose gradient
1 864 11
DAP3
MRPS18B
mtRNA
polymerase
C
P
mt-SSU
MRPL12
MRPL3
ICT1
mt-LSUC
P
C
P
C
P
C
P
C
P
A
B
Porin
C P
mtRNA
polymerase
Fig. 5. Isokinetic gradient analysis of mitochondrial lysates. A. Mitochondrial lysates were
prepared from patient (P) and control (C) fibroblasts and 300 μg of each was separated
through 10–30% (w/v) isokinetic sucrose gradients. The levels of 28S small subunit
(SSU) and 39S large subunit (LSU) proteins were determined by western blot analysis.
55S corresponds to the assembled mitoribosome. The steady state level (panel B. porin
as loading control) and distribution (panel A) of POLRMT was also examined. Antibodies
as in previous legends except POLRMT (Abcam).
ND5
COXI
ND4
cytb
ND2
ND1
COXIII/COXII
ATP6
ND6
ND3
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ATP8
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staining
Autoradiograph
Fig. 6. Mitochondrial protein synthesis. De novo synthesis of mitochondrial proteins
was determined in patient (P) and control (C) fibroblasts under conditions that
inhibited cytosolic translation [45]. In vivo incorporation of 35S-methionine/cysteine
into mitochondrially encoded proteins was visualised by separation of cell lysate
(50 μg) through SDS–PAGE, exposure of the dried gel to a PhosphorImage screen,
followed by Storm and ImageQuant analysis (upper panel). To the right of the gel are
the aligned densitometric profiles of the patient (lower trace) and control (upper
trace). The gel was subsequently rehydrated and stained with Coomassie blue to con-
firm equal loading (lower panel).
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ribosomal proteins (reviewed in Ref. [37]). This modification has now
been confirmed to be present inmammalianMRPL12 [59]. In eubacteria,
association of L7/12 to the large subunit takes place via the L10 protein
such that two L7/L12 heterodimers normally associate per LSU [60]. In-
terestingly these dimers are actively exchanged on the 70S molecule
without disruption of the ribosomal particle [54,61]. The dimerization
status and number of dimers attached to the human 55S has not been
clarified. In order to identify if the stoichiometry of MRPL12 per
mt-LSUwas altered as a consequenceof themutation,we performed im-
munoprecipitation (IP) analysis on subject and control fibroblasts using
antibodies toMRPL12. Analysis of the immunoprecipitate demonstrated
similar levels small subunit polypeptides including DAP3 and MRPS18B
in subject and control samples. In contrast, the total amount of MRPL12
was reduced (Fig. 7B). In the patient the IP is restricted toMRPL12 in the
large subunit or the fully assembled 55S with the total amount of
MRPL12 being reduced as it lacks the “free” population. The densitomet-
ric measurements indicate that the patient IP has ~49% MRPL12 com-
pared to control, in accordance with the gradient and steady state data.
ICT1 appears to be sensitive to the MRPL12 levels and so is reduced in
both the IP (~58% of control) and in the steady state westerns (Fig. 4).
The lower levels of MRPL12 could reflect loss of multimerization but
since the region in the bacterial protein involved in multimerization is
towards the N-terminus [62], thismutation is unlikely to have an impact
on dimer/multimer formation. The translation factor bound dimer has
been suggested to have an increased affinity for the ribosome [54,61].
Thus a possible explanation is that themutation affects translation factor
binding, thereby reducing the affinity of the mutant MRPL12 for the ri-
bosome. If this were the case, however, then we would expect an in-
crease in the pool of free MRPL12 whereas the subject exhibits a
reduced pool of freeMRPL12,which interactswith POLRMT [57]. The im-
munoprecipitation was performed using an MRPL12 specific antibody
and so should contain all free MRPL12, MRPL12 associated with
uncomplexed mt-LSU and MRPL12 as part of the fully assembled 55S.
Since the levels of small and large subunit proteins appeared to be similar
in subject and control, these data suggest that the mt-LSU and 55S as-
sembly are unaffected by the mutation consistent with the gradient
data for the protein and RNA components. Thus the reduced levels of
mutant MRPL12 in this subject correspond to i) loss of stability, ii) a de-
crease in the free pool that is believed to interact with the mitochon-
drial RNA polymerase and iii) reduced translation potentially
resulting from decreased interactions with translation factors, but
with no detectable increase in aberrant translation products.
In conclusion,we report amutation in humanMRPL12 that results in
growth retardation and neurological distress. It is interesting to note
that whereas the eubacterial orthologue is not essential for in vitro
translation assays, thisMRPL12mutation induces amitochondrial trans-
lation defect in human. This lack of predictability between orthologous
proteins makes it important to examine and not assume what impact
mutant forms or loss of MRPs may have on mitochondrial homeostasis
and the resulting clinical manifestation. The data presented here pro-
vide another example, amongst a growing list of translation factors,
which despite their apparent universal contribution to the synthesis
of all mitochondrially encoded proteins, has a selective effect on the
different oxidative phosphorylation complexes.
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